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Abstract 
Pulmonary  arterial  hypertension  (PAH)  is  a  progressive  disease  characterised  by 
vasoconstriction and remodelling of the pulmonary vasculature.  The consequence of this 
is  increased  pulmonary  arterial  pressure,  right  heart  failure  and  eventual  death  if  left 
untreated.  Even in those patients receiving advanced PAH therapy, mortality rates remain 
high.  Therefore, the development of novel therapeutic approaches in the treatment of PAH 
is urgently required.  A better understanding of PAH pathogenesis is critical to achieving 
this.  Gender differences exist in human PAH, with females up to three-fold more likely to 
present  with  disease  than  males.    Limited  evidence  suggests  that  estrogens  may  be 
accountable for these differences.  For example, the use of oral contraceptives has been 
associated  with  the  development  of  PAH.    Paradoxical  to  this  however,  experimental 
models of PAH exhibit male susceptibility which has limited research into the role of 
estrogens in the pathogenesis of PAH.  
 
Serotonin is implicated in both experimental and human PAH.  Activity of the serotonin 
transporter (SERT) modulates the development of PAH and mice over-expressing SERT 
(SERT+ mice) exhibit PAH and exaggerated hypoxia-induced PAH.  In the central nervous 
system, estrogens regulate expression of several serotonin signalling components including 
tryptophan hydroxylase (TPH), the 5-HT receptors and SERT.  One hypothesis is that 
similar estrogen effects on serotonin signalling may also be apparent in the pulmonary 
vasculature, and this is one hypothesis for the increased female susceptibility observed in 
PAH.  To examine this, the influence of gender and estrogen on the development of PAH 
in  SERT+  mice  was  investigated.    This  was  repeated  following  exposure  to  chronic 
hypoxia.  Pulmonary vascular reactivity was determined using small vessel myography.  
The genotypic differences in SERT+  mice were also assessed via microarray analysis.  
Genes of interest were validated by qRT-PCR analysis and immunoblotting.  To translate  
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clinical relevance to any findings, the effects of female hormones were also investigated in 
human  pulmonary  artery  smooth  muscle  cells  (PASMCs)  derived  from  both  non-PAH 
(control) and idiopathic pulmonary arterial hypertension (IPAH) patients.   
 
PAH  was  assessed  via  measurement  of  right  ventricular  systolic  pressure  (RVSP), 
pulmonary vascular remodelling and right ventricular hypertrophy (RVH).  Male SERT+ 
mice do not develop PAH.  Female SERT+ mice exhibited increased RVSP and pulmonary 
vascular remodelling.  This increased RVSP and pulmonary vascular remodelling were 
completely prevented following ovariectomy in SERT+ mice.  The chronic administration 
of 17β estradiol (1.5mg/kg/day), which is the pre-dominant circulating female hormone in 
pre-menopausal  women,  fully  re-established  PAH  as  assessed  by  increased  RVSP  and 
pulmonary  vascular  remodelling.    Pulmonary  vascular  reactivity  to  serotonin  was 
unaffected in these mice.  In chronic hypoxia, female SERT+ mice exhibited exaggerated 
hypoxia-induced PAH whereas male SERT+ mice remained unchanged compared to their 
respective wildtype (WT) controls.  This exaggerated hypoxia-induced PAH phenotype 
was attenuated in SERT+ mice following ovariectomy, as assessed by a reduction in RVSP 
and  pulmonary  vascular  remodelling.    The  chronic  administration  of  17β  estradiol 
completely re-established exaggerated hypoxia-induced PAH in ovariectomized SERT+ 
mice.  Similar to normoxia, serotonin-induced pulmonary vascular contraction was also 
unaffected  in  these  mice.    The  stimulation  of  PASMCs  with  17β  estradiol  increased 
tryptophan hydroxylase-1, SERT and 5-HT1B receptor expression.  Consistent with our in 
vivo findings, physiological concentrations of 17β estradiol (1nmol/L) stimulated PASMC 
proliferation whereas estrone, estriol and progesterone had no effect.  This proliferation 
was  successfully  blocked  by  both  the  tryptophan  hydroxylase  inhibitor  para-
chlorophenylalanine and the 5-HT1B receptor antagonist SB224289. 
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Microarray  analysis  in  the  pulmonary  arteries  of  female  SERT+  mice  confirmed  the 
dysregulation of multiple pathways with relevance to PAH including those associated with 
metabolism, cell differentiation and contraction.  A large number of PAH-related pathways 
were also dysregulated in female SERT+ mice exposed to chronic hypoxia.  In contrast, 
pathways were altered in normoxic and chronically hypoxic male SERT+ mice to a much 
lesser extent.  For microarray validation, qRT-PCR analysis was performed in ten selected 
genes (FOS, CEBPB, CYP1B1, MYL3, HAMP2, LTF, PLN, NPPA, UCP1 and C1S) and 
100%  concordance  was  reported.    Three  genes  were  selected  for  further  investigation 
(FOS, CEBPB and CYP1B1).  Immunoblotting confirmed that protein expression of c-
FOS, C/EBPβ and CYP1B1 was increased in the pulmonary arteries of female SERT+ 
mice  compared  against  female  WT  mice.    With  relevance  to  human  PAH,  we  also 
confirmed  that  mRNA  expression  of  FOS,  CEBPB  and  CYP1B1  was  increased  in 
PASMCs derived from IPAH patients.  Protein validation with immunoblotting confirmed 
that c-FOS, C/EBPβ and CYP1B1 expression was also increased in IPAH PASMCs.   
 
In summary of these findings, we have identified that females may be at an increased risk 
to the development of PAH via the effects of 17β estradiol.  Specifically, 17β estradiol 
appears  to  increase  expression  of  several  key  serotonin  pathway  mediators  including 
tryptophan hydroxylase-1 (the rate-limiting enzyme in serotonin synthesis), SERT and the 
5-HT1B receptors, all of which have been previously implicated in the pathogenesis of 
PAH.  Our results suggest that 17β estradiol stimulates PASMC proliferation via activation 
of the serotonin pathway.  Microarray analysis in the pulmonary arteries of SERT+ mice 
confirmed  that  a  large  number  of  genes  associated  with  PAH-related  pathways  were 
differentially expressed in females.  RNA and protein validation further confirmed these 
differences in selected genes (CEBPB, CYP1B1 and FOS).  With relevance to human 
PAH, we also confirmed the dysregulation of several key genes at both mRNA and protein 
level in PASMCs derived from IPAH patients.  Taken together, these findings describe the  
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critical role of 17β estradiol in PAH, and this may offer an explanation for the increased 
susceptibility observed in females.     
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1.1  The Pulmonary Circulation 
1.1.1  Structural Organisation 
The pulmonary circulation constitutes the entire cardiac output from the right ventricle, 
which  receives  mixed  venous  blood  draining  into  the  right  atria  from  the  systemic 
circulation via the superior and inferior vena cava.  The pulmonary artery originates at the 
anterior  base  of  the  right  ventricle  where  it  bifurcates  to  become  the  left  and  right 
pulmonary artery, both of which extend into the hilum of their corresponding lungs.  The 
left lung is divided into the superior and inferior lobe, separated by the oblique fissure and 
each receives an arterial branch from the left pulmonary artery.  In contrast, the right lung 
is divided into three lobes (superior, middle and inferior) separated by interlobular fissures 
and each is supplied with a branch resulting from bifurcation of the right pulmonary artery, 
one entering the superior lobe and the other supplying the middle and inferior lobes.  Each 
of the five lobes can be further subdivided into distinct anatomical compartments termed 
bronchopulmonary  segments  (Sealy  et  al.,  1993).    Each  of  these  contains  segmental 
bronchi and it’s accompanying (tertiary) pulmonary artery.  Subsequent distal branching of 
the  pulmonary  arterial  circulation  continues  irregularly  but  in  parallel  series  with  the 
bronchial tree until the terminal alveoli are reached, which is equivalent to fifteen orders of 
branching.   
 
1.1.2  Functional Organisation 
This order of branching can be numerically categorised by function using the convergent 
approach (Huang et al., 1996).  In convergence, the most peripheral pulmonary arteries 
(the  pre-capillary arteries)  are termed  order  1 and  this  numbering  continues  with each 
proximal  branch-point  until  the  main  pulmonary  artery  (order  15)  is  reached.    The 
proximal elastic arteries (orders 15-13) are highly compliant and typically have an internal  
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diameter greater than 1mm and also have increased elastic laminae in the tunica media to 
facilitate compliance.  The more distal muscular arteries (orders 13-4) progressively lose 
their compliance with continual branching, as a direct consequence of increased smooth 
muscle and decreased elastic laminae in the tunica media.  These pulmonary arteries can be 
phenotypically characterised by the increased presence of medial smooth muscle relative to 
the rest of the vasculature (Heath and Edwards, 1958), and are important in blood pressure 
regulation.  Medial  smooth  muscle  is  completely  diminished  in  the  non-muscular  pre-
capillary arteries (orders 4-1) (Meyrick and Reid, 1983; deMello et al., 1997), which exist 
as  extremely  thin-walled  vessels  composed  of  endothelial  cells  and  pericytes 
(undifferentiated smooth muscle cells) to facilitate blood-gas exchange (Figure 1.1). 
 
The network of pulmonary pre-capillary arteries contains more than 300 million vessels 
over 15 orders of branching.  This ultimately becomes the pulmonary capillary network, 
which  serves  as  an  extremely  distensible  complex  arrangement  of  almost  280  billion 
capillaries.  Each capillary has an internal diameter less than 10µm and supplies blood to 
several alveoli.  Together, the capillaries form a large surface area (125m
2) to efficiently 
facilitate  blood  oxygenation,  and  this  is  the  primary  function  of  the  lung.    Following 
completion  of  circulation  through  the  pulmonary  capillaries,  the  re-oxygenated  blood 
enters the pulmonary venous circulation via the venules and convergent branching of the 
pulmonary veins continue until the left and right pulmonary veins are formed from their 
corresponding lungs, and these enter into the left atria. 
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Figure  1.1 Musculature in  the  pulmonary arteries.  The  absence of mature smooth 
muscle cells is apparent in distal pulmonary arteries and typically replaced with immature 
non-muscular pericytes.  Adapted from (MacLean et al., 2000). 
 
1.1.3  Structure of the Pulmonary Vascular Wall 
 
The transverse section of a normal pulmonary artery reveals that the vessel wall typically 
consists of three concentric layers or ‘tunics’ termed the tunica intima, tunica media and 
tunica adventitia (Figure 1.2).  In addition, each tunic is composed of a population of 
phenotypically  distinct  cells.  The  (innermost)  tunica  intima  exists  as  a  monocellular 
endothelial  cell  layer  attached  to  an  underlying  connective  tissue  matrix,  termed  the 
basement  membrane.    The  pulmonary  artery  endothelial  cells  (PAECs)  compose  the 
lumen,  and  are  unique to  the  vascular  wall in  that  they  are  the  only  cells  in  constant  
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physical contact with blood flow.  PAECs are proposed to continually monitor and regulate 
the luminal environment via the release of various factors (Liu et al., 1994; Aaronson et al., 
2002).  The tunica media is typically the predominant of the three tunics and is composed 
of a conserved longitudinal arrangement of smooth muscle cells with an underlying elastic 
layer.  Pulmonary artery smooth muscle cells (PASMCs), of which several heterogeneous 
populations exist (Frid et al., 1997; Stenmark and Frid, 1998), are the only cell type in the 
vascular wall capable of producing a contractile response following their stimulation, and 
therefore are commonly referred to as the ‘effectors’ in determining arterial tone and blood 
pressure.  The outermost tunica adventitia exists as a collagen matrix and helps maintain 
the structural integrity of the vessel wall.  In addition, pulmonary artery fibroblasts (PAFs) 
also exist in the adventitia, and have been identified to play an important role in response 
to environmental stimuli (Stenmark et al., 2006). 
 
 
Figure  1.2  Vascular  cell  types  which  compose  the  pulmonary  vascular  wall.   
Endothelial cells, smooth muscle cells and fibroblasts primarily compose the pulmonary 
vascular wall. 
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1.1.4  Function of the Pulmonary Circulation 
In the adult circulation both the left and right ventricles are arranged in parallel series.  
Therefore, pulmonary blood flow is exactly equal to that of the left ventricular cardiac 
output, which typically equates to 5 litres per minute at rest and up to 25 litres per minutes 
during exercise.  The most essential function of the pulmonary circulation is to facilitate 
the oxygenation of deoxygenated blood arriving from the systemic circulation, via a blood-
gas interface (Comroe, Jr., 1966).  This continuously occurs by the rapid unloading of CO2 
molecules and subsequent binding of O2 molecules to haemoglobin, which resides within 
red blood cells, and this is vital to supply and maintain the metabolic processes throughout 
the body.   
 
In addition to gas exchange, the pulmonary circulation is required to perform additional 
functions.  For example, the pulmonary circulation acts as a physical barrier, by filtering 
and preventing the passage of inhaled foreign bodies from the respiratory system to the 
cardiovascular system (Comroe, Jr., 1966).  Within the cardiovascular system, it also acts 
as  a  physical  barrier  to  prevent  the  passage  of  potentially  lethal  thrombi,  which  are 
typically formed in the systemic venous circulation, to the systemic arterial circulation.  In 
addition,  thrombolytic  medaitors  synthesised  and  released  from  PAECs,  including 
prostacyclin (Gryglewski et al., 1988) and nitric oxide (Nong et al., 1997), act to dissolve 
lodged  thrombi  via  a  process  termed  fibrinolysis.    Similarly,  air  and  lipid  emboli  are 
rapidly  absorbed  and  removed  during  their  passage  through  the  pulmonary  capillaries.  
Together, the blood filtration function of the pulmonary circulation acts to prevent the 
thrombotic or embolic occlusion of essential arterial beds which may otherwise lead to 
infarction.  The pulmonary circulation may also function as a blood reservoir (Comroe, Jr., 
1966).  Under physiological conditions, about 40% of the total lung weight is blood and 
this equates to a total pulmonary blood volume of 500ml, or 10% of the total circulating 
blood  volume.    Moreover,  this  blood  volume  can  be  rapidly  mobilized  back  into  the  
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circulation during periods of trauma or haemorrhagic shock to significantly improve short-
term cardiac output (Shoemaker, 1974).   
 
1.1.5  Control of the Pulmonary Circulation  
The pulmonary circulation is a high-flow, low-resistance, low-pressure system.  In contrast 
to the arteries which comprise the systemic circulation, the pulmonary arteries contain less 
medial  smooth  muscle  and  elastin,  and  therefore  thinner  walled  allowing  for  greater 
distensibility  (Kilner,  2004).    As  a  consequence,  pulmonary  arterial  pressure  (PAP)  is 
typically 24/9mmHg and significantly lower than systemic arterial pressure (SAP), which 
is typically 120/80mmHg (Morgan et al., 2004).  As a result, the mean PAP (mPAP) is 
roughly 1/8
th of the mean SAP (~15mmHg cf. ~93mmHg).  Similarly, the pressure gradient 
throughout the pulmonary circulation is 7 to 9mmHg, and up to ten-fold lower than those 
which exist in the systemic circulation (Mandegar et al., 2004). 
 
1.1.6  Pulmonary Vascular Resistance 
Pulmonary vascular resistance (PVR) is defined as the total peripheral resistance which 
must  be  overcome  to  maintain  continuous  blood  flow  through  the  pulmonary  arteries.  
According to Poiseuille’s law, the diameter (D) is to the fourth power and therefore even 
small changes in this are likely to significantly affect flow and thus PVR (Krenz et al., 
1994).  For example, a 50% reduction in vessel diameter would result in a 16-fold increase 
in PVR.  Physiologically, blood vessel diameter is regulated via changes in basal tone of 
the  smaller  muscular  pulmonary  arteries  (100µm  -  500µm  ID),  with  vasoconstriction 
decreasing this, whereas the opposite effect would occur during vasodilatation.  This would 
result in an increase/decrease of PVR, and as a consequence cause a reflective change in 
PAP.  The relationship between lumen diameter, PVR and PAP is also essential in the 
pathobiology of pulmonary vascular disease states where elevated PAP is apparent, such as  
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pulmonary hypertension.  Intimal thickening of the pulmonary vascular wall, arising from 
vascular  remodelling,  results  in  an  irreversible  reduction  of  lumen  diameter  and  as  a 
consequence leads to a sustained increase in PAP.      
 
1.1.7  Passive Regulation and Distribution of Blood Flow  
The relatively low pulmonary pressures combined with the mid-entry point of the artery 
into the lung results in the uneven distribution of blood flow throughout the pulmonary 
circulation.    When  upright,  pulmonary  blood  flow  through  the  apex  of  the  lung  is 
extremely low.  However, towards the base of the lung blood flow is greatly increased 
(Lee, 1971).  To explain, the lung is divided into three zones as determined by the relative 
values of the pulmonary arterial (Pa), pulmonary venous (Pv) and alveolar (PA) pressure 
(Figure 1.3).  Zone 1 describes the upper portion of the lung where blood flow is extremely 
low, and this can be explained because the apex alveolar pressure is greater than both the 
arterial and venous pressures (PA > Pa > Pv), resulting in collapse of the highly compliant 
vasculature.  Zone 2 exists in the mid-portion were arterial pressure is greatest, however 
alveolar pressure still exceeds venous pressure (Pa > PA >Pv) and therefore blood flow 
remains  impaired.    In  this  portion  of  lung,  a  modest  increase  in  arterial  pressure  is 
sufficient to functionally recruit the vessels back into the pulmonary circulation.  Zone 3 is 
the most inferior and below-heart level.  At rest, this is the area of the lung where vessel 
recruitment for the pulmonary circulation is greatest (Hughes, 1975).  Both the arterial and 
venous pressures are greater than the alveolar pressure (Pa > Pv > PA) which allows the 
vessels to be maximally distended at all times.  During periods of increased blood flow 
(e.g. stress, exercise), there is substantial recruitment of the pulmonary vasculature which 
exist in zone 1 and zone 2, resulting in an even blood flow distribution throughout the lung 
(Harf et al., 1978). 
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1.1.8  Active Distribution and Regulation of Blood Flow 
In addition to the passive distribution of blood flow, the active regulation of blood flow is 
also a major determinant of pulmonary arterial pressure (Barnes and Liu, 1995).  Active 
factors include sympathetic nerves, humoral mechanisms and respiratory gases.  All of 
these influence PVR via the regulation of pulmonary artery smooth muscle contraction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Passive distribution of blood flow throughout the lung.  Each lung is divided 
into three zones as determined by the pulmonary arterial pressure (Pa), pulmonary venous 
pressure (Pv) and alveolar (PA) pressure.  These are important determinants of  passive 
blood flow through the lung. 
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1.1.8.1  Neural Mechanisms  
The  pulmonary  circulation  is  innervated  by  both  the  sympathetic  (adrenergic)  and 
parasympathetic (cholinergic) branches of the autonomic nervous system (Dawson, 1984).  
In addition, a third neural mechanism comprised of nonadrenergic noncholinergic (NANC) 
nerves,  also  regulates  pulmonary  vascular  tone  (Kubota  et  al.,  1988).  All  innervating 
nerves terminate in the perivasculature and release vasoactive neurotransmitters following 
stimulation.    Vasomotor  regulation  is  an  essential  component  in  maintaining  the 
vasoconstrictor-vasodilator balance in the pulmonary vasculature. 
 
Stimulation of the sympathetic nervous system results in increased neuron firing, increased 
pulmonary  vascular  resistance,  and  as  a  consequence  increased  PAP  (Kadowitz  et  al., 
1974).  Vasoconstriction  is  primarily  mediated  via  the  α  adrenoceptors,  which  are 
predominantly expressed in PASMCs (Hyman et al., 1986).  These receptors are stimulated 
following release of their endogenous ligand noradrenaline from stimulated sympathetic 
post-ganglionic nerves (Tong et al., 1978).  Although all α1 adrenoceptor subtypes are 
expressed in the pulmonary arteries  (Xu et al., 1997), the α1D adrenoceptors appear to 
predominantly  mediate  vasoconstriction  (Hussain  and  Marshall,  1997).    The  α2 
adrenoceptors are not expressed in pulmonary arteries, but are thought to play an important 
role in pulmonary venous constriction (Ohlstein et al., 1989).  In addition, both the β1 and 
β2  adrenoceptor  subtypes  are  expressed  in  the  pulmonary  circulation,  and  mediate 
vasodilatation following their stimulation by noradrenaline (Hyman et al., 1981; Hyman et 
al., 1990). 
 
The parasympathetic branch of the autonomic nervous system appears much less dense in 
the pulmonary arteries compared to sympathetic innervation (Downing and Lee, 1980).  In 
addition, this also appears less important in the regulation of pulmonary vascular tone, as 
its  pharmacological  blockade  does  not  influence  pulmonary  vascular  resistance  or  
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pulmonary arterial pressure (Murray et al., 1986).  However, exogenous administration of 
the  parasympathetic  post-ganglionic  neurotransmitter  acetylcholine  (ACh)  relaxes 
endothelium-intact human pulmonary arteries (Greenberg et al., 1987) via stimulation of 
the endothelial muscarinic (M) receptors (McCormack et al., 1988). 
 
Functional NANC nerves have also been identified in the pulmonary arteries, as observed 
by frequency dependent nitric oxide mediated relaxations which are completely unaffected 
by  adrenergic  or  cholinergic  blockade  in  isolated  pulmonary  arteries  (Scott  and 
McCormack, 1999).  Multiple NANC neurotransmitters have been described as important 
in  this,  including  substance  P,  ATP,  calcitonin-gene  related  peptide  and  adenosine 
(Kobayashi  and  Amenta,  1994).    The  effect  of  NANC  nerves  in  the  regulation  of 
pulmonary vascular tone remains to be described in vivo.   
 
1.1.9  Pulmonary Vascular Contraction 
Increased intracellular [Ca
2+]
 is the major determinant in vasoconstriction, and plays an 
essential  role  in  the  mechanism  of  smooth  muscle  cell  contraction  (Figure  1.4).    The 
calcium-binding protein calmodulin (CaM) forms a complex with Ca
2+ and this construct 
binds  to  and  activates  myosin  light  chain  kinase  (MLCK).    When  activated,  MLCK 
phosphorylates myosin light chain (MLC) in an adenosine 5’ triphosphate (ATP) driven 
process, resulting in a conformational change which allows the interaction of myosin with 
actin filaments (Kuriyama et al., 1982).  These interactions are collectively termed cross-
bridge  cycling  and  it  is  this  mechanism  which  forms  the  basis  of  smooth  muscle 
contraction  (Gunst  and  Fredberg,  2003).    Contraction  is  terminated  via  the  de-
phosphorylation of MLC by myosin light chain phosphatase (MLCP).   
  
  12 
1.1.10  Hypoxic Pulmonary Vasoconstriction 
The pulmonary arteries are unique from those which comprise the systemic circulation in 
that  they  constrict  in  response  to  hypoxia  (Fishman,  1961).    Hypoxic  pulmonary 
vasoconstriction (HPV) is an intrinsic adaptive response to alveolar hypoxia (Madden et 
al., 1992), which results in the redistribution of blood flow throughout the lung to segments 
with greater oxygen supply.  The small resistance arteries (~200µm ID) are the primary 
site  of  HPV  (McCulloch  et  al.,  2000).    This  regulative  shunting  mechanism  ensures 
optimal  ventilation-perfusion  matching,  and  as  a  consequence  more  efficient  blood  re-
oxygenation.  Several observations in the systemic circulation have identified that they 
dilate in response to hypoxia (Gregor and Janig, 1977), confirming that HPV is intrinsic to 
the pulmonary vasculature.  PASMCs are proposed to be the cell type which monitors the 
hypoxic environment in the vasculature.  This is supported by evidence which shows that 
HPV  still  occurs  in  endothelium-denuded  pulmonary  arteries  (Marshall  and  Marshall, 
1992).  Additionally, a contractile response is also observed in cultured PASMCs derived 
from  pulmonary  resistance  arteries  following  their  exposure  to  hypoxia  (Zhang  et  al., 
1997).  In opposition to this others have proposed that, although not essential to HPV, the 
endothelium must be present and functional for a prolonged contractile response following 
sustained hypoxia (Holden and McCall, 1984; Archer et al., 2004).  This suggests the 
existence  of  both  endothelium-dependent  and  endothelium-independent  components  in 
HPV.   
 
HPV is likely initiated by the inhibition of redox-sensitive membrane Kv channels via 
adaptive changes in mitochondria derived reactive oxygen species (ROS) generation.  In 
turn, this leads to cell depolarisation and the opening of L-type Ca
2+ channels, resulting in 
pulmonary vascular contraction.   However at present, several detailed mechanisms have 
been  proposed  for  HPV  (Aaronson  et  al.,  2006).    There  is  general  agreement  that  all 
classical  vasoactive  mediators  which  mediate  constriction  in  both  the  pulmonary  and  
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systemic arteries (e.g. 5-HT, endothelin-1) are unlikely to be involved.  On this basis, the 
initial  mediator  of  HPV  must  be  uniquely  expressed  in  the  pulmonary  vasculature, 
however this component remains to be unanimously identified (Figure 1.5).  Downstream, 
rho-kinase mediated Ca
2+ sensitization of the smooth muscle contractile apparatus is an 
important regulatory component of HPV (Robertson et al., 2000).  The mitochondrial-
derived generation of reactive oxygen species (ROS) is also considered pivotal although 
their exact role still remains unclear as both an increase and decrease of ROS generation 
have been reported in hypoxia (Archer et al., 1989; Archer et al., 1989; Archer et al., 1989; 
Michelakis et al., 2002; Killilea et al., 2000).  The involvement of both Kv1.5 channels and 
L-type Ca
2+ channels has also been described.  In PASMCs, hypoxia leads to decreased 
Kv1.5 and Kv2.1 expression (Wang et al., 1997; Wang et al., 2005), resulting in the net 
reduction of tonic K
+ cellular efflux and as a consequence depolarisation and the opening 
of the L-type Ca
2+ channels.  If hypoxia is adequately sustained for a prolonged period, this 
increase  in  intracellular  Ca
2+  not  only  results  in  vasoconstriction  but  also  stimulates 
expression of several pro-proliferative target genes resulting in hypoxia-induced PASMC 
proliferation (Platoshyn et al., 2007). 
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Figure  1.4  The  mechanism  underlying  pulmonary  vascular  smooth  muscle 
contraction.  Intracellular [Ca
2+] is the major determinant of smooth muscle tone.  The 
formation  of  a  Ca
2+-calmodulin  (CaM)  complex  activates  myosin  light-chain  kinase 
(MLCK), which subsequently phosphorylates myosin light-chain (MCL) to facilitate actin 
and  myosin  interaction  to  promote  contraction.    Contraction  is  terminated  via  the  de-
phosphorylation of MLC by myosin light chain phosphatase (MLCP).    
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Figure  1.5  Proposed  mechanism  of  hypoxic  pulmonary  vasoconstriction  (HPV).  Hypoxia  results  in  decreased  Kv  channel  function,  increased 
intracellular K
+ and membrane depolarisation.  Increased Ca
2+ influx occurs via the depolarisation-activated L-type Ca
2+ channels.  Hypoxia also activates 
the receptor-operated Ca
2+ channels (ROCs) and store-operated calcium channels (SOCCs), further increasing intracellular Ca
2+.  As a consequence, the 
increased cytosolic Ca
2+ promotes smooth muscle contraction, and if sustained will stimulate proliferation.   
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1.2  Pulmonary Arterial Hypertension  
1.2.1  Classification 
Pulmonary  arterial  hypertension  (PAH)  is  a  progressive  disease  characterised  by 
vasoconstriction and remodelling of the pulmonary vasculature, resulting in right heart 
failure  and  eventual  death.  According  to  the  latest  clinical  classification,  PAH  is 
diagnosed if mean pulmonary arterial pressure (mPAP) is greater than 25mmHg at rest 
(Simonneau et al., 2009).  This is typically confirmed following right heart catheterization 
(Barst  et  al.,  2004).    Further  clinical  assessment  is  also  performed  to  confirm  PAH 
aetiology, as multiple diseases not directly associated with the pulmonary circulation (e.g. 
left  heart  failure)  can  indirectly  influence  PAP  (Oudiz,  2007).    Patients  with  mild  or 
moderate PAH typically present asymptomatic at both rest and during physical activity 
(Simonneau et al., 2009).  Only in late-stage/severe PAH, are clinical symptoms apparent 
and include dyspnoea, syncope, chest pain and fatigue.   
 
The mean age of PAH diagnosis is 56 years of age (NCASP Pulmonary Hypertension 
Audit 2010), and patients have a median survival time of 2.8 years if left untreated (Gaine 
and Rubin, 1998).  Although the development of PAH can arise from multiple aetiologies, 
all share a common phenotypic pathobiology (Voelkel and Cool, 2004).  According to the 
World Health Organisation (Rosenkranz and Erdmann, 2008), PAH is subcategorized into 
the following clinical classification (Table 1.1): idiopathic (IPAH), hereditable (HPAH), 
drug  &  toxin  induced,  associated  with  chronic  haemolytic  anaemia,  schistosomiasis, 
congenital heart diseases, portal hypertension, HIV infection or connective tissue diseases, 
and persistent pulmonary hypertension of the newborn (PPHN). Non-arterial pulmonary 
hypertension  can  also  occur  and  is  classified into  the  following  categories;  pulmonary 
hypertension with unclear multifactorial mechanisms; chronic thromboembolic pulmonary 
hypertension (CTEPH), pulmonary hypertension owing to lung diseases and/or hypoxia,  
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pulmonary hypertension owing to left heart disease and pulmonary veno-occlusive disease 
(PVOD) and/or pulmonary capillary hemangiomatosis (PCH).   
Clinical Classification of Pulmonary Hypertension  
4th World Health Organisation Symposium on Pulmonary Hypertension, Dana Point 
2008 
 
1. Pulmonary arterial hypertension (PAH) 
  1.1. Idiopathic PAH 
  1.2. Heritable 
    1.2.1. BMPR2 
    1.2.2. ALK1, endoglin (with or without hereditary hemorrhagic 
telangiectasia) 
    1.2.3. Unknown 
  1.3. Drug- and toxin-induced 
  1.4. Associated with: 
    1.4.1. Connective tissue diseases 
    1.4.2. HIV infection 
    1.4.3. Portal hypertension 
    1.4.4. Congenital heart diseases 
    1.4.5. Schistosomiasis 
    1.4.6. Chronic hemolytic anemia 
  1.5 Persistent pulmonary hypertension of the newborn 
1. Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary 
hemangiomatosis   (PCH) 
2. Pulmonary hypertension owing to left heart disease 
  2.1. Systolic dysfunction 
  2.2. Diastolic dysfunction 
  2.3. Valvular disease 
3. Pulmonary hypertension owing to lung diseases and/or hypoxia 
  3.1. Chronic obstructive pulmonary disease 
  3.2. Interstitial lung disease 
  3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern 
  3.4. Sleep-disordered breathing 
  3.5. Alveolar hypoventilation disorders 
  3.6. Chronic exposure to high altitude 
  3.7. Developmental abnormalities 
4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
5. Pulmonary hypertension with unclear multifactorial mechanisms 
  5.1. Hematologic disorders: myeloproliferative disorders, splenectomy 
  5.2. Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis:  
    lymphangioleiomyomatosis, neurofibromatosis, vasculitis 
  5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid  
         disorders 
    5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on  
     dialysis 
 
Table  1.1  Current  WHO  clinical  classification  of  pulmonary  hypertension.  Dana 
Point 2008.  BMPR2, bone morphogenetic protein receptor type 2; ALK1, activin receptor 
like kinase-1, HIV, human immunodeficiency virus.  
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Current World Health Organization/ New York Heart Association Classification of 
Functional Status of Patients with Pulmonary Hypertension 
   
 
Class I: 
 
 
Patients  with  PH  without  limitation  of  usual  activity.    Ordinary 
physical activity does not cause increased dyspnoea, fatigue, chest 
pain or pre-syncope. 
 
 
 
Class II: 
 
Patients with PH with slight limitation of usual physical activity.  
There is no discomfort at rest, but normal physical activity causes 
increased dyspnoea, fatigue, chest pain or pre-syncope. 
 
 
 
Class 
III: 
 
Patients with PH with marked limitation of usual physical activity.  
There is no discomfort at rest, but less than ordinary activity causes 
increased dyspnoea, fatigue, chest pain or pre-syncope. 
 
 
 
Class 
IV: 
 
Patients  with  PH  with  inability  to  perform  any  physical  activity 
without  symptoms  and  who  may  have  signs  of  right  ventricular 
failure.    Dyspnoea  and/or  fatigue  may  be  present  at  rest  and 
symptoms are increased by almost any physical activity. 
 
Table  1.2  Current  World  Health  Organisation/  New  York  Heart  association 
Classification of functional status in patients with pulmonary hypertension.  
 
The  severity  of  PAH  in  patients  can  be  categorized  using  the  NYHA  (class  I  –  IV) 
functional classification system (Table 1.2).  It is the physical limitations imposed on the 
patient  by  the  disease  which  determines  the  functional  classification.    For  example, 
asymptomatic patients with early-stage PAH reside within class I and those most affected 
(late-stage PAH with right heart failure) are class IV.  The NYHA (class I – IV) system is 
an important factor in both the choice of PAH therapy and is also an accurate predictor of 
patient mortality.      
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1.2.2  Current Therapeutic Strategies in PAH 
PAH results in an elevation of PVR, and as a consequence increased PAP.  To date, all 
current therapeutic strategies act to decrease PVR via the promotion of vasodilatation or 
the inhibition of vasoconstriction.  To date, none of these treatments have proven effective 
in the prevention and/or regression of remodelling in PAH.  These PAH drug therapies can 
be  broadly  categorised  into  the  following  four  groups;  prostanoids,  calcium  channel 
blockers,  endothelin  receptor  antagonists  and  phosphodieasterase-5  (PDE-5)  inhibitors 
(Figure 1.6).  These are typically prescribed in combination as the most effective treatment 
of PAH. 
 
1.2.2.1  Prostanoids 
The  prostanoid  analogue  epoprostenol  was  the  first  FDA-approved  drug  used  in  the 
treatment of PAH, and is still prescribed for severe PAH (NYHA class III and class IV).  
Prostacyclin  (PGI2),  an  endogenous  prostanoid  synthesised  in  PAECs,  is  a  potent 
vasodilator  in  the  pulmonary  circulation  and  also  exhibits  anti-mitogenic  and  anti-
thrombotic properties in experimental PAH (Hoshikawa et al., 2001; Geraci et al., 1999).  
Previously, it has been reported that a deficiency in circulating PGI2, via decreased lung 
expression of PGI2 synthase, contributes to the pathogenesis of PAH (Christman et al., 
1992).    Data  generated  from  clinical  trials  confirm  that  the  chronic  administration  of 
exogenous epoprostenol demonstrate a marked improvement in haemodynamic function, 
exercise capacity and survival time in NYHA class III and class IV PAH patients (Barst et 
al., 1996; Sitbon et al., 2002; Badesch et al., 2000; McLaughlin et al., 2002).  However, the 
chronic intra-venous infusion and short half-life (<6mins) of epoprostenol are the major 
limitations  of  its  use.    Common  side  effects  include  flushing,  jaw  pain,  headache  and 
sepsis, with the latter resulting from intra-venous catheter complications.  Treprostinil is a 
modern generation prostanoid analogue with similar beneficial haemodynamic effects to  
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epoprostenol, but has the advantage of an improved half-life (~3 hours), and can also be 
administered subcutaneously.  Recently, the inhaled prostanoid iloprost has also been FDA 
approved for therapeutic use, and this improved route of administration will bypass the 
side effects associated with other prostacyclin-based treatments. 
 
1.2.2.2  Calcium Channel Blockers 
Calcium channel blockers (CCBs) comprise a class of drugs which act to functionally alter 
calcium channel Ca
2+ conductance.  In PASMCs, the consequence is a net decrease in 
[Ca
2+]i  and  cellular  hyperpolarisation,  resulting  in  pulmonary  vascular  smooth  muscle 
relaxation.  Clinical trials involving the use of CCBs in PAH have shown their beneficial 
therapeutic  effects, with  a  marked  improvement  in  survival  rate observed (Rich et al., 
1992).  However, this was only apparent in a subset of patients.  Subsequently, it was 
identified that CCB therapy is only an effective treatment in patients who are vasoreactive 
(the pulmonary vasculature still responds to local mediators via relaxation or contraction) 
(Sitbon et al., 2005).  Only a reported 5-10% of PAH patients exhibit vasoreactivity, and 
therefore CCBs have limited therapeutic use.  Significant adverse events including the 
increased risk of fatality can also occur as side-effects of CCB administration.  This is 
typically observed in NYHA class IV PAH patients with right ventricular failure, and is a 
likely consequence of their pronounced negative ionotropic effects. 
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Figure 1.6 Current therapeutic targets in PAH.  Current PAH therapies (endothelin 
receptor  antagonists,  phosphodiesterase  type  5  inhibitors,  inhaled  nitric  oxide  and 
prostacyclin derivatives) act to promote vasodilatation and inhibit proliferation.  Adapted 
from (Humbert et al., 2004). 
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1.2.2.3  Endothelin Receptor Antagonists 
Endothelins are a class of vasoactive peptides which are synthesised and released from 
both  systemic  and  pulmonary  artery  endothelial  cells.  Endothelin-1  (ET-1)  is  the 
predominant isoform within the pulmonary circulation, and circulating levels are reported 
to be increased in at least two different forms of PAH (Giaid et al., 1993; Galie et al., 
2004).  ET-1  is  a  potent  vasoconstrictor  in  pulmonary  arteries  and  also  stimulates 
proliferation in PASMCs (McCulloch et al., 1998).  Currently, two endothelin receptor 
isoforms  (ETA  and  ETB)  have  been  identified,  both  of  which  are  G-coupled  protein 
receptors (GPCRs).  Endothelin receptor A (ETA) is primarily expressed in the PASMCs 
and  mediates  both  vasoconstriction  and  smooth  muscle  cell  proliferation  following 
stimulation  (Zamora  et  al.,  1993).    In  comparison,  endothelin  receptor  B  (ETB)  is 
predominantly expressed in the PAECs and to a lesser extent in PASMCs (Hori et al., 
1992).  In the lung, ETB stimulation appears to promote pulmonary artery vasodilatation 
via both NO and PGI2 mediated release, which would decrease pulmonary vascular tone 
(Fukuroda et al., 1992).  Therefore on this basis, selective ETA inhibitors would prove most 
effective for endothelin-based therapy in PAH.   
 
Sitaxsentan and ambrisentan, both which are ETA selective antagonists, are currently under 
clinical investigation for their potential use in PAH (Benza et al., 2007; Benza et al., 2008; 
Galie  et  al.,  2008;  Galie  et  al.,  2005).  To  date,  the  non-selective  endothelin  receptor 
antagonist bosentan is the only FDA-approved drug for treatment in its class (Sitbon et al., 
2003;  Channick  et  al.,  2001;  Channick  et  al.,  2001).  Clinical  trials  have  reported  an 
improvement  in  pulmonary  haemodynamics,  exercise  capacity  and  functional  class 
following  its  use.  Bosentan  is  generally  well-tolerated,  but  hepatic  toxicity  and  a 
prolonged time period (~12 weeks) from the start of treatment to clinical improvement are 
the major disadvantages to this therapy.   
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1.2.2.4  Phosphodiesterase Type 5 Inhibitors 
NO released from PAECs acts paracrinally on the underlying PASMCs to activate the 
NO/cGMP pathway, resulting in increased levels of the second messenger cyclic guanosine 
monophosphate (cGMP).  Activation of this pathway results in cGMP-mediated protein 
kinase  G  (PKG)  activation,  decreased  [Ca
2+]i  and  vasodilatation.  Phosphodiesterases 
(PDEs) are a class of enzymes which mediate the hydrolysis of cGMP.  Phosphodiesterase-
5 (PDE-5) is the most abundantly expressed PDE-isoform within the lung, and its activity 
and expression is also reported to be further increased in PAH (Black et al., 2001).  The 
highly selective PDE-5 inhibitor sildenafil acts to inhibit the hydrolysis of cGMP, therefore 
prolonging its half-life.  As a consequence, this leads to improved vasodilatation. PDE-5 
inhibition is reported to inhibit PASMC proliferation (Wharton et al., 2005) and attenuate 
hypoxia-induced  PAH  (Zhao  et  al.,  2001).    Indeed,  improvements  in  both  NYHA 
functional  class  and  exercise  capacity  have  been  reported  in  PAH  patients  when 
administered sildenafil treatment (Galie et al., 2005).  Although randomized clinical trials 
remain to be carried out, PDE-5 inhibitors have thus far proven to be an effective PAH 
treatment.  However, minor side effects are reported (headache, indigestion, muscle aches) 
and in rare cases ventricular arrhythmia, stroke and hearing loss have also been described. 
 
1.2.2.5  Combination Therapy 
It is generally considered that the simultaneous targeting of multiple pathways is the most 
effective treatment strategy in PAH (Benza et al., 2007).  This is achieved via adjunctive or 
combinational therapy.  Multiple clinical trials involving the use of multiple treatments 
have  been  described,  and  results  appear  promising  with  improvements  in  both 
haemodynamics and exercise capacity being reported (Benza et al., 2008). 
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1.2.3  Future Perspectives in the Treatment of PAH 
Although recent advances in PAH therapy have led to significant improvements in survival 
rate,  prognosis  still  remains  relatively  poor  in  patients.    A  15%  mortality  rate  is  still 
reported at 2 years even in those undergoing advanced PAH therapy.  For this reason, an 
improvement  in  current  therapies  and  the  discovery  of  novel  treatments  is  urgently 
required.  This has led to the research-led discovery of multiple novel drugs which may be 
beneficial for the treatment of PAH. 
 
1.2.3.1  Tyrosine Kinase Inhibitors 
Platelet-derived growth factor (PDGF) signalling is one potential target in the treatment of 
PAH (Grimminger and Schermuly, 2010).  The family of PDGF ligands, which exist as 
PDGF A-D and form homodimers or heterodimers, bind to and activate PDGF receptors 
(PDGFRs).  To date, two PDGFR isoforms have been identified, and are termed PDGFR-α 
and  PDGFR-β.  The  stimulation  of  PDGFR-α  and  PDGFR-β  activates  multiple  signal 
transduction  pathways,  resulting  in  the  phosphorylation  of  various  mitogen-activating 
protein  kinases  (MAPKs)  including  ERK  and  P38.    As  a  consequence,  these  undergo 
nuclear translocation and regulate expression of multiple immediate early-response target 
genes (e.g. c-fos).  These genes directly regulate proliferation, migration, differentiation 
and  apoptosis,  all  of  which  are  essential  cellular  components  in  pulmonary  vascular 
remodelling.  Indeed, PDGF stimulation of PASMCs results in increased proliferation (Yu 
et al., 2003).  In vivo, the PDGF receptor inhibitor STI571 (Imatinib) reverses established 
disease in at least two experimental models of PAH (Schermuly et al., 2005).  In human 
PAH,  PDGF  is  also  important  (Perros  et  al.,  2008)  and  several  clinical  studies  have 
demonstrated the beneficial effects of Imatinib in the treatment of PAH (Ghofrani et al., 
2005).  Imatinib has been recently investigated in a phase II clinical trial (Ghofrani et al., 
2010),  which  demonstrated  that  NYHA  functional  class  III-IV  showed  a  marked  
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improvement following treatment highlighting its potential therapeutic benefits in severe 
PAH. 
 
1.2.3.2  Statin Therapy 
Another novel approach in the treatment of PAH is statin therapy.  Statins act to reduce 
isoprenoid  synthesis  via HMG-CoA  reductase  inhibition  (Goldstein  and Brown, 1990).  
Cholesterol is the most widely recognised isoprenoid.  Statins are involved in the post-
translational modification of rho and ras GTPases, and their use have been reported to 
decrease reactive-oxygen species (ROS) generation, inflammation and proliferation.  This 
may be mediated in part via the upregulation of endothelial nitric oxide synthase (eNOS) 
(Laufs  et  al.,  1998).  Experimentally,  simvastatin  treatment  successfully  prevents 
(Nishimura  et  al.,  2002)  and  reverses  (Nishimura  et  al.,  2003)  monocrotaline-induced 
PAH.  Similar results have also been observed in hypoxia-induced PAH (Girgis et al., 
2003; Girgis et al., 2007).  The inhibition of rho-kinase appears important to this (Girgis et 
al., 2007).  In human PAH, a moderate improvement is observed in patients prescribed 
simvastatin (Wilkins et al., 2010).  However, this effect appears transient and lasts less 
than 12 months.  An improvement in drug design and/or drug delivery may result in a more 
sustained beneficial effect for this therapy. 
 
In addition to PDGF inhibition and statin therapy, a number of potentially beneficial PAH 
treatments are also under investigation.  In combination with current PAH therapies, these 
may be effective in the treatment of PAH.   
 
1.2.4  Pathobiology of PAH 
PAH is a disease with a multifactorial pathobiology.  Vasoconstriction, thrombosis and 
vascular remodelling all contribute to increased pulmonary vascular resistance observed in  
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PAH (Tuder et al., 2009).  Within the vasculature, increased vasoconstriction is recognized 
as the initiating factor which promotes disease progression (Mandegar et al., 2004).  This 
sustained elevation in vasoconstriction consequently results in an elevation of pulmonary 
vascular resistance.  If this persists, the activation of multiple stress-related pathways occur 
within pulmonary vascular cells (endothelial cell, smooth muscle cell, fibroblast), resulting 
in  vascular  remodelling.  Currently,  pulmonary  vascular  remodelling  is  an  irreversible 
component of PAH, and is considered the hallmark of disease pathogenesis (Hassoun et al., 
2009).  As a consequence of this, the pressure-intolerant right ventricle is subjected to 
increased after-load and subsequently right  ventricular  hypertrophy.  Although  initially 
compensatory, this eventually leads to right ventricular failure, and this is the primary 
cause  of  mortality  in  PAH  patients  (Klepetko  et  al.,  2004).  The  identification  and 
pharmacological  targeting  of  signalling  pathways  which  promote  pulmonary  vascular 
remodelling  is  considered  the  best  treatment  approach  in  the  regression  of  PAH.  
Currently, several aberrant signalling pathways have been identified, which are stimulated 
by  their  respective  pathway  mediators.    These  include  serotonin,  endothelin-1, 
prostacyclin, nitric oxide, angiopoetin-1, cytokines, chemokines and TGF-β.  
 
1.2.4.1  Vasoconstriction 
Excessive vasoconstriction is considered an essential initiating factor in the development 
of PAH (Mandegar et al., 2004).  If sustained, this leads to endothelial cell dysfunction and 
the impaired production of vasodilators such as nitric oxide and prostacyclin.  This in 
combination  with  the  increased  synthesis  of  several  vasoconstrictors  (e.g.  serotonin, 
endothelin-1)  results  in  a  marked  elevation  of  pulmonary  vascular  resistance.    This 
sustained elevation of pulmonary arterial pressure is considered the ‘pre-cursor’ resulting 
in pulmonary vascular remodelling.            
  
  27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 Histopathological changes associated with human and experimental PAH.  
Top  Left,  A:  A  normal  human  pulmonary  artery.    Top  Right,  B:  Smooth  muscle 
hypertrophy  leading  to  medial  hyperplasia  typically  observed  in  mild/moderate  human 
PAH.  Middle Left, C:  Adventitial fibrosis typically observed in moderate human PAH.  
Middle  Right,  D:    Plexiform  lesion  characterised  by  lumen  obliteration  observed  in 
severe/end-stage human PAH.  Bottom Left, E:  Normal mouse pulmonary artery, Bottom 
Right, F:  Medial hypertrophy observed in a mouse pulmonary artery following exposure to 
chronic hypoxia, note the failure to recapitulate plexiform lesion formation.  A-D adapted 
from (Cool et al., 2005). 
B  A 
C  D 
E  F  
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1.2.4.2  Pulmonary Vascular Remodelling 
PAH is characterised by intimal thickening of the pulmonary vascular wall, resulting in the 
impairment  of  blood  flow  through  the  lumen.    This  disease  component  arises  from  a 
process termed pulmonary vascular remodelling, and is considered the hallmark in PAH 
pathogenesis  (Tuder  et  al.,  2009).  PAH  is  associated  with  increased  proliferation 
combined  with  suppression  of  apoptosis,  and  this  is  the  primary  cause  of  pulmonary 
vascular remodelling.  Each of the three predominating cell types (endothelial, smooth 
muscle, fibroblast) contributes to this.  Typically, a transverse section of a remodelled 
pulmonary artery reveals neointimal thickening and fibrosis, smooth muscle hypertrophy 
arising from PASMC hyperplasia and adventitial thickening and/or fibrosis (Figure 1.7). 
 
There are  several  histopathological subtypes  of  pulmonary  vascular remodelling which 
exist in human PAH (Cool et al., 2005).  Smooth muscle hyperplasia and thickening is 
widely  apparent  and  typically  observed  in  mild/early-stage  PAH.  Patients  with 
moderate/mid-stage PAH also exhibit marked advential fibrosis in addition to increased 
medial thickness (Humbert et al., 2004).  In severe/end-stage PAH, plexiform lesions are 
usually present and represent the most severe subtype of pulmonary vascular remodelling.  
These  are  most  commonly  observed  at  bifurcation  points  in  smaller  resistance  arteries 
(<200µm  external  diameter)  and  exist  as  an  accumulation  of  disarranged  proliferative 
endothelial  cells  which  result  in  pronounced  neointimal  formation  and  marked  intimal 
thickening  (Cool  et  al.,  2005).    The  consequence  of  plexiform  lesion  development  is 
complete obliteration of the artery, resulting in the severe impairment and cessation of 
blood flow through the lumen (Tuder et al., 1994). The pathological process leading to 
their formation remains an area of intense investigation.  Neoplasia likely contributes to 
plexiform  lesion  formation.    For  example,  loss  of  the  tumour  suppressor  gene        
peroxisome proliferator-activated receptor-γ (PPAR-γ), is reported in plexiform lesions of 
PAH patients (Ameshima et al., 2003).  PPAR-γ is antiproliferative and anti-inflammatory  
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(Jiang et al., 1998) and has been previously shown to mediate an important protective role 
in  experimental  PAH  (Hansmann  et  al.,  2008).    Restoring  function  of  such  apoptotic 
pathways would result in inhibition of progressive pulmonary vascular remodelling, and 
considered the most effective therapeutic strategy in PAH.    
 
Established  models  of  PAH  (e.g.  hypoxia,  monocrotaline)  fail  to  recapitulate  severe 
plexiform lesion histopathology.  Recently, several experimental models which exhibit a 
similar lung pathobiology have been recently generated for study into their progressive 
pathobiology.  These include the S100A4/mts1 over-expressing murine model (Greenway 
et al., 2004; Spiekerkoetter et al., 2008), schistosomiasis murine model (Crosby et al., 
2010), and vascular endothelial growth factor (VEGF) antagonist Sugen 5416 + hypoxia 
rat model (Abe et al., 2010).     
 
The exact stimulus leading to abnormal endothelial cell proliferation remains unknown but 
may include shear stress, hypoxia, drugs/toxins and/or genetic susceptibility (Humbert et 
al., 2004).  Initial endothelial apoptosis is considered important to this, which results in 
both  a  vasoconstrictor/vasodilator  imbalance  whilst  also  exposing  the  PASMCs  to 
circulating  mitogenic  factors.    For  example,  BMPR-II  signalling  promotes  survival  in 
PAECs  (Teichert-Kuliszewska  et  al.,  2006).    Therefore,  an  overall  reduction  in  this 
signalling pathway (i.e. as observed in BMPR-II loss of function mutation carriers) may 
instead  promote  endothelial  cell  apoptosis  (Teichert-Kuliszewska  et  al.,  2006).  As  a 
consequence, loss of functional endothelium may promote the stimulation of PASMCs via 
their exposure to circulating mitogenic factors. 
 
One feature common to PAH is the distal progression of smooth muscle into the normally 
non-muscular  small  peripheral  pulmonary  arteries.  This  results  in  pronounced 
muscularisation of the terminal portion of the pulmonary arterial circulation (MacLean et  
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al., 2000).  Neointimal formation is also a common feature in severe PAH, as discussed 
previously.  The neointima is composed of a pronounced extracellular matrix surrounded 
with a layer of myofibroblasts, and is situated between the endothelium and internal elastic 
laminae.  Regardless  of  the  histopathologic  subtype,  pulmonary  vascular  remodelling 
always results in increased obstruction of the lumen and the impairment of blood flow. 
 
1.2.5  Genetic Basis of Pulmonary Arterial Hypertension 
1.2.5.1  Bone Morphogenetic Protein Type 2 Receptor 
PAH is a disease with underlying genetic susceptibility.  That is, those individuals who 
inherit specific genotypes are more likely to develop PAH.  This is termed heritable PAH 
(HPAH).    The  inheritance  pattern  for  HPAH  is  autosomal  dominant  (Thompson  and 
McRae,  1970).    Therefore,  each  child  of  an  affected  individual  is  at  a  50%  risk  of 
inheriting the mutant allele.  Both genetic anticipation and female bias exists in HPAH 
(female 3:1 male).  Therefore, it is predicted that younger females are the risk category 
most susceptible to the development of HPAH.  Initially, the first identified disease locus 
was  mapped  to  chromosome  2q31-32,  and  was  termed  PPH1  (Morse  et  al.,  1998).  
Subsequently,  this  gene  was  identified  as  the  bone-morphogenetic  protein  receptor-2 
(BMPR-II) (Lane et al., 2000).  BMPR-II mutations are widely recognized as the most 
common  cause  of  HPAH,  with  mutation  carriers  up  to  ~100,000  times  more  likely  to 
develop HPAH. These individuals are also accountable for up to 80% of HPAH cases 
(Morrell, 2010).  Despite this, penetrance for the gene remains relatively low as only ~20% 
of  mutation  carriers  actually  develop  HPAH  (Newman  et  al.,  2004).    Therefore,  it  is 
assumed  that  other  genetic  and/or  modifying  risk  factors  contribute  to  this  disease 
pathogenesis. 
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BMPR-II mediated dysfunction of transforming growth factor β (TGF- β) signalling is the 
pre-dominant  genetic  cause  of  PAH  (Figure  1.8).    However  in  addition  to  BMPR-II 
mutations,  alternative  members  of  the  TGF-β  family  may  also  render  those  affected 
individuals susceptible to the development of PAH.  Activin receptor-like kinase 1 (ALK-
1) receptor mutations are associated with hereditary hemorrhagic telangiectasia (HHT), but 
may also render those individuals susceptible to the development of PAH (Trembath et al., 
2001; Harrison et al., 2003).  This mutation, which results in defective SMAD signalling, 
leads to both an earlier-age of PAH onset and poorer prognosis in carriers when compared 
to those without the mutation. 
 
1.2.5.2  Serotonin Transporter  
Another genetic risk factor is the serotonin transporter (SERT).  SERT is encoded by the 
solute carrier family 6 member 4 (SLC6A4) gene located on chromosome 17 position 
17q11.2.  The SERT promoter region (SERTPR) contains a polymorphism which exists as 
short (S) or long (L) repeats in the region, the S allele has 14 repeats of a sequence, whilst 
the L allele has 16 repeats.  The S allele results in reduced SLC6A4 transcription and 
therefore reduced SERT protein expression.  SERT is an integral membrane protein that 
facilitates the transport of serotonin across the membrane in a  Na
+ dependant manner.  
SERT is implicated in the pathogenesis of both experimental and human PAH.  Mice over-
expressing  the  human  SERT  gene  construct  (SERT+  mice)  develop  PAH  and  severe 
hypoxia-induced PAH (MacLean et al., 2004).  Similarly, mice with targeted SERT over-
expression in the PASMCs develop PAH (Guignabert et al., 2006), whilst mice devoid of 
the SERT gene are protected against the development of hypoxia-induced PAH (Eddahibi 
et al., 2000).  SERT expression is also increased in PASMCs derived from idiopathic PAH 
(IPAH) patients and these proliferate to a greater extent than those from controls following 
serotonin  stimulation,  which  is  dependent  on  SERT  activity  (Eddahibi  et  al.,  2006).   
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Indeed, the LL allele SERTPR polymorphism, which leads to increased activity/expression 
of SERT, has been associated with the increased development of PAH in a small cohort of 
patients (Eddahibi et al., 2001).  Subsequent studies in larger patient studies have failed to 
support these findings, although patients with the SERT polymorphism may present at an 
earlier age than those without (Willers et al., 2006). 
 
1.2.5.3  Transient Receptor Potential Channel 6 
Recently,  a  single-nucleotide  polymorphism  (SNP)  in  the  transient  receptor  potential 
cation  channel,  subfamily  C,  member  6  (TRPC6)  has  been  identified  which  may 
predispose  those  individuals  to the development  of PAH  (Yu et  al., 2009).  Increased 
frequency  of  the  -254  (C→G)  SNP  in  the  TRPC6  gene  is  associated  with  increased 
incidence of PAH.  It is assumed that this SNP leads to both increased transcription and 
function  of  TRPC6,  and  as  a  consequence  defective  cytosolic  Ca
2+  handling  in  the 
PASMCs, leading to increased vasoconstriction and proliferation. 
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Figure  1.8  Bone  morphogenetic  protein  receptor-2  signalling  in  PAH.  Following 
ligand binding (BMP-2,-4,-7), BMPR-II heterodimerizes with a type-I receptor (BMPR1A, 
1B,  ALK-1)  and  phosphorylates  the  type-I  glycine-serine  rich  tail  domain.  
Heterodimerization  initiates  nuclear  translocation  of  PSmad1/5/8  via  co-Smad  4,  or 
alternatively initiates smad independent P38MAPK signalling.  As a consequence, these 
pathways regulate transcription of several target genes (e.g cyclin D1, GATA-4, Id1, Id2) 
which regulate transcription and proliferation.        
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1.3  Serotonin Biosynthesis and Metabolism  
Serotonin (5-hydroxytryptamine; 5-HT) was first described following its isolation from 
serum  (Rapport  et  al.,  1948).  Physiologically,  serotonin  circulates  at  very  low 
concentrations  (<1nmol/L)  and  is  maintained  via  SERT-mediated  uptake  into platelets, 
which act as a store for up to 99% of total peripheral serotonin.  Over 80% of peripheral 
serotonin synthesis occurs in the intestinal enterochromaffin cells, with the remaining 20% 
synthesised in other cell types including serotonergic neurons and PAECs (Hoyer et al., 
2002).  Serotonin  controls  many  physiological  functions  in  the  cardiovascular  system, 
including heart rate and vascular tone (Berger et al., 2009).  In addition to this, serotonin 
regulates the  function of  multiple other  organs including the brain (e.g. the control  of 
respiration, memory, nociception) and intestine (Hoyer et al., 2002).   
 
Serotonin  is  synthesised  via  the  hydroxylation  and  subsequent  decarboxylation  of  its 
biochemical pre-cursor tryptophan (Figure 1.9).  This two-step biosynthetic pathway is 
catalysed by tryptophan hydroxylase (TPH) and the aromatic L-amino acid decarboxylase, 
respectively.    TPH  is  the  rate-limiting  enzyme  involved  in  serotonin  synthesis,  and 
specifically catalyses the hydroxylation of tryptophan via the addition of a hydroxyl group 
(–OH)  to  the  5  position,  resulting  in  the  formation  of  5-hydroxytryptophan  (5-HTP).  
Currently, two genes have been identified which encode for TPH, and are termed tph1 and 
tph2 (Walther et al., 2003).  These tph isoforms share 71% sequence homology.  Although 
both  are  functionally  identical,  TPH1  mediates  peripheral  serotonin  synthesis  whereas 
TPH2 mediates central serotonin synthesis. 
 
Serotonin  inactivation occurs  via  its  rapid  metabolism  in  the liver  and  lung  (Hart  and 
Block, 1989).  Monoamine oxidase-A (MAO-A) initiates this metabolism via oxidative 
deamination (removal of –NH2 group) of the amino chain.  The product, 5-hydroxyindol-
acetaldehyde,  is  subsequently  oxidised  to  5-hydroxyindole  acetic  acid  (5-HIAA)  by  
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aldehyde dehydrogenase.  5-HTIAA is the primary serotonin metabolite produced and is 
excreted in the urine following conjugation.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  1.9  Serotonin  biosynthesis  and  metabolism.  The  amino  acid  tryptophan  is 
converted to 5-hydroxy-L-tryptophan/5-HTP via tryptophan hydroxylase.  This is the rate-
limiting  enzyme  in  serotonin  synthesis.    Subsequently,  non-specific  decarboxylase 
enzymes convert 5-HTP to serotonin.  Serotonin metabolism to 5-hydroxyindoleacetic acid 
occurs via both monoamine oxidase and aldehyde dehydrogenase.  Adapted from (Druce et 
al., 2009).          
  36 
1.4  Serotonin Signalling 
A  wealth  of  evidence  exists  which  suggests  that  the  serotonin  system  facilitates  the 
development of human and experimental PAH (MacLean and Dempsie, 2010).  Elevated 
levels of circulating serotonin have also been reported in PAH (Herve et al., 1995).  The 
exogenous administration of serotonin promotes the development of PAH in rats and also 
uncovers a PAH phenotype in BMPR-II-/- mice (Long et al., 2006).  Within the pulmonary 
circulation, serotonin signalling is mediated via three distinct pathway components.  These 
are TPH1, SERT and the 5-HT receptors.  In addition, stimulation of SERT and/or the 5-
HT  receptors  initiates  multiple  downstream  signalling  pathways  which  are  essential  to 
serotonin signalling. 
 
1.4.1  Tryptophan Hydroxylase 
Tryptophan  hydroxylase  (TPH)  catalyses  the  rate-limiting  step  involved  in  serotonin 
synthesis.  Currently, two TPH isoforms have been described (Walther et al., 2003), and 
are termed TPH1 and TPH2.  These are distinguishable by sequence heterology and their 
location of expression.  TPH2 is exclusively expressed in the central nervous system, and 
completely  absent  in  the  periphery.  In  contrast,  TPH1  mediates  peripheral  serotonin 
synthesis and is predominantly expressed in the intestinal enterochromaffin, and to a lesser 
extent  in  PAECs.    Although  the  enterochromaffin  cells  synthesise  up  to  80%  of  total 
peripheral  serotonin,  local  serotonin  synthesis  within  the  PAECs  is  also  considered 
important.  This local synthesis is thought to facilitate a ‘serotonin micro-environment’ 
which promotes the vasoconstrictive and mitogenic effects of serotonin on the underlying 
PASMCs.  Indeed,  this  appears  to  play  a  role  in  the  pathogenesis  of  PAH  as  TPH1 
expression  is  increased  in  both  the  lungs  and  PAECs  derived  from  IPAH  patients 
(Eddahibi et al., 2006).          
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TPH1  expression  is  influenced  by  a  number  of  physical,  environmental  and  humoral 
factors.  As a consequence, this affects serotonin synthesis.  For example, TPH1 expression 
is  increased  in  pulmonary  neuroendocrine  cells  following  stimulation  by  mechanical 
stretch (Pan et al., 2006).  Also, stimulation of the Tie-2 receptor via the growth factor 
angiopoietin-1  (Ang-1)  stimulates  serotonin  synthesis  in  PAECs  via  increased  TPH1 
expression (Dewachter et al., 2006). 
 
Previously, we have made unpublished observations that TPH1 is abundantly expressed in 
the pulmonary arteries of mice following exposure to chronic hypoxia.  Specifically, TPH1 
appears to be localised to the pulmonary endothelium.  Indeed, mice deficient of the tph1 
gene  (tph1-/-  mice)  do  not  develop  hypoxia-induced  PAH  (Morecroft  et  al.,  2007), 
suggesting the importance of peripheral serotonin synthesis in its development.  
 
1.4.2  5-HT Receptors  
There are a total of 14 structurally distinct 5-HT receptor types (Figure 1.10).  These are 
divided into seven classes (5-HT1-7), defined by their structure and downstream coupling to 
signal transduction pathways (Alexander et al., 2006).  In addition, several isoforms can 
exist for the same 5-HT receptor subtype (e.g. 5-HT1 receptors comprise the 5-HT1A, 5-
HT1B and 5-HT1D) as a result of alternative splicing and RNA editing.  All of the 5-HT 
receptors  exist  as  membrane-bound  G  protein  coupled  receptors  (GPCRs),  with  the 
exception of the 5-HT3 receptor which operates as a ligand-gated ion channel (Hoyer et al., 
2002).   
 
The 5-HT GPCRs all share similar structural homology.  They contain an extracellular N 
terminus domain, seven transmembrane α-helices and an intracellular C terminal domain 
(Figure 1.11).  Following ligand binding at the extracellular portion of the receptor, this  
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initiates  activation  of  the  associated  (or  ‘coupled’)  G-protein.    G-proteins  exist  as 
heterotrimeric structures composed of α, β and γ subunits.  These are typically classified by 
their  α-subunit  type,  of  which  four  exist;  Gs,  Gi,  Gq  and  G12/13  (Figure  1.12).  Each 
respective G-protein initiates its own unique downstream signalling transduction pathways, 
and therefore the cellular function of a GPCR will be ultimately determined by the G-
protein it is coupled with.  For example, the Gs subunit increases adenylyl cyclase (AC) 
whereas the Gi subunit inhibits AC.  Also, the Gq and G12/13 subunits activate phospholipase 
C (PLC) and small G-proteins, respectively.  In addition, five β subunits and twelve γ 
subunits have also been described (Milligan and Kostenis, 2006).  G-proteins are typically 
coupled  to  their  respective  GPCR  via  a  direct  interaction  with  the  second  or  third 
intracellular loop (Hoyer et al., 2002).  Specifically, the binding of a ligand to its receptor 
initiates  a  conformational  change  which  promotes  the  exchange  of  guanosine  5'-
diphosphate  (GDP)  for  guanosine  5'-triphosphate  (GTP)  at  the  guanosine  nucleotide 
binding site within the Gα subunit (Hamm, 1998).  In turn, G-protein activation results in 
dissociation of the Gα subunit from the Gβγ complex, and both entities activate downstream 
signalling pathways.   
 
Figure  1.10  Classification  of  the  14  structurally  distinct  5-HT  receptor  subtypes.  
Those highlighted in red have been previously shown to mediate serotonin effects in PAH.  
5-HT receptor subtypes denoted in lower case indicate that their physiological role remain 
to be described   
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Figure  1.11  Representative  structure  of  a  G-protein  coupled  receptor  (GPCR).  
GPCRs typically exist of an extracellular N-terminus domain, seven transmembrane alpha-
helices and an intracellular C-terminus domain.  The ligand binds directly to the GPCR, 
and glycosylation of the N-terminus domain is involved in cell trafficking. 
 
 
 
 
 
Receptor     Type             Mechanism  
   
5-HT1      Gi/Go            Decreased cAMP    
5-HT2      Gq/G11           Increased IP3 and  
                  DAG     
5-HT3      Ligand-gated Na
+ and K
+ cation channel.   Depolarisation  
5-HT4      Gs            Increased cAMP  
5-HT5      Gi/Go            Decreased cAMP  
5-HT6      Gs            Increased cAMP    
5-HT7      Gs            Increased cAMP 
      
Figure 1.12 5-HT receptor subtype signalling pathways.  All 5-HT receptor subtypes act 
via an intracellular second messenger, with the exception of 5-HT3, which is a ligand-gated 
ion channel.  
Glycosylation 
Transmembrane 
Domains 
Extracellular Loops 
Ligand 
Plasma Membrane 
Intracellular Loops  
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1.4.2.1  5-HT1 Receptor Subtypes 
The 5-HT1 class of receptors comprise five subtypes (5-HT1A, 5-HT1B, 5-HT1D, 5-ht1E and 
5-ht1F), and these share 40-63% sequence homology.  Both the 5-ht1E and 5-ht1F receptors 
are  represented  in  lower  case  to  denote  that  their  physiological  role  remains  to  be 
determined.  All 5-HT1 receptors are coupled to the Gi protein.  Therefore, stimulation of 
the receptor and G-protein activation results in the inhibition of AC and cAMP production.  
All 5-HT1 receptor subtypes are expressed in both the CNS and periphery.  Specifically, it 
is the 5-HT1B and 5-HT1D receptors which predominantly mediate serotonin effects in the 
cardiovascular  system.    Although  5-HT1D  receptor  expression  is  relatively  low  in 
comparison to the 5-HT1B receptor, it has been shown to evoke serotonin release from 
cardiomyocytes in humans, and is also important in inflammation (Hoyer et al., 2002).  
Indeed, 5-HT1D receptor antagonists are currently prescribed in the treatment of migraine 
(Cutrer et al., 1999).   
 
The 5-HT1B receptors are expressed in nerve terminals where they act as auto-receptors in 
the release of several neurotransmitters including noradrenaline and acetylcholine (Hoyer 
et al., 2002).  In the cardiovascular system, it mediates serotonin-induced vasoconstriction 
in  both  cerebral  (van  den  Broek  et  al.,  2002)  and  pulmonary  (Morecroft  et  al.,  1999) 
arteries.  With respect to the pulmonary circulation in humans, the 5-HT1B subtype is the 
primary 5-HT receptor which mediates receptor-driven serotonin signalling.  For example, 
it  is  implicated  in  both  serotonin-induced  pulmonary  arterial  vasoconstriction  and 
proliferation, both of which are hallmarks of PAH.  Indeed, up-regulation of the 5-HT1B 
receptor  has  already  been  described  in  experimental  PAH  (Rondelet  et  al.,  2003).    A 
functional role for the 5-HT1B receptor was initially described following the observation 
that  sumatriptan  (5-HT1B/1D  receptor  agonist)  stimulated  contraction  of  human  small 
muscular pulmonary arteries (MacLean et al., 1996).  In support of this, serotonin-induced 
vasoconstriction  was  also  successfully  inhibited  with  the  5-HT1B/1D  receptor  antagonist  
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GR55562.  Subsequently, the role of the 5-HT1B receptor was confirmed by the observation 
that the selective 5-HT1B receptor antagonist SB224289 abolished sumatriptan-mediated 
vasoconstriction whereas BRL15572 (a selective 5-HT1D receptor antagonist) had no effect 
(Morecroft et al., 1999).  The 5-HT1B receptor is also involved in the contraction of non-
human pulmonary arteries.  Although, sumatriptan does not the stimulate contraction of 
bovine pulmonary arteries in basal conditions, it promotes vasoconstriction in the presence 
of U44619 tone (MacLean et al., 1994).  This is an example of pharmacological synergism.  
Additional  factors  often  described  in  PAH  (e.g.  decreased  NOS  expression  leading  to 
reduced NO bioavailability) have also been found to potentiate 5-HT1B receptor-mediated 
contraction  (Dempsie  and  MacLean,  2008).    In  non-human  pulmonary  arteries,  it  is 
typically assumed that serotonin-induced vasoconstriction is via the 5-HT2A receptor in the 
absence of tone, whilst via the 5-HT1B receptor in the presence of tone.   
 
Animal  models  of PAH have  also described a  role for the 5-HT1B receptor in disease 
pathogenesis.  In rats, the 5-HT1B receptor antagonist GR127935 attenuates the severity of 
hypoxia-induced PAH (Marcos et al., 2003).  In addition, 5-HT1B receptor knockout mice 
exhibit a reduction in RVSP and pulmonary vascular remodelling following exposure to 
hypoxia  (Keegan  et  al.,  2001).    Indeed,  increased  5-HT1B  receptor  expression  is  also 
reported in an overcirculation-induced model of PAH in piglets (Rondelet et al., 2003).  
Fawn-hooded rats, which exhibit altered serotonergic function and develop exaggerated 
hypoxia-induced PAH, also show increased 5-HT1B receptor mediated contraction in the 
pulmonary arteries (Morecroft et al., 2005).   
 
1.4.2.2  5-HT2 Receptor Subtypes 
Serotonin exerts multiple physiological effects via the activation of multiple 5-HT receptor 
subtypes.  In the cardiovascular system, the 5-HT1 and 5-HT2 receptor subtypes mediate  
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most of the serotonin effects (Hoyer et al., 2002).  The 5-HT2 subtypes include the 5-HT2A, 
5-HT2B and 5-HT2C receptors, which share 46-50% of overall sequence homology.  The 
majority of these receptors are coupled to the Gq protein, which signals via the activation 
of PLC to form inositol 1,4,5 trisphosphate (IP3) and 1,2-diacylglycerol (DAG).  In turn, 
these second messengers increase [Ca
2+]i.  The 5-HT2A receptor is widely expressed in both 
the central nervous system and periphery, and mediates many physiological functions.  In 
the cardiovascular system, this receptor promotes vasoconstriction in both the systemic and 
pulmonary  arteries.    Indeed,  the  5-HT2A  receptor  antagonist  ketanserin  is  a  proven 
therapeutic  treatment  for  systemic  hypertension  in  humans.    In  contrast, its  use  in  the 
treatment  of  PAH  is  much  less  effective  (Domenighetti  et  al.,  1997).    In  one  study 
involving  a  cohort  of  PAH  patients,  ketanserin  had  no  effect  on  pulmonary  vascular 
resistance  until  extremely  high  doses  were  administered,  and  this  effect  was  minimal 
compared to those observed on systemic vascular resistance.  Therefore, expression of the 
5-HT2A receptor in both the systemic and pulmonary arteries has limited its effectiveness as 
a therapeutic target in the treatment of PAH.  Multiple serotonin effects mediated via the 5-
HT2A receptor have also been described in animal models of PAH.  For example, serotonin 
promotes vasoconstriction in mouse, rat, dog and cow pulmonary arteries predominantly 
via the 5-HT2A receptors (MacLean and Dempsie, 2010).  This is in contrast to human 
pulmonary  arteries,  where  both  the  5-HT2A  and  5-HT1B  receptors  mediate  serotonin-
induced vasoconstriction.  In isolated rat  PASMCs, the 5-HT2A receptor has  also been 
shown to directly inhibit Kv channels, which results in decreased K
+ cellular efflux and 
depolarisation (Varghese et al., 2006).   
 
The 5-HT2A receptor is also involved in the proliferation of pulmonary vascular cells.  It 
has been shown to mediate the exaggerated serotonin-induced proliferative response of 
PAFs in chronic hypoxia (Welsh et al., 2004).  In bovine PASMCs, this receptor may also 
stimulate  serotonin-induced  proliferation  via  the  phophatidylinositol-3-kinase/protein  
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kinase  B  (PI3K/PKB)  pathway  (Liu  and  Fanburg,  2006).  In  addition,  this  subtype 
promotes platelet aggregation and thrombosis (Nagatomo et al., 2004), which is a common 
feature in PAH. 
 
The 5-HT2B receptor has also been shown to mediate multiple serotonin effects in the 
pulmonary  vasculature.    Nordexfenfluramine,  which  is  an  active  metabolite  of 
dexfenfluramine  and  potent  5-HT2B  receptor  agonist,  stimulates  the  contraction  of 
pulmonary arteries (Ni et al., 2004).  This 5-HT2B agonist also activates MAPK signalling 
in  cells  expressing  the  recombinant  5-HT2B  receptor  (Fitzgerald  et  al.,  2000).    This 
pathway has previously been shown to stimulate the proliferation of both PASMCs (Liu 
and Fanburg, 2006) and PAFs (Welsh et al., 2001).  In vivo, the development of hypoxia-
induced PAH is completely ablated in 5-HT2B receptor knockout mice, and is also similarly 
ablated in mice treated with the 5-HT2B receptor antagonist RS-127445 (Launay et al., 
2002).  In addition, evidence which suggests that the 5-HT2B receptor is involved in the 
regulation of plasma serotonin levels has also been described in mice (Callebert et al., 
2006).  The 5-HT2B receptor is also essential in heart development during embryogenesis 
(Nebigil et al., 2000).  It appears to promote the survival of adult cardiomyocytes (Nebigil 
et al., 2003), which may be a feature of serotonin-induced right ventricular hypertrophy.  
However  its  therapeutic  target  in  the  treatment  of  PAH  is  limited,  as  loss  of  5-HT2B 
receptor function may actually predispose to the development of dexfenfluramine-induced 
PAH in humans (Blanpain et al., 2003).  
 
1.4.2.3  Additional 5-HT Receptor Subtypes 
In  addition  to  the  5-HT1  and  5-HT2  receptors  previously  discussed,  the  expression  of 
additional 5-HT receptors has also been described in the pulmonary circulation.  mRNA 
transcripts for the 5-HT1A, 5-HT1D, 5-HT3A, 5-HT3B, 5-HT4, 5-HT6 and 5-HT7 receptors  
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have  been  identified  in  rabbit  pulmonary  arteries  (Molderings  et  al.,  2006),  whilst  5-
HT1B/1D, 5-HT2A, 5-HT2B, 5-HT4 and 5-HT7 receptor transcripts have been found in porcine 
pulmonary arteries.  In the latter, this is an identical receptor expression profile to that 
observed in human PASMCs with the exception of the 5-HT4 receptor, which appears to be 
absent  in  humans  (Ullmer  et  al.,  1995).    Multiple  physiological  functions  have  been 
described for the majority of these 5-HT receptor subtypes, however these appear to play a 
minor role in the receptor-dependent effects of serotonin in the pulmonary circulation.  
Therefore, it is assumed that the 5-HT1B, 5-HT2A and 5-HT2B receptors mediate receptor 
driven serotonin signalling in PAH.     
 
1.4.3  5-HT Receptor and Serotonin Transporter Interactions 
Functional interactions between the 5-HT1B receptors and SERT have also been described.  
In the pulmonary circulation, this results in increased vasoconstriction and proliferation.  In 
rat  pulmonary  arteries,  synergy  between  the  inhibitory  effects  of  5-HT1B  receptor 
antagonism  and  SERT  inhibition  on  serotonin-induced  contraction  have  been  reported 
(Morecroft  et  al.,  2005).    Similar  interactions  have  also  been  described  in  mouse 
pulmonary arteries (Morecroft et al., 2010).  Indeed, dual inhibition of both the 5-HT1B 
receptors and SERT is more effective in preventing hypoxia-induced PAH in mice than 
inhibition  of  SERT  alone  (Morecroft  et  al.,  2010).    SERT  is  considered  to  mediate 
serotonin-induced proliferation in cells, however involvement of the 5-HT1B receptor is 
also considered important.  In bovine PASMCs, stimulation of the 5-HT1B receptor results 
in activation of rho small G protein and its downstream mediator rho-kinase (ROCK), and 
in turn facilitates the nuclear translocation of SERT-induced phosphorylated ERK1/2 (Liu 
et  al.,  2004).    This  interaction  between  SERT  and  the  5-HT1B  receptors  stimulates 
proliferation  via  the  transcriptional  regulation  of  multiple  proliferative  genes  including 
GATA-4 and cyclin D1.  In human PASMCs, stimulation of the 5-HT1B receptor promotes  
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ERK1/2 phosphorylation and proliferation in a RAGE dependent manner (Lawrie et al., 
2005).  5-HT1B receptor stimulation results in the phosphorylation of ERK1/2, and via a 
mechanism  involving  serotonin  metabolism,  generated  reactive  oxygen  species  (ROS) 
facilitated nuclear translocation occurs.  Inside the nucleus, target genes are activated (e.g. 
GATA-4)  resulting  in  increased  mts1  synthesis  and  release.  As  a  consequence,  Mts1 
activates membrane-bound RAGE receptors to stimulate proliferation (Lawrie et al., 2005).  
Dual blockade of both the 5-HT1B receptors and SERT is also more effective than singular 
SERT blockade at inhibiting serotonin-induced proliferation in both non-IPAH and IPAH 
PASMCs (Morecroft et al., 2010).  5-HT1B receptor expression appears confined to the 
pulmonary  circulation  and  mediates  both  serotonin-induced  vasoconstriction  and 
proliferation.  On this evidence, the 5-HT1B receptor is one viable future therapeutic target 
in the treatment of PAH.      
 
1.4.4  Serotonin Transporter 
1.4.4.1  Structure  
A single gene encodes for the serotonin transporter (SERT; 5-HTT), which is located on 
chromosome 17q11.2, and its transcriptional regulation and function is controlled by the 
repetitive sequence of varying length in the promoter region of the gene (Ramamoorthy et 
al., 1993).  The alleles are composed of either fourteen (short; S) or sixteen (long; L) 
repeated sequences. The L allele promotes a higher rate of SERT gene transcription than 
the S allele, and is also associated with increased mRNA expression, protein expression 
and functional activity (Lesch et al., 1996).  The  SERT protein  is a ~630 amino  acid 
sequence  (molecular  weight  70kDa)  which  consists  of  an  intracellular  N-terminus,  12 
transmembrane  spanning  domains  (6  extracellular  and  5  cytoplasmic  loops)  and  an 
intracellular C-terminus (Figure 1.13).   
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1.4.4.2  Function 
SERT expression is reported in multiple cell types across both the central nervous system 
and cardiovascular system.  Specifically, it is abundantly expressed in both the platelets 
(Talvenheimo and Rudnick, 1980) and PASMCs (Eddahibi et al., 2001), and these cell 
types  have  been  described  in  the  pathobiology  of  PAH.  SERT  operates  as  a  Na
+-
dependant  transporter,  utilising  the  Na
+  concentration  gradient  to  facilitate  serotonin 
transport across the membrane (Torres et al., 2003).  It is assumed that serotonin flux only 
occurs when the transporter simultaneously binds Na
+, Cl
- and serotonin.  Specifically, the 
aspartic acid residue (D98) situated at transmembrane domain 1 (TMD1) is essential for 
serotonin recognition via charge interactions with the negatively charged serotonin amine 
group (Nelson, 1998).  This interaction induces a conformational change to facilitate the 
transport of serotonin, in accompaniment with Na
+ and Cl
-, across the membrane.  The 
SERT must also bind an intracellular K
+,
 via an active cysteine residue located on TMD3, 
which is consequently transported outside the cell.  This allows the inactivation of SERT 
back to its native/resting state.  Typically, serotonin is transported into the cell via SERT 
and  this  direction  of  transport  is  energetically  unfavourable  (net  loss  of  K
+).    To 
compensate,  the  Na
+/K
+  ATPase-mediated  continuous  influx  of  K
+  coupled  with  the 
continuous  efflux  of  Na
+  acts  as  an  equilibrator  to  maintain  the  transmembrane 
concentration gradient. 
 
1.4.4.3  Pre and Post Translational Modifications  
SERT activity is regulated via pre- and post-translational modifications.  As discussed 
earlier, the allelic variation of the SERT gene leading to altered expression and activity, is 
the primary determinant of pre-translational function.  However, SERT activity is also 
regulated to a large extent via post-translational modifications.  The phosphorylation levels 
of SERT, which are regulated via protein kinase C (PKC), protein phosphatase 2A (PP2A)  
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and P38, are important in modulating SERT function (Ramamoorthy et al., 1998).  There 
are  multiple  serine  and  threonine  binding  sites  located  on  the  transmembrane  domain 
cytoplasmic  loops  and  these  are  the  target-site  of  phosphorylation  for  these  kinase 
pathways.    The  functional  consequence  of  SERT  phosphorylation  is  the  regulation  of 
SERT expression via trafficking from the cell membrane.  For example, the activation of 
PKC has been shown to phosphorylate SERT resulting in increased sequestration from the 
membrane.  In contrast, PPA2 appears to maintain higher levels of membrane expression, 
as its inhibition results in increased SERT membrane sequestration.  The activation of P38 
is also associated with increased SERT activity.  P38 inhibition reduces serotonin uptake 
via reduction in SERT membrane expression (Samuvel et al., 2005).  Indeed, receptor-
mediated P38 activation can also increase SERT function itself independent of expression 
levels (Zhu et al., 2005).  Moreover, it is observed that serotonin can also directly decrease 
SERT  phosphorylation.    This  negative  feedback  mechanism  may  act  to  prevent  the 
internalisation of SERT in circumstances where extracellular serotonin levels are higher 
than normal.  Combined, the regulation of SERT expression and activity via these pre- and 
post-translational modifications are important in SERT function. 
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Figure 1.13 Structure of the serotonin transporter.  The serotonin transporter exists as 
an  intracellular  N-terminus,  twelve  transmembrane  domains  and  an  intracellular  C-
terminus.  The serotonin transporter also contains several sites which can undergo post-
translational modification to affect its function. 
 
1.5  Serotonin Hypothesis of PAH 
Serotonin is a potent mitogen and vasoconstrictor in the pulmonary vasculature (Figure 
1.14).  Serotonin was first implicated in the pathogenesis of PAH following introduction of 
the ‘serotonin hypothesis’ of anorexigen-induced PAH.  These appetite suppressant drugs 
act to inhibit SERT-mediated serotonin uptake whilst also increasing serotonin release.  In 
the  1960’s,  use  of  the  indirect  serotonergic  agonist  aminorex,  which  is  an  appetite-
suppressant drug, was associated with >30 fold increased incidence of PAH (Abenhaim et 
al., 1996; Kramer and Lane, 1998).  The subsequent generation of anorexigens, termed 
fenfluramines, were introduced in the 1980’s, and also found to be associated with an 
increased risk of PAH.  Following a multicentre study investigation, it was observed that  
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use of these anorexigens for a period greater than three months, was associated with a >30 
fold  increased  risk  of  developing  PAH.    This  discovery  resulted  in  the  complete 
withdrawal  of  all  aminorex/fenfluramine-based  anorexigens  for  clinical  use  in  the 
treatment of obesity. 
 
Both aminorex and fenfluramine are amphetamine-like compounds which act to influence 
serotonin signalling.  Specifically, both are SERT substrates which results in their uptake 
into cells.  Inside the cell, both aminorex and fenfluramine compete with monoamines at 
the vesicular monoamine transporter (VMAT) for entry into storage vesicles.  Once inside 
they  disrupt  monoamine  storage,  resulting  in  the  reversal  of  normal  serotonin  flux  to 
instead  promote  serotonin  release.    Indeed,  fenfluramine  has  been  shown  to  increase 
plasma  serotonin  concentrations  by  evoking  its  release  from  platelets  and  neurons 
(Rothman  et  al.,  1999).    Fenfluramines  were  often  prescribed  in  combination  with 
phentermine (fen-phen), which is also a SERT substrate and MAO inhibitor, resulting in 
the  further  potentiation  of  plasma  serotonin  levels  via  increased  serotonin  release  and 
decreased metabolism.  These observations formed the basis of the ‘serotonin hypothesis’ 
in PAH. 
 
It was initially proposed that the anorexigen-mediated release of serotonin from platelets, 
leading  to  the  accumulation  of  plasma  serotonin,  resulted  in  the  development  of 
anorexigen-induced PAH.  Consistent with this, elevated circulating levels were observed 
in  PAH  patients  and  individuals  affected  with  platelet  storage  disorders  also  appear 
susceptible to the development of PAH (Herve et al., 1995; Herve et al., 1990).  Normal 
circulating levels of serotonin reside at ~1nmol/L, but have been reported to increase up to 
30-fold (~30nmol/L) in PAH patients.  However in fenfluramine-induced PAH, it was 
observed  that  serotonin  levels  were  minimally  elevated  and  still  within  normal 
physiological range (Kawut et al., 2006).  Of further interest, fenfluramine administration  
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leading to decreased plasma serotonin levels, has also been described (Stubbs et al., 1986).  
This converging evidence suggests that elevated plasma serotonin levels are not essential 
in the development of anorexigen-induced PAH. 
 
In humans, fenfluramines promote the development of PAH, and these effects have also 
been  investigated  in  experimental  PAH.    For  example,  dexfenfluramine  promotes  the 
development of PAH in both mice (Dempsie et al., 2008) and rats (Eddahibi et al., 1998).  
However the exact role of this drug remains controversial, as it has been shown to protect 
against  the  development  of  both  hypoxia-induced  PAH  (Rochefort  et  al.,  2006)  and 
monocrotaline-induced PAH (Mitani et al., 2002).        
   
Non-serotonin mediated mechanisms have also been described for fenfluramines in PAH.  
For  example,  it  can  both  directly  inhibit  potassium  channels  and  increase  intracellular 
[Ca
2+], which act to promote vasoconstriction and proliferation (Weir et al., 1996).  In 
addition,  fenfluramine  metabolism  results  in  formation  of  the  active  fenfluramine-
derivative  nordexfenfluramine,  which  has  been  shown  to  mediate  pulmonary  arterial 
vasoconstriction via activation of the 5-HT2B receptors (Hong et al., 2004).  Indeed, this 
receptor may be involved in disease pathogenesis as 5-HT2B receptor knockout mice do not 
develop hypoxia-induced PAH (Launay et al., 2002).   
 
However, it is considered that serotonin effects of fenfluramines, as opposed to the non-
serotonin effects, promote the development of anorexigen-induced PAH.  Indeed, this has 
been confirmed experimentally as mice deficient of peripheral serotonin (tph1-/- mice) do 
not develop dexfenfluramine-induced PAH (Dempsie et al., 2008). 
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1.6  The Serotonin Transporter in PAH 
The SERT is highly expressed in both the platelets and lungs.  These play an important 
role  in  the  regulation  of  plasma  serotonin  concentrations,  and  are  thought  to  store  or 
inactivate up to  95%  of total  circulating  levels, therefore reducing serotonin effects in 
pulmonary vascular cells.  However, serotonin is implicated in the pathogenesis of PAH, 
and this is mediated in part via SERT.  One study in a small cohort of IPAH patients 
identified that 65% of those were homozygous for the SERT L-allele variant (LL), which 
is associated with increased SERT expression and activity, compared to only 27% of non-
PAH  controls  (Eddahibi  et  al.,  2001).    Although  subsequent  studies  in  larger  patient 
cohorts have failed to support these findings (Machado et al., 2006), patients with the LL 
allele polymorphism may still present at an earlier age than those without (Willers et al., 
2006).  Irrespective  of  genotype,  SERT  expression  is  increased  in  the  lungs  of  IPAH 
patients (Eddahibi et al., 2001).  In addition, PASMCs derived from IPAH patients also 
exhibit increased SERT expression and these proliferate to a greater extent than those from 
controls following serotonin stimulation, and this is dependent on SERT activity (Eddahibi 
et al., 2006).  The SERT-mediated uptake of serotonin has been shown to activate multiple 
signalling pathways relevant to PAH, and this activation of has been reported in several 
pulmonary vascular cell types.  For instance, the role of SERT is implicated in increased 
Mts1 synthesis and release from PASMCs, which in turn stimulates proliferation via the 
RAGE pathway (Spiekerkoetter et al., 2005).  In bovine PASMCs, ROS derived from 
serotonin metabolism results in the phosphorylation and nuclear translocation of ERK1/2, 
and  this  is  dependent  on  SERT  function  (Liu  et  al.,  2004).  Once  inside  the  nucleus, 
pERK1/2  can  itself  then  phosphorylate  multiple  nuclear  factors  including  elk-1,  erg-1, 
GATA-4  and  cyclin  D1,  all  of  which  stimulate  proliferation.  The  serotonin-induced 
proliferation of PAFs is also mediated via SERT, as citalopram can successfully block 
these effects (Welsh et al., 2004).  Alternatively, intracellular serotonin can directly bind to 
and activate small GTPases which also reside within the cytoplasm in a process termed  
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serotonylation (Liu et al., 2010).  This further promotes the mitogenic effects of serotonin.  
Independent of serotonin, the SERT itself has also been shown to directly transactivate the 
PDGF receptors (Liu et al., 2007). 
   
Animal models of PAH have also implicated SERT in the development of PAH.  For 
example,  mice  over-expressing  SERT  (SERT+  mice)  exhibit  increased  RVSP  and 
pulmonary  vascular  remodelling,  and  also  develop  exaggerated  hypoxia-induced  PAH 
(MacLean  et  al.,  2004).    Similarly,  mice  with  targeted  SERT  over-expression  in  the 
PASMCs (under the guidance of its own SM22 promoter) develop PAH (Guignabert et al., 
2006).  Conversely, mice devoid of the SERT gene are less susceptible to the development 
of hypoxia-induced PAH (Eddahibi et al., 2000).  Also, the SERT inhibitor citalopram 
attenuates  the  severity  of  hypoxia-induced  PAH  in  both  wildtype  and  SERT+  mice 
(Morecroft et al., 2010), and prevents hypoxia-induced PAH in rats (Marcos et al., 2003).  
Hypoxia also appears to regulate SERT expression, as its expression is decreased in the 
lungs of hypoxic mice (MacLean et al., 2004). 
  
SERT is also a target for many drugs/toxins which promote the development of PAH.  The 
SERT substrate dexfenfluramine is one such example.  Dexfenfluramine enters the cell 
through SERT and then subsequently enters the storage vesicles via the VMAT.  Once 
inside these vesicle, dexfenfluramine acts to evoke serotonin release.  The consequence of 
this  is  increased  circulating  serotonin  levels.  Methamphetamines  also  act  to  release 
serotonin via a similar mechanism, and have also been associated with the development of 
PAH (Rothman and Baumann, 2007; Zolkowska et al., 2006). 
 
A wealth of evidence exists which implicates the serotonin system in the pathogenesis of 
PAH.  Serotonin appears to act via the 5-HT receptors and the SERT to promote both  
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vasoconstriction  and  proliferation  in  the  pulmonary  vasculature.  The  pharmacological 
target of these serotonin pathway mediators is one viable option in the treatment of PAH.       
 
1.7  Gender Differences in Cardiovascular Disease 
Gender differences exist in cardiovascular disease.  Although mortality rates are equally 
prevalent in both males and females, the age of disease onset is typically later in women. 
Also, pre-menopausal females are at a reduced risk of cardiovascular disease compared to 
males.    The  beneficial  effects  of  estrogens  in  the  cardiovascular  circulation  are  likely 
related to these differences (Mendelsohn and Karas, 1999).  This is further supported by 
the increased incidence of cardiovascular disease in women following surgically-induced 
or natural menopause.  Similarly, incidence is also decreased in those undergoing hormone 
replacement therapy (Bush et al., 1987; Stampfer et al., 1991) (estrogen and/or progestin).  
Experimentally, a wealth of evidence highlights the protective effects of estrogens, and 
particularly 17β estradiol in cardiovascular disease. 
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Figure  1.14  Serotonin  signalling  in  the  pulmonary  vasculature.  Tryptophan 
hydroxylase-1 (TPH1) mediates serotonin synthesis in pulmonary artery endothelial cells.  
Serotonin  is  then  released  where  its  acts  on  the  underlying  pulmonary  artery  smooth 
muscle cells.  Specifically, serotonin can stimulate contraction via the 5- HT2A and 5-HT1B 
receptors,  or  alternatively  enter  the  via  the  serotonin  transporter  (SERT)  to  stimulate 
proliferation. Additionally, stimulation of the 5-HT1B receptor also promotes proliferation.     
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1.8  Estrogen  
1.8.1  Synthesis and Metabolism  
Female  steroid  hormones  (female  sex  hormones)  comprise  both  estrogens  and 
progesterone.  The majority of estrogen synthesis occurs in both the ovarian follicles and 
corpus  luteum  and  to  a  lesser  extent  the  liver,  adipose  tissue  and  skin.    In  addition, 
estrogen-synthesising  enzymes  are  also  expressed  in  both  the  endothelial  and  smooth 
muscle cells within the vasculature, suggesting the importance of ‘local’ estrogen synthesis 
within  the  cardiovascular  system.    In  humans,  estrogen  synthesis  is  continuously 
modulated by the influence of various endocrine hormones, which are typically secreted 
from  the  brain.    For  example,  the  release  of  pituitary-derived  luteinising  hormone 
stimulates the estrogen synthesis.  This continuous modulation of estrogen is the basis of 
both the menstrual (in humans) and estrous (in mammals) cycle.  Estrogens exist as a 
family of steroid compounds which include three major subtypes; estrone, 17β estradiol 
and  estriol.    17β  estradiol  is  the  pre-dominant  circulating  hormone  in  pre-menopausal 
women,  whereas  estrone  and  estriol  circulate  at  lower  concentrations  and  have  little 
contribution.  Estrone appears important only in post-menopausal women, whilst increased 
circulating levels of estriol are reported during pregnancy (Goodwin, 1999).   
 
The biosynthesis of 17β estradiol is well-described (Payne and Hales, 2004).  Cholesterol, 
which is the common pre-cursor in steroidogenesis, is converted to pregnenolone (Figure 
1.15).  The synthesis  of androstenedione then acts  as  an intermediate step in  estrogen 
synthesis.    17β  estradiol  is  derived  from  androstenedione  via  two  distinct  biosynthetic 
pathways.  The enzyme aromatase converts androstenedione to estrone, which in turn is 
converted  to  17β  estradiol  via  17β  hydroxysteroid  dehydrogenase.    Alternatively,  17β 
estradiol can be directly derived from aromatase-mediated testosterone metabolism.  In 
pre-menopausal females, circulating levels of 17β estradiol typically range between 0.1- 
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1nmol/L (Rosselli et al., 1994), and this is influenced to a large extent on the menstrual 
cycle stage.     
 
Following its synthesis, 17β estradiol is rapidly metabolized.  There are multiple pathways 
which are involved in this (Zhu and Conney, 1998).  All convert 17β estradiol to various 
hormonally inactive non-estrogenic metabolites ready for elimination from the body.  The 
first-step  of  17β  estradiol  metabolism  is  oxidative  metabolism  (hydroxylation)  which 
occurs in the liver, and to a lesser extent in several extrahepatic tissues including the brain 
and vasculature.  Several members of the cytochrome P450 (CYP450) family are essential 
in mediating this NADPH-dependent oxidative metabolism of 17β estradiol.  Specifically, 
CYP1A1, CYP1A2, CYP1B1 and CYP3A4 appear critical to this (Martucci and Fishman, 
1993).  In the liver, around 80% of 17β estradiol is metabolized to 2-hydroxyestradiol via 
CYP1A1,  CYP1A2  and  CYP3A4,  whereas  the  remaining  20%  is  metabolized  to  4-
hydroxyestradiol  via  CYP1B1.    In  extrahepatic  tissues  2-hydroxyestradiol  formation  is 
predominantly via CYP1B1.  In addition to this, several other CYP isoforms (CYP2A6, 
CYP2C8, CYP3A5 and CYP3A7)  also play a minor role in 17β estradiol metabolism, 
resulting in the formation of multiple other metabolites including 6α, 6β, 7α, 12β, 15α, 
15β, 16α and 16β hydroxyestradiol (Martucci and Fishman, 1993).  All of these water-
soluble  catechol  metabolites  are readily  eliminated  by  the  kidneys  via  urine  excretion.  
Alternatively, these hydroxyestradiol metabolites can themselves undergo metabolism via 
their  COMT  mediated  O-methylation  conversion  to  monomethoxyestradiols  (e.g.  2-
methoxyestradiol, 4-methoxyestradiol) before excretion from the body.   
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Figure 1.15 Estrogen biosynthesis and metabolism.  Androstenedione is derived from the steroid hormone pre-cursor cholesterol via cytochrome P450-
11A  (CYP11A)  and  CYP17.    (17β)  estradiol  is  derived  from  testosterone  or  estrone  via  CYP19  or  17β  hydroxysteroid  dehydrogenase  (17β-HSD), 
respectively.  (17β)  estradiol  is  metabolised  to  2-  and  4-hydroxyestradiol  via  CYP1A1,  CYP1A2,  CYP3A4  and  CYP1B1.    Subsequently,  the 
hydroxyestradiol compounds are metabolised to mono-methoxyestradiol compounds via catechol-O-methyltransferase (COMT).  Adapted from  (Tsuchiya et 
al., 2005).  
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1.8.2  Estrogen Receptors 
Both non-rapid and rapid 17β estradiol effects have been described and these are typically 
referred to as ‘genomic’ and ‘nongenomic’ effects, respectively (Mendelsohn, 2002).  The 
genomic  effects  of  17β  estradiol  are  well-described,  and  involves  ligand-binding  to 
intracellular  estrogen  receptors  to  directly  regulate  transcription  of  a  target  gene.  In 
contrast, nongenomic effects do not require the regulation of gene transcription but instead 
act through signal transduction.  Recent evidence, through the use of cell-impermeable 
BSA conjugated 17β estradiol, suggests that these rapid nongenomic effects are mediated 
via the stimulation of estrogen receptors expressed in the plasma membrane (Pietras and 
Szego, 1977; Aronica et al., 1994).  Indeed, these observations are further supported by the 
observation  that  17β  estradiol  stimulates  responses  in  non-nuclear  cells  (e.g.  platelets) 
which are not capable of gene transcription (Moro et al., 2005; Jayachandran et al., 2005; 
Jayachandran  et  al.,  2010).  It  is  this  activation  of  both  intracellular  and  membrane 
estrogen receptors which mediate the effects of 17β estradiol.           
 
1.8.2.1  Estrogen Receptor α and β 
Intracellular estrogen receptors are ligand-activated transcription factors which typically 
exist as nuclear hormones receptors.  Similar to all steroid hormone receptors, estrogen 
receptors  share  a  common  structure  of  four  functionally  active  units  or  ‘domains’ 
(Katzenellenbogen et al., 2000; Katzenellenbogen et al., 2000).  These include the variable 
domain, which is typically the most heterologous domain between receptors, the DNA-
binding  domain,  the  hinge  domain  and  the  ligand-binding  domain  (Figure  1.16).  
Currently,  two  intracellular  estrogen  receptor  (ER)  isoforms  have  been  identified  and 
referred to as ERα and ERβ (Kuiper et al., 1996).  Each receptor is encoded by a separate 
gene (ESR1 and ESR2 respectively).  Both ER subtypes share an equal affinity for 17β 
estradiol, although estrone selectively binds ERα, whereas estriol selectively binds ERβ.   
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Both  ERα  and  ERβ  are  expressed  in  a  variety  of  tissues  including  the  uterus,  testes, 
prostate, ovaries, bone, breast, liver and brain (Heldring et al., 2007).  With respect to the 
cardiovascular  system,  ERβ  predominates  and  is  expressed  in  the  cardiomyocytes, 
endothelial and vascular smooth muscle cells (Imamov et al., 2005).   
 
Although both ERα and ERβ share 97% sequence homology for the DNA-binding domain 
and 56% for the ligand-binding domain, the N terminus shares relatively poor homology at 
24%, which impacts their function.  ERs must co-operate as dimers in order to translocate 
from the cytosol to the nucleus.  Following this, the transcriptional activation of both ERs 
is mediated via two distinct activation functions (AFs) termed AF-1 and AF-2, which are 
located in the ligand-binding domain.  AF-1 is constitutively active and resides at the N-
terminus  domain  (Kushner  et  al.,  2000),  while  AF-2  is  located  at  the  C-terminus  and 
typically requires ligand-dependent activation for transcriptional activation.  With respect 
to both ER isoforms, ERα mediates transcriptional activation via AF-1 to a much greater 
extent than ERβ, which instead appears to regulate transcription via AF-2 function.  This 
balance of AF-1 and AF-2 is critical to the nuclear receptor-dependent cellular effects of 
17β estradiol.  Both AF-1 and AF-2 signal via the recruitment of co-regulator complexes 
(either  co-activators  or  co-repressors)  to  activate  or  suppress  gene  expression.  
Specifically,  the  binding  of  the  ERs  to  specific  DNA  sequences  (estrogen  response 
elements, EREs) are responsible for regulating the transcription of genes (Kushner et al., 
2000).  As a consequence, this regulates protein translation which consequently will affect 
cell function.  Alternatively, ER dimers can recognize and bind non-ERE DNA sequences 
which  are  primarily  a  target  for  other  transcription  factors.  This  commonly  includes 
cAMP-responsive elements (Sabbah et al., 1999).  Collectively, ERα/ERβ transcriptional 
regulation is the basis of the ‘genomic’ effects of 17β estradiol (Figure 1.17). 
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The ERs are themselves also subject to pre- and post-translational modification which can 
influence their expression and/or function.  For example, estrogen receptors are subject to 
phosphorylation,  acetylation,  ubiquitination  and  SUMOlation  (Mendelsohn  and  Karas, 
2010).    Numerous  promoters  have  also  been  identified  for  both  ERα  and  ERβ,  which 
directly regulate their expression.  Also, a number of ERα gene polymorphisms have been 
identified, which most commonly exist as a variable number of tandem repeats within the 
promoter region.  These are associated with the increased development of multiple diseases 
including  breast  cancer  (Dunning  et  al.,  2009),  prostate  cancer  (Tanaka  et  al.,  2003), 
osteoporosis (Styrkarsdottir et al., 2008) and cardiovascular disease (Lu et al., 2002).  ERβ 
polymorphisms have also been associated with the increased incidence of cardiovascular 
disease  in  women  (Rexrode  et  al.,  2007).  Specifically,  the  rs1271572  polymorphism 
variant A allele (A→ C transposition in the promoter region) is associated with increased 
incidence of cardiovascular disease and myocardial infarction in women (Rexrode et al., 
2007).  Whether ER polymorphisms contribute to the development of PAH remains to be 
investigated. 
 
1.8.2.2  G-Protein Coupled Receptor 30 
17β estradiol also mediates its effects via ligand-binding to a third receptor, termed the G-
protein  coupled  receptor  30  (GPR30,  GPER,  mER)  (Filardo  et  al.,  2007).    GPR30  is 
described to act via both transcriptional regulation and activation of signal transduction 
pathways.  These signalling pathways include those associated with Ca
2+ mobilization, 
ERK1/2 MAPK activation and NO production.  At the cellular level, GPR30 expression is 
localised at both the plasma membrane and endoplasmic reticulum, and has been identified 
in the stomach, pancreas, duodenum and the endothelial and smooth muscle cells of the 
vasculature.  Indeed,  GPR30  is  an  important  regulator  of  17β  estradiol  effects  in  the 
cardiovascular  system  (Olde  and  Leeb-Lundberg,  2009).    GPR30  activation  mediates  
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endothelial dependent NO-derived relaxation in isolated carotid arteries from both male 
and female rats (Broughton et al., 2010).  In addition, 17β estradiol-induced apoptosis of 
vascular  SMCs  requires  ERK  phosphorylation,  and  this  appears  dependent  on  GPR30 
(Ding et al., 2009).  Deletion of the GPR30 gene in vivo (GPR30-/- mice) results in the 
elevation of systemic blood pressure, and impaired glucose tolerance (Haas et al., 2009).  
In the pulmonary vasculature, the role of GPR30 remains poorly defined.    
   
 
Figure  1.16  Estrogen  receptor  structure.  Estrogen  receptors  (ERs)  exist  as  a  four 
domain structure.  The N-terminal variable domain, which is the most heterologous part of 
the  receptor,  is  essential  for  receptor  transactivation.    Both  the  DNA  binding  domain 
(DBD) and hinge domain are important in DNA binding receptor activity.  The ligand-
binding domain, which is located at the C-terminus, directly interacts with the ligand and is 
also important in nuclear translocation.  Adapted from (Jordan and O'Malley, 2007). 
 
1.8.3  17β Estradiol Effects in the Systemic Circulation 
17β estradiol has multiple physiological effects in multiple target organs including bone, 
breast,  prostate,  heart  and  the  vasculature  (Vitale  et  al.,  2009).    In  the  cardiovascular  
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system, a wealth of evidence highlights a cardio-protective and vaso-protective role for 
17β estradiol in cardiovascular disease.  In women, the incidence of cardiovascular disease 
is negatively correlated with circulating estrogen levels, which are modulated by a number 
of factors including menopause and hormone replacement therapy.  For example, women 
are at an increased risk of cardiovascular disease following menopause (Rosano et al., 
2003).   
 
17β estradiol stimulates both NO-mediated (Caulin-Glaser et al., 1997) and prostacyclin-
mediated  (Mikkola  et  al.,  1995)  vasodilatation.    In  addition,  this  hormone  limits  the 
progression  of  atherosclerosis  by  reducing  low-density  lipoprotein  and  also  reduces 
vascular inflammation, coagulation and fibrinolysis.  Indeed, 17β estradiol attenuates the 
development  of  atherosclerosis  in  apolipoprotein  E  (ApoE)  deficient  (ApoE-/-)  mice 
(Bourassa et al., 1996).  A wealth of evidence highlights the specific vaso-protective role 
of ERα in the vasculature.  In endothelial cells, ERα stimulation activates multiple kinases 
including P38 to promote eNOS-derived NO production, thereby promoting vasodilatation 
(Anter et al., 2005).  In vivo, ERα appears to mediate the protective effects of 17β estradiol 
following vascular injury, as ERα knockout mice do not show vascular recovery following 
treatment  with  17β  estradiol  compared  to  wildtype  mice  (Brouchet  et  al.,  2001).    In 
contrast, ERβ-/- mice fully recover from vascular injury following 17β estradiol treatment, 
providing  further  evidence  that  this  vascular  response  is  ERα-mediated.    Instead,  ERβ 
appears important in other forms of cardiovascular disease.  For example, the development 
of age-related systolic and diastolic hypertension is reported in ERβ-/- mice (Zhu et al., 
2002).  This phenotype is not observed in ERα-/- mice.  Vasodilatation appears to be 
mediated via ERα (Darblade et al., 2002; Pendaries et al., 2002).  Disruption of ion channel 
function is also apparent in vascular SMCs derived from ERβ-/- mice (Zhu et al., 2002).  
These mice also develop systemic hypoxia arising from lung dysfunction, and as a result 
develop  systemic  hypertension  and  left  ventricular  hypertrophy  (Morani  et  al.,  2006).   
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Taken together, a wealth of evidence supports a vasoprotective role for both ERα and ERβ 
in systemic vascular function and regulation of blood pressure. 
 
However,  under  certain  circumstances  estrogen  exposure  may  conversely  lead  to  an 
increased incidence of cardiovascular disease.  In one study cohort, the Women’s Health 
Initiative reported that those prescribed estrogen for hormone replacement therapy were at 
an increased risk of cardiovascular events (Anderson et al., 2004).  This appeared most 
significant  during  the  initial  12  months  of  therapy.    This  is  also  termed  the  ‘timing’ 
hypothesis.  The mechanisms underlying this pathophysiology of estrogens are unclear.  
Increased expression of both ERα and ERβ is reported in both cardiac hypertrophy and 
heart failure in humans (Mahmoodzadeh et al., 2006; Nordmeyer et al., 2004).  However, 
this must be further investigated as a wealth of evidence has shown that both ERα and ERβ 
protect against the development of cardiovascular disease. 
 
1.8.4  17β Estradiol Metabolite Effects in the Systemic Circulation 
17β  estradiol  metabolites  are  also  vasoactive  in  the  systemic  circulation.  2-
hydroxyestradiol, 2-methoxyestradiol and 4-methoxyestradiol all inhibit the migration and 
proliferation of human and rat vascular SMCs.  Moreover, these metabolites do not appear 
to be ERα/ERβ dependent as the non-selective ER antagonist ICI-182,780 does not exert 
any inhibitory effects (Dubey et al., 2005).  In vivo, the metabolite 2-methoxyestradiol 
prevents the elevation of systemic arterial blood pressure associated with chronic NOS 
inhibition and also reduces inflammation, collagen synthesis and proliferation in the heart 
(Tofovic  et  al.,  2005).  2-methoxyestradiol  appears  most  potent  in  the  prevention  and 
regression of systemic cardiovascular disease.  Specifically, it is proposed to act via the 
inhibition of tubulin polymerization, which is an important component of the cytoskeleton 
and involved in cell growth.      
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Figure 1.17 17β estradiol signalling.   17β estradiol (E2) mediates both nongenomic and 
genomic effects.  E2 enters the cell where it can act on ER alpha and ER beta to regulate 
the transcription of target genes (genomic effects).  Alternatively, E2 can act on GPR30 to 
stimulate  a  more  rapid  mechanism  of  action  (nongenomic  effects).    Membrane-bound 
estrogen receptors are also proposed to exist, however their precise function remains to be 
determined.  
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1.8.5  17β Estradiol Effects in the Pulmonary Circulation 
In both idiopathic and heritable forms of PAH there is a gender bias, with females up to 
three fold more likely to present with disease (Peacock et al., 2007; Humbert et al., 2006; 
Thenappan et al., 2007).  Currently, BMPR-II mutations are not considered pivotal to this, 
confirmed by one study which showed no influence of gender in BMPR-II affected PAH 
patients  (Girerd  et  al.,  2010).    Therefore,  the  mechanisms  attributing  to  these  gender 
differences remain obscure.  Estrogen is one risk factor in PAH.  For example, the use of 
oral contraceptives have previously been associated with PAH (Masi, 1976) and female 
PAH patients exhibit increased expression of ESR1, which is the gene encoding for ERα, 
compared to unaffected (non-PAH) females (Rajkumar et al., 2010).  Decreased expression 
of  the  estrogen-metabolising  enzyme  cytochrome  P450  1B1  (CYP1B1),  leading  to 
alterations  in  estrogen  metabolism,  has  also  been  identified  in  female  PAH  patients 
harbouring a BMPR-II mutation compared to unaffected female carriers (West et al., 2008; 
Austin et al., 2009). 
 
In  contrast,  experimental  models  of  PAH  have  repeatedly  shown  that  females  exhibit 
moderate  PAH  compared  to  males.    For  example,  male  rats  develop  increased  RVSP, 
pulmonary vascular remodelling and RVH compared to female rats following exposure to 
hypoxia (Rabinovitch et al., 1981).  Similar observations are also reported in mice (Stupfel 
et  al.,  1984).  In support  of this, male  swine  and  chicken  also exhibit  an exaggerated 
hypoxia-induced PAH phenotype compared to females.  These protective effects appear to 
be mediated via female hormones, as ovariectomy can increase the severity of hypoxia-
induced PAH (Resta et al., 2001).  Specifically, 17β estradiol appears to mediate these 
effects  as  its  exogenous  administration  can  attenuate  increased  RVSP  and  pulmonary 
vascular remodelling in ovariectomized females (Resta et al., 2001).  In transgenic models, 
male ApoE -/- mice subjected to a high-fat diet develop increased RVSP and pulmonary 
vascular remodelling compared against high-fat treated ApoE -/- female mice (Hansmann  
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et al., 2007).  Also, male VIP-/- mice are more susceptible to PAH than female VIP-/- mice 
(Said et al., 2007).  The loss of ERβ function, as is observed in ERβ-/- mice, also results in 
the development of right ventricular hypertrophy (Morani et al., 2006).  Estrogens appear 
to promote both NO-mediated (Gonzales et al., 2001) and prostacyclin-mediated (Sherman 
et  al.,  2002)  endothelium-dependent  vasodilatation  in  the  pulmonary  circulation.    For 
example,  17β  estradiol  has  been  shown  to  promote  vasodilatation  in  the  pulmonary 
vasculature.  In pulmonary arteries isolated from proestrus rats (highest circulating levels 
of  17β  estradiol  in  the  menstrual  cycle),  both  phenylephrine  and  hypoxia-induced 
vasoconstriction  is  markedly  attenuated  compared  to  those  responses  observed  in 
pulmonary arteries isolated from estrus, diestrus and male rats (Lahm et al., 2007).  In 
support of this, hypoxic pulmonary vasoconstriction is reduced in female sheep compared 
to males, and 17β estradiol attenuates this response.  Hypoxic pulmonary vasoconstriction 
is  also  reduced  in  the  pulmonary  arteries  of  dogs  and  rats  during  pregnancy,  when 
circulating levels of estrogen are elevated.  17β estradiol has also been reported to increase 
endothelial nitric oxide synthase (eNOS) mRNA expression and activity in PAECs via an 
estrogen  receptor-dependant  mechanism  (MacRitchie  et  al.,  1997).    In  addition,  17β 
estradiol also inhibits hypoxia-induced endothelin-1 gene expression (Earley and Resta, 
2002). 
 
Taken together, these findings indicate a protective role for female gender in experiment 
PAH.  This may not be entirely unexpected, as estrogens are beneficial in several forms of 
human PAH distinct from IPAH and HPAH.  For example, estrogens may protect against 
the  development  of  PAH  in  high-altitude  natives.    The  incidence  of  high  altitude 
pulmonary edema (HAPE), which occurs as a result of pronounced hypoxic pulmonary 
vasoconstriction, is also higher in males than females.  There is also an increased incidence 
of  sclerosis-related  PAH  in  post-menopausal  females,  and  its  risk  of  development  is 
reduced  in  those  prescribed  hormone  replacement  therapy.  To  date,  the  absence  of  a  
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suitable experimental model of PAH which replicates the female susceptibility observed in 
IPAH and HPAH has limited research into the role of estrogens in the pathogenesis of 
PAH.   
 
1.8.6  17β Estradiol Metabolite Effects in the Pulmonary Circulation 
Non-estrogenic  17β  estradiol  metabolites  also  mediate  protective  effects  within  the 
pulmonary  circulation.  Those  most  extensively  studied  are  the  hydroxyestradiol  and 
methoxyestradiol compounds.  2-hydroxyestradiol, which is derived from the CYP1A1-
mediated  hydroxylation  of  17β  estradiol  (and  to  a  lesser  extent  CYP1B1),  attenuates 
increased  RVSP,  pulmonary  vascular  remodelling  and  RVH  associated  with 
monocrotaline-induced  PAH  in  rats  (Tofovic  et  al.,  2005).  The  administration  of  this 
metabolite also successfully prevents isoproterenol-induced RVH and cardiac fibrosis in 
rats (Tofovic et al., 2008).  In support of this, 2-hydroxyestradiol successfully inhibits 
serum-induced proliferation of cardiac fibroblasts (Dubey et al., 2005).   
 
The subsequent O-methylation of 2-hydroxyestradiol, which is derived via COMT, results 
in the formation of 2-methoxyestradiol.  The anti-mitogenic effects of this metabolite are 
well-described in PAH.  For example, 2-methoxyestradiol attenuates the development of 
monocrotaline-induced PAH (Tofovic et al., 2004) and hypoxia-induced PAH (Zhang et 
al., 2005).  Pharmacological concentrations of this metabolite also inhibit serum-induced 
proliferation in PAECs, PASMCs and PAFs (Tofovic et al., 2008).  2-ethoxyestradiol, 
which is a potent synthetic analogue of 2-methoxyestradiol, also successfully inhibits the 
proliferation  of  PAECs,  PASMCs  and  PAFs.    In  vivo,  2-EE  successfully  prevents  the 
elevation of RVSP and pulmonary vascular remodelling in monocrotaline-induced PAH. 
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1.9  Estrogen and Serotonin Interactions 
Interactions between estrogen and serotonin are widely investigated in the central nervous 
system.  In most cases, estrogens are reported to increase expression of multiple serotonin 
pathway mediators, which as a consequence would likely  promote serotonin signalling.  In 
the dorsal raphe nucleus, 17β estradiol increases both SERT expression and function in 
acutely  ovariectomized  mice  (Bertrand  et  al.,  2005).  Increased  SERT  binding  is  also 
reported  in  the  basolateral  amygdala  and  lateral  septum  of  these  mice.  Similar 
observations are also reported in rats (McQueen et al., 1997).  These 17β estradiol effects 
can  be  successfully  blocked  with  the  selective  estrogen  receptor  modulators  (SERMs) 
tamoxifen  and  raloxifine,  suggesting  the  involvement  of  estrogen  receptors  in  this 
induction (Sumner et al., 2007).  In addition, 17β estradiol is also reported to increase 5-
HT2A  receptor  expression  in  rats  (Sumner  et  al.,  2007).    Increased  expression  and/or 
function in the dorsal raphe nucleus and cerebral cortex is similarly reported in acutely 
ovariectomized  mice  subjected  to  17β  estradiol  administration,  and  an  increase  is  also 
observed in chronically ovariectomized rats and macaques following chronic 17β estradiol 
administration (Chavez et al., 2010; Rivera et al., 2009).  Similar to SERT, 17β estradiol-
induction of the 5-HT2A receptor is also proposed to act via an ER-dependent mechanism 
as both tamoxifen and raloxifine can block this effect (Sumner et al., 2007).   
 
The  synthesis  and  metabolism  of  serotonin  is  also  influenced  via  17β  estradiol  in  the 
central nervous system.  Both mRNA and protein expression of TPH (the rate-limiting 
enzyme involved in serotonin synthesis) is increased in the brain of 17β estradiol-treated 
animals  following  ovariectomy  (Pecins-Thompson  et  al.,  1996),  and  its  induction  is 
similarly blocked in the presence of tamoxifen.  In addition, dorsal raphe expression of the 
serotonin-metabolizing  enzyme  MAO-A  is  decreased  following  17β  estradiol 
administration  (Smith  et  al.,  2004).  In  combination,  these  likely  facilitate  increased  
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serotonin bioavailability.  Overall, 17β estradiol appears to increase expression of TPH, 
SERT and the 5-HT receptors in the central nervous system.  
 
Although estrogen-serotonin interactions are widely reported in the central nervous system, 
these remain poorly defined in the cardiovascular system.  Only functional interactions 
have been described.  A reported increase in serotonin-induced contraction is observed in 
the  mesentery  vascular  bed  of  17β  estradiol-treated  rats  compared  to  vehicle  controls 
(Mark et al., 2007).  To date, this study is the only to report the potentiated response of 
serotonin  in  the  presence  of  17β  estradiol  in  the  cardiovascular  system.    Therefore, 
interactions between estrogen and serotonin remain to be investigated in the pulmonary 
circulation.     
 
1.10 Aim 
The principle research aim was to investigate the influence of gender in the development of 
PAH.  This may offer insight into the increased incidence of PAH in women.  This was 
evaluated through investigation of the following experimental study aims: 
 
  In vivo characterisation of gender and estrogen via assessment of PAH phenotype 
in a transgenic model of PAH (SERT+ mouse model).  
  Determine  genotypic  differences  in  the  pulmonary  arteries  of  female  and  male 
SERT+ mice. 
  In vitro characterisation of female hormones in pulmonary artery smooth muscle 
cells. 
  Influence of estrogen on serotonin signalling in pulmonary artery smooth muscle 
cells. 
  Identify novel genes in important in SERT+ PAH and human PAH.  
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Chapter 2 
Materials and Methods 
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Materials 
2.1.1  Chemicals and Reagents 
All chemicals and reagents were of the highest grade obtainable and supplied by Sigma-
Aldrich  (Poole,  UK),  Invitrogen  (Paisley,  UK),  Fisher  Scientific  (Loughborough,  UK), 
Tocris Bioscience (Bristol, UK), Roche Diagnostics (West Sussex, UK) or BDH Prolabo 
(West Sussex, UK), as stated.  All cell culture reagents were supplied by Sigma-Aldrich 
(Poole, UK) or Gibco (Paisley, UK), unless otherwise stated.  Fetal bovine serum (FBS) 
was supplied by Sera Laboratories International (West Sussex, UK).   
 
Methods 
All experimental procedures conform with the United Kingdom Animal Procedures Act 
(1986) and with the ‘Guide for the Care and Use of Laboratory Animals’ published by the 
US National Institutes of Health (NIH publication No. 85-23, revised 1996).  All in vivo 
procedures  were  performed  under  the  project  license  60/3773  held  by  Professor  M.R 
MacLean (University of Glasgow, UK).      
 
2.1.1  SERT+ Mice 
Mice over-expressing the serotonin transporter (SERT+ mice) were generated and supplied 
by Professor Tony Harmer, University of Edinburgh, UK.   The generation SERT+ mice 
was achieved using the C57BL/6xCBA background strain.  The transgene introduced was 
a  500kb  yeast  artificial  chromosome  (YAC35D8)  containing  the  human  SERT  gene 
flanked  by  150  kb  of  5'  and  300  kb  of  3'  sequence,  with  the  short  (S)  allele  of  the 
SERTLPR in the promoter region and the 10-repeat allele of the variable number tandem 
repeat in intron 2.  Previously, in situ hybridization analysis has shown that human SERT  
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mRNA is similarly expressed in a manner which resembles that of the endogenous mouse 
SERT gene.  Genotyping was performed to confirm the presence of the human SERT 
transgene.  Mice were housed with littermates in the central biological services research 
facility  at  the  University  of  Glasgow.    All  mice  were  subject  to  a  continuous  12hour 
light/dark cycle with access to food and water ad libitum.  PAH phenotype was assessed in 
female  and  male  SERT+  mice  at  both  8  and  20  weeks  of  age  (Figure  2.1),  and 
C57BL/6xCBA littermate mice studied as controls.   
 
2.1.2  Bilateral Ovariectomy 
For pre-operative care, mice were administered 0.1mg/kg buprenorphine (an analgesic) and 
4ml/kg sterile saline via intra-peritoneal injection.  Surgical removal of the left and right 
ovaries (bilateral ovariectomy) was performed under general anaesthesia (1%-3% (v/v) 
isoflurane supplemented with O2) in 8 week old female mice.  This is a commonly used 
surgical technique used to deplete circulating ovarian hormone levels.  Briefly, a dorsal 
midline skin incision was performed to expose the dorsal back.  This was followed by 
incision through the muscle caudal to the posterior border of the ribs, and lateral blunt 
dissection was performed to advance into the abdominal cavity through the muscles of the 
abdominal posterior wall.  The ovary (including periovarian fat) was located underneath 
the muscle, and removed via cauterization through the distal uterine tube.  1-2 simple 
interrupted sutures were performed to repair incision through the muscle.  This surgical 
procedure was repeated to excise the remaining ovary.  2-3 surgical staples were used to 
close the dorsal midline skin incision.  For post-operative care, 2.5mg/kg carprofen (a non-
steroidal anti-inflammatory drug) and 4ml/kg sterile saline were administered via intra-
peritoneal injection.  Successful removal of the ovaries was confirmed at necropsy via 
weight measurement of the uterus.  The assessment of PAH was carried out 12 weeks 
following surgery (20 week old mice).  Sham-operated mice were studied as controls.  
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2.1.3  17β Estradiol Administration  
17β estradiol containing pellets (0.1mg/21 day pellet, Innovative Research of America, 
Florida, USA) or vehicle pellets were subcutaneously implanted into the dorsal neck.  This 
was performed under general anaesthesia (1%-3% (v/v) isoflurane supplemented with O2) 
using a sterile 12-gauge hypodermic needle.  These pellets have been previously shown to 
have a constant rate of drug release (Karas et al., 2001), and therefore an effective dosing 
method.  The  selected  dose  of  17β  estradiol  has  been  previously  shown  to  produce 
physiologically relevant (~1nmol/L) concentrations of circulating 17β estradiol.  Following 
completion of the 21 day dosing regime, the assessment of PAH was carried out.    
 
2.1.4  Chronic Hypoxia 
The  development  of  hypoxia-induced  PAH  was  achieved  in  mice  using  a  hypobaric 
hypoxic  chamber.    Following  acclimatization,  mice  were  exposed  to  550mbar  for  a 
continuous period of 14 days.  As a consequence of atmospheric depressurization from 
~1000mbar (ambient room pressure) to 550mbar, oxygen availability is decreased from 
21% O2 to 10% O2, resulting in sustained HPV and the development of PAH.  Temperature 
(21
oC-23
 oC) and relative humidity (30-50%) were maintained within a normal range and 
mice were re-housed with clean bedding and food/water every five days.   
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Figure 2.1 In vivo study design.  Chapter 3 - Female SERT+ mice were subject to sham/ovariectomy (at 8 weeks of age), vehicle/17β estradiol 
administration (at 17 weeks of age) and normoxia/ hypoxia (at 18 weeks of age) and PAH phenotype assessed at 20 weeks of age (A).  Chapter 4 - 
Female and male SERT+ mice were exposed to hypoxia (at 6 weeks of age) and PAH phenotype assessed at 8 weeks of age.  WT mice were studied as 
control (B).  
8 weeks                                                                                                 17 weeks    18 weeks  20 weeks
Sham/ovariectomy
Vehicle/17βestradiol
Normoxia/hypoxia
PAH phenotype
Normoxia/hypoxia
PAH phenotype
6 weeks     8 weeks
A.
B.
WT/SERT+ mice
WT/SERT+ mice 
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2.2  Assessment of PAH 
2.2.1  Haemodynamic Measurements  
The induction of general anaesthesia was performed via exposure to 3% (v/v) isoflurane 
supplemented  with  O2.    Mice  were  immediately  weighed  and  1-2%  (v/v)  isoflurane 
continuously  administered  via  a  facemask  to  maintain  general  anaesthesia.    General 
anaesthesia was confirmed by the absence of a hind-limb and tail reflex.  These reflexes 
were  also  routinely  assessed  throughout  surgery.    Following  confirmation  of  general 
anaesthesia, both right ventricular pressure (RVP) and systemic arterial pressure (SAP) 
were measured. 
 
2.2.2  Right Ventricular Pressure 
Right ventricular pressure (RVP) was measured via a transdiaphragmatic approach.  The 
continuous measurement of RVP was assessed via a heparinised saline-filled calibrated 25-
gauge needle attached to an Elcomatic E751A pressure transducer connected to a MP100 
data acquisition system (BIOPAC Systems Inc, Santa Barbra, USA).  Briefly, a portion of 
skin was removed from the ventral chest to expose the anterior sternum.  The 25-gauge 
needle  was  then  advanced  through  the  mid-portion  of  the  sternum,  into  the  abdomen.  
Following entry into the diaphragm (confirmed by a negative pressure reading), the needle 
was advanced directly into the right ventricle via puncture through the right ventricular 
free wall.  This was confirmed by the characteristic pressure waveform typically observed 
inside  the  right  ventricle  (Figure  2.2).    From  this  recording,  right  ventricular  systolic 
pressure  (RVSP)  was  deduced  and  used  as  an  index  of  PAH.    Following  RVP 
measurement,  two  additional  controls  were  performed  to  confirm  successful  right 
ventricular catheterisation.  This was achieved by further advancing the needle into the left 
ventricle to measure left ventricular pressure, which is typically positioned inferior to the  
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right ventricle in situ.  At necropsy, the heart was also microscopically assessed to confirm 
the presence of a puncture in the right ventricular free wall. 
 
 
 
 
 
 
Figure  2.2  Representative  recording  of  right  ventricular  pressure.  Three  second 
representative measurement of right  ventricular pressure in  mice.    Y-axis expressed  in 
mmHg. 
 
2.2.3  Systemic Arterial Pressure 
Systemic Arterial Pressure (SAP) was measured via cannulation of the left common carotid 
artery (Figure 2.3).  Briefly, this was approached via skin incision through the ventral neck 
to expose the trachea.  Lateral blunt dissection was performed through the muscle lying 
inferior to the trachea.  The left common carotid artery is typically positioned ~2mm lateral 
(left) and less than 1mm posterior to the trachea.  Precision dissection was performed to 
separate the artery from both the vagus nerve and the recurrent laryngeal nerve.  Distal 
suture  (7-0  silk  non-braided)  was  used  for  isolation  of  the  artery  and  an  arterial  clip 
positioned at the most proximal arterial segment to temporarily occlude blood flow through 
the  lumen.    Following  incision  through  the  arterial  wall,  a  heparinised  saline-filled 
polypropylene cannula (Harvard Apparatus, Boston, USA) was proximally inserted 4-5mm 
into  the  lumen  and  secured  using  suture.    Similar  to  the  technique  used  for  RVP  
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measurement,  the  systemic  arterial  cannula  was  also  attached  to  an  Elcomatic  E751A 
pressure transducer connected to a MP100 data acquisition system (BIOPAC Systems Inc, 
Santa Barbra, USA). 
 
 
 
 
 
 
 
Figure  2.3  Representative  recording  of  systemic  arterial  pressure.  Three  second 
representative measurement of systemic arterial pressure in mice.   Y-axis expressed in 
mmHg. 
 
Following measurement of RVP and SAP, mice were killed by cervical dislocation.  The 
heart and lungs were dissected en bloc and placed in ice-cold physiological saline solution 
(PSS; pH 7.4; mmol/L, NaC1 119, NaHCO3 25, KCl 4.7, KH2PO4 1.2, MgSO4 0.6, CaC12 
2.5,  C6H12O6  11.1).    Where  appropriate,  the  uterus  was  also  removed  for  weight 
measurement in female mice.   
 
2.2.4  Right Ventricular Hypertrophy 
The atria, large blood vessels and pericardial fat were dissected free from the ventricles.  
The right ventricular free wall (RV) was dissected from the left ventricle plus septum 
(LV+S) and both were dry blotted.  Right ventricular hypertrophy (RVH) was assessed by 
weight measurement of the RV and LV+S.  The ratio expressed is RV/LV+S, and used as 
an index of PAH.  
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2.2.5  Pulmonary Vascular Remodelling  
Three 5µm sagittal sections of lung were elastica-Van Gieson stained and microscopically 
assessed for the muscularisation of pulmonary arteries (<80µm external diameter) in a 
blinded fashion.  Remodelled arteries were confirmed by the presence of a double elastic 
laminae.  Lung sections from 4 to 6 mice for each group were studied.  Approximately 150 
arteries from each sagittal lung section were assessed (~450 vessels from each animal in 
total).  This was expressed as a percentage of pulmonary vascular remodelling (remodelled 
vessels/total pulmonary vessels x 100 = % pulmonary vascular remodelling).  
 
2.3  Pulmonary Vascular Reactivity  
2.3.1  Dissection 
The  intralobar  pulmonary  artery  (internal  diameter  200µm-250µm)  from  the  superior 
(large) lobe of the left lung was studied for pulmonary vascular reactivity.  Dissection was 
approached from the visceral surface of the lung, and the artery was positioned laterally 
and posterior to the secondary bronchi.  Once isolated, the surrounding parenchyma and 
airway  smooth  muscle  was  carefully  dissected  free  from  the  pulmonary  artery  and 
suspended in ice-cold PSS until use.          
 
2.3.2  Small Vessel Wire Myography 
Small vessel wire myography was performed to investigate pulmonary vascular reactivity 
in mice.  In preparation of mounting the arteries, each organ bath chamber was filled with 
5ml PSS heated to 37
oC + 0.5
oC and continuously bubbled with 16% O2, 5 % CO2 and 
79% N2.  This gas composition was used to replicate the partial pressure of O2 (pO2) 
typically  observed  within  the  lung  in  vivo.  Following  dissection  from  the  lung,  the 
intralobar pulmonary artery (~5mm length) was divided into 2mm segments.  Two sections  
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of stainless steel wire (40µm diameter, 3cm length) were passed through the lumen and 
tied to their respective myograph clamp to securely position the artery.  Once achieved, the 
artery was equilibrated for at least 20 minutes under resting/zero tension. 
 
2.3.3  Application of Tension 
The pulmonary circulation operates as a high flow, low pressure circuit.  In control (non-
PAH) mice, the mean PAP typically resides at 15mmHg, whilst in mice exposed to chronic 
hypoxia this is increased to ~30mmHg.  Therefore to replicate similar conditions in vitro, a 
transmural pressure of 12-16mmHg (normoxia) or 27-32mmHg (hypoxia) was applied to 
the artery.  Isometric tension was applied to the artery to replicate transmural pressure.  
Pressure was then deduced from the force of tension (Figure 2.4).  For these, resting/zero 
tension (XO), active tension (Xi) and passive force (F) values were required.  In addition, 
the constant value of 2 (mm) was used for vessel length (L).  
 
Pi = (2π) x F/2 x L (205.6 + (Xi- Xo)) 
 
Figure 2.4 Equation to calculate transmural pressure.  The given value (Pi) must be 
divided by 0.133 in order for successful conversion to mmHg. 
 
Tension was incrementally applied to the artery until the appropriate transmural pressure 
was achieved.  Following this, the artery was again equilibrated under active tension for at 
least 20 minutes prior to the addition of 50mmol/L KCl for a 30 minute period.  KCl-
induced contraction was used to confirm both a contractile response is apparent, and also 
to  normalise  this  contraction.    This  step  was  subsequently  repeated,  and  a  contractile 
response  of  ≥1millinewton  (mN)  in  the  artery  was  considered  sufficient  to  perform  a 
cumulative concentration response curve.  
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2.3.4  Cumulative Concentration Response Curve 
Prior to the construction of a serotonin concentration response curve, a baseline tension 
was  established  for  at  least  30  minutes.    Serotonin  (serotonin  hydrochloride,  Sigma-
Aldrich, Poole, UK) was initially added at 1x10
-9mol/L and increased in 0.5 log increments 
until a final concentration of 1x10
-4 mol/L was achieved.  To maintain consistency between 
the addition of each drug concentration, the subsequent concentration was added once the 
vascular response had reached a plateau which was typically every three minutes.  Where 
appropriate, all antagonists and inhibitors were added to the organ bath at least 30 minutes 
prior to the addition of the initial drug concentration. 
 
2.3.5  Analysis 
The contractile response to an agonist was normalised against the maximum contractile 
response to 50mmol/L KCl and expressed as a percentage.  For comparison, the logEC50 
(defined as the agonist concentration required to produce 50% of the maximal contraction) 
was generated and used as an index to describe serotonin potency.  This was calculated 
using the ‘log [Agonist] Variable Slope - Best Fit’ function (Graphpad 5.0, CA, USA), 
which assumes baseline is 0% response and maximal contraction is 100% response.  The 
Emax value, defined as the maximum contractile response generated by an agonist, was used 
as  an  index  of  efficacy.    Where  appropriate,  this  was  used  to  compare  the  maximum 
contractile responses across groups. 
 
2.4  Histology 
2.4.1  Fixation 
Following death, the inferior and middle lobes of the right lung were dissected free and 
fixed in 10% (v/v) neutral-buffered formalin (NBF; 90% dH2O, 10% formalin, 33mmol/L  
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NaH2PO4, 45mmol/L Na2HPO4) for three days, under gentle agitation.  Formalin-fixed 
lungs  were  then  paraffin-embedded  and  5µm  sagittal  sections  cut  and  mounted  onto 
salinized glass microscope slides. 
 
2.4.2  Immunohistochemistry  
5µm sagittal lung sections were deparaffinized and re-hydrated through a xylene-ethanol 
gradient (100% xylene > 100% ethanol > 90% ethanol > 70% ethanol; 10 minutes each 
step) and washed in deionised water for 10 minutes.  Following hydration, heat-induced 
epitope retrieval (HIER/antigen retrieval) was performed by the incubation of lung sections 
in 10mmol/L citric acid (pH 6.0) at 90
oC-100
oC for 20 minutes, which was then cooled to 
room temperature.  Lung sections were then rinsed in deionised water for 10 minutes, 
before endogenous peroxidise activity was blocked via incubation in methanol containing 
3%  (v/v)  hydrogen  peroxide  (Sigma-Aldrich,  Poole,  UK)  for  30  minutes  at  room 
temperature.    After  this,  sections  were  washed  in  deionised  water  for  10  minutes  and 
further PBS washed for 10 minutes.  Non-specific blocking was carried out using 10% 
(v/v) goat serum and 5% (w/v) BSA in 0.01mol/L PBS, and incubation performed in a 
humidified  chamber  for  1  hour  at  room  temperature.    The  next  step  was  to  block 
endogenous biotin, which was performed in a two-step process.  Initially, lung sections 
were incubated in avadin D blocking solution for 15 minutes followed by a PBS wash, then 
subject to an additional incubation in biotin blocking solution for 15 minutes followed by 2 
x 10 minute PBS washes.  The lung sections were then incubated in a humidified chamber 
at 4
oC overnight with primary antibody diluted in 15% (v/v) primary antiserum and 10% 
(w/v) BSA in PBS.  The negative control slide was incubated in identical diluent, with the 
only exception the absence of primary antibody.  Subsequent to this, sections were washed 
in  PBS  for  2  x  10  minutes  at  room  temperature  prior  to  the  biotinylated-conjugated 
secondary  antibody  incubation.    The  purpose  of  the  biotinylated-conjugated  secondary  
  82 
antibody was to selectively bind the primary antibody.  To perform this, lung sections were 
incubated in a humidified chamber for 1 hour at room temperature with the appropriate 
secondary antibody diluted in 0.01mol/L PBS.  Sections were then 3 x 10 minute PBS 
washed, and incubated with avadin-biotin complex (ABC) solution (Vector Laboratories, 
Peterborough, UK) for 1 hour at room temperature.  To stop this reaction, sections were 
rinsed  with  PBS  and  then  subjected  to  a  further  2  x  10  minute  PBS  wash.    For 
immunoperoxidase  staining,  the  DAB  Substrate  kit  (3,3-diaminobenzidine,  hydrogen 
peroxide and nickel solution; Vector Laboratories, Peterborough, UK) was used and the 
solution was incubated with lung sections until dark brown staining was apparent, which 
was typically 2-5 minutes.  To stop the immunoperoxidase staining reaction, sections were 
placed in deionised water.  The lung sections were further washed in deionised water for 
10  minutes  before  ethanol-xylene  dehydration  (70%  ethanol  >  90%  ethanol  >  100% 
ethanol > 100% xylene; 10 minutes each step).  Finally, glass coverslips were mounted 
onto each slide using Tissue-Mount (Sakura Finetek, Alphen aan den Rijn, Netherlands).  
Immunostaining was visualised using a light microscope and positive protein-staining was 
brown/dark-brown in appearance.  Where appropriate, adjacent sagittal lung sections were 
counter-stained  with  hematoxylin  and  eosin  (H&E),  which  stain  for  the  nucleus  and 
cytoplasm respectively.   
 
2.5  Tissue Culture  
Tissue  culture  was  performed  in  sterile  conditions  using  a  Biological  Safety  Class  II 
vertical  laminar  flow  cabinet.    Tissue  explants  and  cells  were  incubated  at  37
oC  and 
maintained in 5% CO2, 95% air.  Human pulmonary artery smooth muscle cells (PASMCs) 
were the cellular model studied.   
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2.5.1  Human Pulmonary Artery Smooth Muscle Cells  
Human pulmonary artery smooth muscle cells (PASMCs) were provided by Prof N.W 
Morrell,  University  of  Cambridge,  UK.    Briefly,  PASMCs  were  derived  from  the 
pulmonary  arteries  (1-3mm  internal  diameter)  of  three  non-heritable  idiopathic  PAH 
(IPAH)  patients.    PASMCs  derived  from  macroscopically  normal  lung  biopsies 
(pulmonary arteries; 1-3mm internal diameter) excised from non-PAH donors were studied 
as control.  The homogeneity of PASMCs was confirmed via cell morphology (Figure 2.5) 
and positive staining for α-smooth muscle actin.  PASMCs were incubated in a 75cm
2 
culture  flask  and  media  was  aspirated  and  replenished  every  48  hours.    These  were 
cultured  in  Dulbecco's  Modified  Eagle  Medium  (DMEM;  Gibco,  Paisley,  UK) 
supplemented  with  2mmol/L  L-glutamine,  antibiotic  antimycotic  solution  (contains 
100U/ml penicillin, 100µg/ml streptomycin, 0.25 µg/ml amphotericin B; Sigma-Aldrich, 
Poole,  UK)  and  10%  (v/v)  fetal  bovine  serum  (Sera  Laboratories  International,  West 
Sussex, UK).  Cells were routinely passaged when monolayer cell growth reached 95% 
confluency, to prevent cell growth arrest via contact inhibition.  For passaging, cells were 
phosphate-buffered saline (PBS; 2.7mmol/L KCl, 0.137mol/L NaCl, pH 7.4) washed and 
twice rinsed with 0.06% (v/v) trypsin-ethylenediamine tetra-acetic acid (trypsin-EDTA; 
Gibco, Paisley, UK) suspended in 0.01mol/L PBS and incubated at 37
oC until detached 
from the flask, which was typically less than 5 minutes.  Trypsinization of the cells was 
immediately stopped following the addition of 10ml 10% (v/v) FBS DMEM which acts to 
neutralize trypsin, and the cell-suspension used for sub-culturing.  Where appropriate, cell 
density was assessed via cell counts using a haemocytometer. 
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Figure  2.5  Typical  morphology  of  human  pulmonary  artery  smooth  muscle  cells.  
Scale bar 100µm. 
 
2.5.2  Proliferation Assays  
2.5.2.1  Cell Counting 
Cell counts were performed to identify total cell number.  PASMCs (passage 3-7) were 
seeded in 24-well plates at a density of 20,000 per/well and grown to 60% confluency in 
10% FBS DMEM before quiescence in 0.2% (v/v) FBS DMEM for 24 hours.  PASMCs 
were  then  exposed  to  the  required  agonist  (in  the  presence  of  2.5%  (v/v)  FBS)  and 
proliferation assessed at 4-5 days.  Where appropriate, cells were stimulated with steroid 
hormone-depleted FBS for throughout experiments.  For the cell counting proliferation 
assay,  media  was  aspirated  and  70µl  0.06%  (v/v)  trypsin-EDTA  added.    This  was 
immediately aspirated and 150µl trypsin-EDTA added to each well and incubated at 37
oC 
until  the  cells  were  free-suspended,  which  was  typically  5-10  minutes.    To  inhibit  
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trypsinization, 400µl 10% FBS DMEM was simultaneously added to each well and gently 
mixed.  The total volume of each well (550µl) was then transferred to 1.5ml tubes and 
centrifuged  (10,000rpm)  at  4
oC  for  10  minutes.    Following  this,  the  supernatant  was 
carefully aspirated and the remaining cell pellet re-suspended via vortex in 200µl 10% FBS 
DMEM.  Cell counts were performed using a haemocytometer and the mean value used to 
calculate the total cell number per well (mean x 2000 = cells per well).  Data are expressed 
as total cell number. 
 
2.5.2.2  [
3H] Thymidine Incorporation 
The [
3H] thymidine proliferation assay is based on the use of a radioactive nucleoside ([
3H] 
thymidine)  which  is  incorporated  into  chromosomal  DNA  during  mitosis.    This  is  an 
accurate method to determine the rate of proliferation, as previously shown.  PASMCs 
were seeded in 24-well plates at a density of 20,000 per/well and grown to 60% confluency 
in 10% FBS DMEM before quiescence for 24 hours.  Following this, cells were then 
exposed  to  the  agonist  of  interest  for  the  required  time.  Where  appropriate,  all 
antagonists/inhibitors were added at least 30 minutes prior to the addition of agonist.  For 
the last 24 hours, 0.2μCi [
3H] thymidine was added to each well.  The experiment was 
stopped by twice rinsing each well with 0.01mol/L PBS.  Protein was precipitated by three-
times  washing  each  well  with  5%  (w/v)  trichloroacetic  acid,  which  was  performed 
immediately prior to the addition of 0.3mol/L NaOH for 30 minutes.  The total volume of 
each well (500µl) was then transferred to 1.5ml tubes and 1ml Ecoscint A scintillation 
fluid (Ecoscint, Atlanta, USA) added.  The radioactivity level of [
3H] thymidine was an 
index of DNA synthesis and measured using a Wallac scintillation counter (PerkinElmer, 
Cambridgeshire, UK).  Data are expressed as percentage change compared to 2.5% FBS-
induced proliferation. 
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2.6  Western Blotting 
2.6.1  PASMCs 
Human  PASMCs  (passage  3-7)  were  seeded  in  6-well  plates  at  a  density  of  25,000 
per/well and grown to 80% confluency in 10% FBS DMEM before quiescence for 24 
hours.  Following agonist stimulation for the required time, experiments were stopped by 
6-well plate incubation on ice.  Immediately, the media was aspirated and each well PBS-
rinsed three times.  Ice-cold RIPA buffer (50mmol/L HEPES pH 7.5, 150mmol/L NaCl, 
1% (v/v) Triton X-100, 0.5% (v/v) sodium deoxycholate, 0.1% (v/v) SDS, 0.01M sodium 
phosphate, 5mmol/L EDTA, 0.1mmol/L PMSF, 1μg/ml soybean trypsin inhibitor, 1μg/ml 
benzamidine)  was  then  added  to  each  well  for  15  minutes,  under  gentle  agitation.  
Following this, cell lysates were collected by scraping.  Whole cell lysates were stored at -
80
oC for Western blot analysis.   
 
2.6.2  Pulmonary Arteries 
The  main,  left  and  right  pulmonary  arteries  were  studied  for  Western  blot  analysis.  
Proximal pulmonary arteries were investigated as these were the smallest that could be 
practically dissected from mice, and more representative of the pulmonary vasculature than 
whole lung analysis.  Immediately following death, the arteries were dissociated free from 
the heart and lungs, snap-frozen in liquid N2 and stored at -80
oC until use.  In order to 
obtain  a  sufficient  concentration  of  protein  for  analysis,  arteries  from  4  mice  were 
suspended  in  250µl  lysis  buffer  (50mmol/L  tris  pH  7.4,  1mmol/L  DTT,  1x  complete-
protease inhibitor tablet; Roche Diagnostics, West Sussex, UK) and homogenised using a 
micro-rotary blade.  Protein samples were aliquoted as required, and stored at -80
oC for 
Western blot analysis.  For protein validation of novel genes, pulmonary arteries were  
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isolated and prepared from age-matched littermate mice to those studied for microarray 
analysis.    
   
2.6.3  SDS-PAGE 
Protein was separated on the basis of their molecular weight by performing SDS-PAGE 
using NuPage Gel Electrophoresis system (Invitrogen, Paisley, UK) as per manufacturer’s 
instructions.    Briefly,  protein  samples  were  subjected  to  reducing  conditions  in  the 
presence of 10µl 4x NuPage (lithium dodecyl sulfate) LDS sample buffer and 10x NuPage 
sample  reducing  agent  (10mmol/L  dithiothreitol),  and  heated  to  70
oC  for  10  minutes.  
Samples  were  loaded  into  NuPage  Novex  4%-12%  Bis-Tris  Mini  Gels  (Bis-Tris-HCl 
buffer  pH  6.4,  4%-12%  acrylamide,  bis-acrylamide,  0.1%  ammonium  persulfate)  and 
subjected to 150V constant in the presence of NuPage MES or MOPS running buffer.  
SeeBlue Plus2 pre-stained size standard was used as a surrogate for protein molecular 
weight.  Once SDS-PAGE fractionation was complete, protein and size standard was then 
transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore, County Durham, 
UK) at 30V constant for 1 hour.  The protein-loaded PVDF membrane was then three-
times 15 minutes washed with Tris-buffered saline (20mmo/L Tris pH 7.5, 150mmol/L 
NaCl) containing 0.1% (v/v) Tween-20 (TBST; Sigma-Aldrich, Poole, UK). 
 
2.6.4  Immunoblotting 
Immunoblotting was performed for protein expression analysis.  Briefly, membranes were 
blocked for 1 hour in 5% (w/v) dried milk suspended in tris-buffered saline supplemented 
with 0.2% (v/v) Tween (TBST) at room temperature under gentle agitation.  Following 
this,  membranes  were  TBST-washed  and  incubated  overnight  at  4
oC  with  primary 
antibody diluted in 5% (w/v) bovine serum albumin (BSA; Sigma-Aldrich, Poole, UK) 
suspended  in  TBST.  Optimized  antibody  dilutions  are  summarized  in  Table  2.1.   
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Subsequently,  membranes  were  TBST-washed  prior  to  1  hour  room  temperature 
incubation with horse-radish peroxidise (HRP) conjugated-secondary antibody diluted in 
5% dried milk-TBST.  Following secondary antibody incubation, membranes were TBST-
washed.    Protein  visualisation  was  performed  using  the  enhanced  luminol-based 
chemiluminescence detection system (ECL-detection system, Amersham Bioscience UK 
Ltd, Buckingham, UK).  To perform this, membranes were exposed to 1:1 dilution of ECL 
solution mix for 60 seconds, dry blotted and placed in a light-sensitive cassette.  General 
purpose Kodak X-ray film was used for the chemiluminescent visualisation of proteins. 
 
2.6.5  Quantitative Expression of Protein  
α  tubulin  was  used  as  the  protein  loading  control,  which  did  not  overlap  with  the 
molecular  weight  of  any  protein(s)  which  had  been  previously  probed  on  the  PVDF 
membrane.    To  confirm  equal  protein  loading,  densitometry  was  employed.  
Densitometrical analysis was performed in scanned X-ray film visualised protein using 
TotalLab TL100 software, via calculation of the protein:α tubulin ratio.  To maintain ratio 
consistency across biological experimental replicates, multiple α tubulin time points were 
assessed and analysed.        
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Reactive   Molecular  Supplier and    Antibody   1
o Dilution  2
o Dilution 
Protein  Weight  Order Number  Description 
 
TPH1  55kDa  Chemicon    Rabbit    1:250    Anti-rabbit 
         AB15570    polyclonal to      HRP  
               TPH1        1:1000 
 
5-HT1B   47kDa  Abcam     Rabbit    1:250    Anti-rabbit 
Receptor      AB85937    polyclonal to      HRP   
              5--HT1B        1:1000 
   Receptor 
   
SERT    70kDa  Abcam     Goat     1:500    Anti-goat 
        AB36127    polyclonal to      HRP 
   SERT        1:1000 
 
C/EBPβ  32kDa  Abcam     Rabbit   1:1000   Anti-rabbit 
        AB32358    polyclonal to      HRP 
   C/EBPβ      1:1000 
 
CYP1B1  70kDa  Abcam     Rabbit   1:500    Anti-rabbit 
      AB33586    polyclonal to      HRP 
   CYP1B1      1:1000 
 
c-FOS  60kDa  Abcam     Rabbit    1:1000   Anti-rabbit 
   AB7963    polyclonal to      HRP 
   c-FOS       1:2000 
 
α tubulin  50kDa  Abcam     Mouse     1:5000   Anti-mouse 
  AB7291    monoclonal to     HRP 
      α-tubulin      1:5000 
 
Table  2.1  Immunoblotting  antibody  table.    List  of  antibodies  used  for  immunoblotting.  
Primary (1
o) antibodies were incubated overnight at 4oC in 5% (w/v) BSA-TBST.  Secondary 
(2
o) antibodies were incubated for 1 hour at room temperature in 5% (w/v) dried milk-TBST.         
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2.7  RNA Extraction  
2.7.1  Pulmonary Arteries 
The main, left and right pulmonary arteries were studied for RNA expression analysis.  
Immediately following death, the arteries were dissociated free from the heart and lungs, 
snap-frozen in liquid N2 and stored at -80
oC in nuclease-free conditions until use.  Total 
RNA extraction was performed in the pulmonary arteries of mice using the RNeasy Mini-
Kit (Qiagen, Crawley, UK) as per manufacturer’s instructions.  Briefly, 400µl of buffer 
RLT was added to each pulmonary artery and subsequently homogenised (2 x 20Hz for 2 
minutes) using the TissueLyser II (Qiagen, Crawley, UK).  Buffer RLT contains guanidine 
isothiocyanate which immediately inactivates nucleases to ensure the isolation of intact 
total RNA.  Samples were then incubated for 10 minutes at 55
oC in proteinase K solution 
(10µl:590µl dilution in nuclease free water) to ensure the optimal lysis and maximum total 
RNA  yield  from  the  fibrous  tissue.    Subsequent  to  this,  each  sample  was  centrifuged 
(10,000rpm, 3 minutes, room temperature), the supernatant transferred to a 1.5ml tube and 
400µl ethanol added to promote ideal binding conditions.  The samples were then loaded 
and centrifuged (10,000rpm, 15 seconds, room temperature) into RNeasy spin columns, 
which  results  in  the  binding  of  total  RNA  to  the  silica-membrane  component  of  the 
column.  The spin column was then washed three times with buffer RWT before RNA 
elution in 30µl RNase-free water (10,000rpm, 1 minute, room temperature).  To further 
increase total RNA yield, the 30µl volume was again centrifuged through the spin column.  
RNA  integrity  and  quantification  was  assessed  using  the  NanoDrop  ND-1000 
Spectrophotometer  (Nano-Drop  Technologies,  Delaware,  USA)  and  Agilent  2100 
Bioanalyzer  system  (Agilent  Technologies,  Berkshire,  UK).    Absorbance  of  the  RNA 
samples was quantified at 260 and 280 nm, and the 260/280 ratio was calculated.  All 
samples showed a 260/280 ratio ≥ 1.9 and RNA Integrity Number (RIN) ≥ 8.0, which was 
indicative of RNA purity.     
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2.7.2  PASMCs 
RNA  was  extracted  from  PASMCs  derived  from  IPAH  patients  and  control  using  the 
RNeasy Mini-Kit (Qiagen, Crawley, UK).  PASMCs (passage 3-5) were seeded in 6 well 
plates  at  25,000  per  well  and  grown  to  95%  confluency.    Following  trypsinization, 
PASMCs were centrifuged (10,000rpm, 10 minutes, 4
oC), the media aspirated and cells re-
suspended in ice cold PBS.  Subsequent to this, centrifuge and aspiration was repeated and 
PASMCs snap-frozen in liquid N2 and stored at -80
oC in nuclease-free conditions until use.  
 
2.7.3  DNase Treatment of RNA 
Currently,  no  RNA  extraction  method  is  sufficient  at  completely  eliminating  DNA 
contamination.  Therefore, DNase digestion is typically performed in RNA samples prior 
to  microarray  or  qRT-PCR  analysis.    To  perform  this,  DNase  treatment  of  RNA  was 
performed  using  TURBO  DNA-free  kit  (Ambion,  Texas,  USA)  according  to 
manufacturer’s instructions.  Briefly, 10% (v/v) of TURBO DNase buffer and 1µl TURBO 
DNase  was  added  to  each  RNA  sample  and  incubated  at  37
oC  for  30  minutes.    To 
terminate this reaction, 10% (v/v) DNase Inactivation Reagent was added to each sample 
and incubated for 3 minutes at room temperature.  The DNase free RNA samples were then 
centrifuged (12,000rpm, 2 minutes, room temperature) and the supernatant stored at -80
oC 
until use. 
 
2.7.4  cRNA Synthesis  
cRNA  synthesis  and  amplification  was  achieved  using  the  Illumina  TotalPrep  RNA 
Amplification  Kit  (Ambion,  Texas,  USA)  according  to  manufacturer’s  instructions.  
Briefly,  reverse  transcription  with  an  oligo(dT)  primer  containing  a  T7  promoter  (a 
genetically engineered reverse transcriptase which generates higher yields than wild type  
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reverse transcriptase enzymes) was performed in 200ng total RNA for first-strand cDNA 
synthesis.  To do this, 9µl Reverse Transcription Master Mix was added to each sample 
and incubated at 42
oC for 2 hours.  Second-strand cDNA synthesis was then performed by 
adding 80µl Second Strand Master Mix to each sample and incubating at 16
oC for 2 hours.  
Following purification, the cDNA is used as a template for in-vitro transcription (IVT) 
with T7 RNA polymerase.  The synthesis of biotinylated cRNA was performed in the 
presence of 7.5µl IVT and incubated at 37
oC for 14 hours, and the reaction stopped by 
adding 75µl RNase-free water.  This biotin-labelling of cRNA is essential for streptavodin-
cy3 staining following array hybridization.  Following cRNA purification, which removes 
unincorporated nucleotide triphosphates (NTPs), enzymes and reagents, the samples were 
analysed  for  integrity  using  the  Agilent  Bioanalyzer  system  (Agilent  Technologies, 
Berkshire, UK).  To determine cRNA concentration (µg/ml), we used the NanoDrop ND-
1000 (Nano-Drop Technologies, Delaware, USA) to obtain the A260 reading, which was 
then multiplied by 40-fold the elute volume (A260 x elute volume x 40 = cRNA µg/ml). 
 
2.8  Microarray Analysis 
Microarray analysis was used to investigate the genotypic changes associated with the 
development of PAH (Available online: Accession number E-MTAB-455).  To perform 
this,  microarray  analysis  was  performed  in  the  pulmonary  arteries  of  normoxic  and 
chronically hypoxic male and female SERT+ mice (8-10 weeks of age).  Age-matched 
C57BL/6xCBA littermate mice were studied as controls. 
 
2.8.1  cRNA Direct Hybridization Assay 
Genome-wide  cRNA  microarray  analysis  was  performed  using  the  MouseRef-8  v1.1 
Expression  BeadChip  (Illumina,  Essex,  UK)  according  to  manufacturer’s  instructions.   
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Briefly, 750ng cRNA was loaded into each BeadChip array and incubated at 58
oC for 16 
hours  under  gentle  agitation.    Once  cRNA  direct  hybridization  was  complete,  the 
Beadchips  were  washed  in  1x  High-Temp  Wash  buffer  at  55
oC  for  10  minutes,  then 
subject to a series of further washes in 0.06% (v/v) E1BC buffer and nuclease free ethanol 
prior to incubation in Block E1 buffer for 10 minutes at room temperature, under medium 
agitation.  Subsequent to this, each BeadChip was transferred into 2ml Block E1 buffer 
containing 1µg/ml streptavidin-Cy3 and incubated at room temperature for 10 minutes, 
under medium agitation. A third room temperature wash was then performed in 0.06% 
(v/v) E1BC buffer for 5 minutes.  BeadChips were then dried by centrifuge (350rpm) at 
25
oC for 4 minutes, and immediately scanned with a BeadStation 500GX (Illumina, Essex, 
UK).  Each beadchip contained approximately 25,600 probe sets which represented a total 
of ~19,100 unique genes.  The direct hybridization signal strength of a gene was indicative 
of its expression. 
 
2.8.2  Statistical Analysis 
Microarray data was analysed with BeadStudio software (Illumina).  Hybridisation signal 
strength was normalised to the median array and expression levels determined using the 
Average  Normalisation  Beadstudio  algorithm.    For  identifying  differentially  expressed 
genes, the following parameters (as recommended by Illumina) were used: P value <0.05, 
Diff Score >15, Average Signal >100.    
 
2.9  Quantitative Real-time PCR 
Quantitative  real-time  PCR  (RT-PCR)  was  employed  to  validate  results  obtained  from 
microarray analysis.  For validation, RNA extracted from mice studied for microarray was 
pooled  into  comparative  groups  (n=4,  repeated  in  triplicate)  and  analysis  performed.   
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Gene-specific primers corresponding to the PCR targets were designed based on published 
sequences in GenBank using the primer 3 program and synthesised by IDT (Integrated 
DNA Technologies, Belgium).  We confirmed the absence of nonspecific amplification by 
examining PCR products by agarose gel electrophoresis ensuring amplification of single 
discrete bands with no primer-dimers.  Real-time PCR was carried out in a DNA Engine 
OPTICON2 (MJ Research).  Each reaction was performed according to the Brilliant II 
SYBRGreen PCR Master Mix (Agilent Technologies, Berkshire, UK) protocol, using 10ng 
of RNA.  Three replicates were performed for each sample plus template-free samples as 
negative controls.  Cycling parameters consisted of an initial reverse transcription step for 
40 minutes at 50°C, followed by a 10 minute incubation at 95°C to fully activate the DNA 
polymerase and 40 amplification cycles at 95°C for 30 seconds, 56°C - 58°C for 30 or 40 
seconds, and 72°C for 30 seconds. Fluorescence measurements were assessed at the end of 
the annealing phase at 78°C, 82°C, and 86°C.  The CT values were determined using the 
Opticon2 software, and the total amount of RNA was normalised against β actin. 
 
2.10 Statistical Analysis  
Data were analyzed using a two-way ANOVA followed by Bonferroni’s post-hoc test, 
one-way ANOVA followed by Dunnett’s post-hoc test or unpaired t-test as appropriate, 
and described in figure legend.  Data are expressed as mean + SEM. 
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Chapter 3 
The Serotonin Transporter, Gender and 
17β Estradiol in the Development of 
Pulmonary Arterial Hypertension 
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3.1  Introduction 
Pulmonary  arterial  hypertension  (PAH)  is  characterised  by  both  remodelling  and 
vasoconstriction of the pulmonary vasculature.  Mutations in the gene encoding for the 
bone morphogenetic protein receptor-2 (BMPR-II) are accountable for ~80% of heritable 
PAH cases, however penetrance for this gene is incomplete as only 20% of BMPR-II 
mutation carriers develop PAH (Newman et al., 2004).  Therefore, it is assumed that other 
genetic or environmental risk factors are involved.  This is the basis of the ‘multiple hits’ 
hypothesis in PAH. 
 
In both idiopathic and heritable forms of PAH there is a gender bias, with females up to 
three-fold more likely to present with disease (Peacock et al., 2007; Humbert et al., 2006; 
Thenappan et al., 2007).  Despite this, the reasons underlying this female susceptibility 
remain unknown.  Estrogens are one possible risk factor in PAH.  The ingestion of oral 
contraceptives have previously been associated with PAH (Masi, 1976; Morse et al., 1999) 
and female PAH patients show increased expression levels of ESR1 (estrogen receptor 1), 
the  gene  encoding  for  ERα,  compared  to  unaffected  females  (Rajkumar  et  al.,  2010).  
Decreased  expression  of  the  estrogen-metabolising  enzyme  cytochrome  P450  1B1 
(CYP1B1) leading to altered estrogen metabolism has also been identified in female PAH 
patients harbouring a BMPR-II mutation compared to unaffected female carriers (Austin et 
al., 2009). 
 
In  contrast,  experimental  models  of  PAH  have  repeatedly  shown  that  female  rodents 
exhibit less severe PAH compared to males.  For example, female rats exposed to chronic 
hypoxia develop moderate PAH compared with severe PAH in males (Rabinovitch et al., 
1981).    Ovariectomized  rats  exhibit  severe  PAH  following  hypoxic  insult  and  this  is 
attenuated with 17β estradiol treatment (Resta et al., 2001).  In addition, male ApoE -/-  
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mice  prescribed  a  high-fat  diet  develop  a  more  established  PAH  phenotype  compared 
against high-fat treated ApoE -/- females (Hansmann et al., 2007).  This absence of a 
suitable  animal  model  which  replicates  the  female  bias  observed  in  human  PAH  has 
limited experimental research to date. 
 
Multiple studies have implicated serotonin, the serotonin transporter (SERT) and 5-HT1B 
receptors in the pathobiology of PAH.  In mice the development of hypoxia-induced PAH 
and  dexfenfluramine-induced  PAH  are  dependent  on  peripheral  serotonin  synthesis 
(Morecroft et al., 2007; Dempsie et al., 2008).  SERT expression is increased in human 
pulmonary artery smooth muscle cells (PASMCs) derived from idiopathic PAH (IPAH) 
patients and this is responsible for increased serotonin-induced proliferation in these cells 
(Eddahibi  et  al.,  2001).      The  5-HT1B  receptor  mediates  human  pulmonary  arterial 
vasoconstriction  (Morecroft  et  al.,  1999)  and  is  also  involved  in  PASMC  proliferation 
(Morecroft et al., 2010).  
 
In the central nervous system, estrogens regulate expression of multiple serotonin pathway 
mediators  including  tryptophan  hydroxylase  (Pecins-Thompson  et  al.,  1996)  (TPH;  the 
rate-limiting  enzyme  in  serotonin  synthesis)  and  SERT  (Lu  et  al.,  2003).    We  have 
previously shown that mice over-expressing the SERT (SERT+ mice) develop PAH and 
severe hypoxia-induced PAH (MacLean et al., 2004).  Here, we investigated the possible 
interactions between serotonin and estrogens in human PASMCs and SERT+ mice. 
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3.2  Results 
3.2.1  Male SERT+ Mice Do Not Develop Spontaneous PAH or 
Exaggerated Hypoxia-induced PAH Compared to Wildtype Mice 
We investigated the effects of gender on the development of PAH in SERT+ mice.  Firstly, 
we assessed right ventricular systolic pressure (RVSP), pulmonary vascular remodelling 
and right ventricular hypertrophy (RVH) in male SERT+ mice.  This was also investigated 
in male SERT+ mice following exposure to chronic hypoxia.  Male SERT+ mice did not 
develop  PAH  or  exaggerated  hypoxia-induced  PAH  compared  to  male  WT  mice,  as 
indicated by no differences in RVSP, pulmonary vascular remodelling or RVH (Figure 
3.1).  Similarly, no changes in mean systemic arterial pressure (MAP; Figure 3.2) or heart 
rate (HR; Figure 3.3) were reported.  To further investigate, PAH was assessed in female 
SERT+ mice.  
 
3.2.2  Female SERT+ Mice Develop Spontaneous PAH and Exaggerated 
Hypoxia-Induced PAH via the Effects of 17β Estradiol 
The  effects  of  gender,  ovariectomy,  SERT  and  17β  estradiol  were  investigated  in  the 
development of PAH in SERT+ mice.  In normoxia, sham-operated female SERT+ mice 
demonstrated increased RVSP (Figure 3.4) and pulmonary vascular remodelling (Figure 
3.5).  Representative resistance pulmonary arteries also appeared remodelled to a greater 
extent in these mice (Figure 3.6).  This was apparent in the absence of RVH (Figure 3.7).  
Absolute  RV,  LV+S  and  body  weight  of  these  mice  is  summarized  in  Table  3.1,  and 
haemodynamics summarized in Table 3.2.  The increased RVSP and pulmonary vascular 
remodelling  observed  in  female  SERT+  mice  was  abolished  following  ovariectomy 
(OVX).    We  subsequently  hypothesized  that  the  pre-dominant  female  hormone  17β 
estradiol was critical to the development of PAH in these mice.  To examine, this, SERT+  
  99 
OVX mice were subject to chronic 17β estradiol administration (1.5mg/kg/21 days).  This 
successfully re-established increased RVSP and pulmonary vascular remodelling in these 
mice.    RVH  was  similar  in  both  wildtype  and  SERT+  mice,  and  ovariectomy  had  no 
further effect on this.  However, ovariectomized SERT+ mice administered 17β estradiol 
exhibited a decrease in RVH.  Following their exposure to chronic hypoxia, female SERT+ 
mice exhibited an exaggerated PAH phenotype, as assessed by a greater increase in both 
RVSP and pulmonary vascular remodelling compared to wildtype mice.  This exaggerated 
hypoxia-induced  PAH  phenotype  was  attenuated  in  ovariectomized  SERT+  mice,  and 
increases in both RVSP and pulmonary vascular remodelling were re-established following 
17β estradiol administration in these mice.  The extent of RVH was also more pronounced 
in  chronically  hypoxic  female  SERT+  mice,  however  was  unaffected  following 
ovariectomy.  We further observed that the administration of 17β estradiol decreased RVH 
in the hypoxic SERT+ mice.  No differences in MAP (Figure 3.8) or HR (Figure 3.9) were 
reported.  Of additional interest, we also observed that hypoxia-induced PAH was more 
established in male wildtype mice than female wildtype mice.  This was confirmed by a 
marked  elevation  in  both  RVSP  and  pulmonary  vascular  remodelling  in  these  males 
compared to females. 
 
This evidence suggests a critical role for female hormones in the development of PAH in 
SERT+ mice.  To further investigate this, we were also interested in assessing the effects 
of hormone depletion in WT mice.  Ovariectomy was performed in WT mice and PAH was 
assessed in both normoxia and following exposure to chronic hypoxia.    
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Figure  3.1  Male  SERT+  mice  do  not  exhibit  spontaneous  PAH  or  exaggerated 
hypoxia-induced PAH compared to male WT mice.  Right ventricular systolic pressure 
(RVSP;  A),  pulmonary  vascular  remodelling  (%  remodelled  vessels;  B)  and  right 
ventricular hypertrophy (RVH; C) is similar in male wildtype and male SERT+ mice in 
both normoxia and following exposure to chronic hypoxia.  Data are expressed as mean + 
SEM  and  analysed  by  two-way  ANOVA  followed  by  Bonferroni’s  post-hoc  test.  
***P<0.001 cf. normoxic mice.   n=8-12. 
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Figure 3.2 Male SERT+ mice exhibit similar systemic arterial pressure to male WT 
mice.  Mean  systemic  arterial  pressure  (MAP)  is  unaffected  in  both  normoxic  and 
chronically hypoxic SERT+ mice compared to their respective wildtype controls.  Data are 
expressed as mean + SEM; n=7-9. 
 
 
 
Figure 3.3 Male SERT+ mice exhibit a similar heart rate  to male WT mice.  Heart-
rate (HR) is unaffected in both normoxic and chronically hypoxic SERT+ mice compared 
to their respective wildtype controls.  Data are expressed as mean + SEM; n=7-9. 
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Figure 3.4 Female SERT+ mice exhibit increased RVSP in normoxia and chronic 
hypoxia, via the effects of 17β estradiol.  Sham-operated SERT+ mice (SERT+) exhibit 
increased  RVSP  compared  to  sham-operated  wildtype  (WT)  mice.    Ovariectomized 
SERT+ mice (SERT+ OVX) exhibit a decrease of RVSP, and this is fully re-established 
following the administration of 17β estradiol (SERT+ OVX + E).  In chronic hypoxia, 
SERT+ mice develop increased RVSP compared to WT mice.  SERT+ OVX mice exhibit 
an  attenuated  hypoxia-induced  elevation  of  RVSP  and  this  is  increased  following  the 
administration of 17β estradiol.  Data are expressed as mean + SEM and analysed by two-
way ANOVA followed by Bonferroni’s post-hoc test.  *P<0.05, **P<0.01, ***P<0.001 cf. 
normoxic mice; †P<0.05, ††P<0.01 cf. wildtype mice; §§P<0.01 cf. sham-operated mice; 
‡‡P<0.01 cf. vehicle-dosed mice.  n=6-9.  
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Figure 3.5 Female SERT+ mice exhibit increased pulmonary vascular remodelling in 
normoxia and chronic hypoxia, via the effects of 17β estradiol.  Sham-operated SERT+ 
mice  (SERT+)  exhibit  increased  pulmonary  vascular  remodelling  compared  to  sham-
operated wildtype (WT) mice.  Ovariectomized SERT+ mice (SERT+ OVX) exhibit a 
reduction in pulmonary vascular remodelling, and this is fully re-established following the 
administration of 17β estradiol in these mice (SERT+ OVX + E).  In chronic hypoxia, 
SERT+ mice develop increased pulmonary vascular remodelling compared to WT mice.  
SERT+  OVX  mice  exhibit  attenuated  pulmonary  vascular  remodelling,  and  this  is 
increased following the administration of 17β estradiol.  Data are expressed as mean + 
SEM and analysed by two-way ANOVA followed by Bonferroni’s post-hoc test.  *P<0.05, 
**P<0.01,  ***P<0.001  cf.  normoxic  mice;  ††P<0.01  cf.  wildtype  mice;  §P<0.05, 
§§P<0.01  cf.  sham-operated  mice;  ‡‡P<0.01  cf.  vehicle-dosed  mice.    n=5.
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Figure 3.6 Photomicrographs of representative resistance pulmonary arteries in SERT+ mice.  Pulmonary arteries are stained with elastica-Van 
Gieson from both normoxic and hypoxic female WT and female SERT+ mice (Scale bar 50µm).  SERT+ mice exhibit remodelling to a greater extent 
than  WT  mice  and  this  is  attenuated  following  ovariectomy  however  can  be  re-established  following  the  administration  of  17β  estradiol  (E). 
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Figure  3.7  Female  ovariectomized  SERT+  mice  exhibit  reduced  right  ventricular 
hypertrophy in normoxia and chronic hypoxia, via the effects of 17β estradiol.  Right 
ventricular hypertrophy (RVH) is unaffected in sham-operated SERT+ mice compared to 
sham-operated wildtype mice (WT).  Ovariectomized SERT+ mice (SERT+ OVX) also 
exhibit RVH to a similar extent.  However, the administration of 17β estradiol reduces 
RVH  in  these  mice  (SERT+  OVX  +  E).    In  chronic  hypoxia,  SERT+  mice  develop 
increased RVH compared to WT mice.  RVH is unchanged in SERT+ OVX mice, however 
is reduced following the administration of 17β estradiol in these mice.  Data are expressed 
as mean + SEM and analysed by two-way ANOVA followed by Bonferroni’s post-hoc 
test.  **P<0.01, ***P<0.001 cf. normoxic mice; †P<0.05 cf. wildtype mice; ‡‡P<0.01 cf. 
vehicle-dosed mice.  n=6-9.   
  
  106 
0
20
40
60
80
100
120
WT
SERT+
SERT+ OVX
SERT+ OVX + E
NORMOXIC                           HYPOXIC
M
A
P
 
m
m
H
g
0
100
200
300
400
500
WT
SERT+
SERT+ OVX
SERT+ OVX + E
NORMOXIC                             HYPOXIC
H
R
 
B
P
M
Figure  3.8  Female  SERT+  mice  exhibit  no  change  in  systemic  arterial  pressure 
compared to female wildtype mice, and this is further unaffected by ovariectomy or 
17β estradiol.  Mean systemic arterial pressure (MAP) is unchanged in normoxic and  
chronically  hypoxic  SERT+  mice  compared  to  their  respective  wildtype  controls.  
Similarly, this is further unaffected following ovariectomy or 17β estradiol administration.  
Data are expressed as mean + SEM; n=6-9. 
Figure 3.9 Female SERT+ mice exhibit no change in heart rate compared to female 
wildtype mice, and this is further unaffected by ovariectomy or 17β estradiol.  Heart 
rate (HR) is unchanged in both normoxic and chronically hypoxic SERT+ mice compared 
to  their  respective  wildtype  controls.    Similarly,  this  is  further  unaffected  following 
ovariectomy or 17β estradiol administration.  Data are expressed as mean + SEM; n=6-9. 
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Group  RV (mg)  LV+S (mg)  RV/LV+S  Body Weight (g) 
 
Normoxic 
 
Wildtype 
Sham  19.34 + 0.78  73.31 + 1.19  0.26 + 0.013  24.75 + 0.99   
Ovariectomy  20.84 + 1.15  78.03 + 3.54  0.26 + 0.014  29.30 + 0.94
§§  
SERT+ 
Sham  17.70 + 0.66  67.94 + 2.52  0.25 + 0.009  21.34 + 0.86 
Ovariectomy  22.04 + 0.88  78.08 + 2.06  0.27 + 0.009  22.62 + 0.53 
Ovariectomy + vehicle  23.92 + 0.75  85.42 + 3.10  0.28 + 0.016  21.44 + 0.80   
Ovariectomy + estradiol   19.91 + 0.58  90.50 + 5.65  0.22 + 0.008
‡‡  20.97 + 0.73 
 
Hypoxic 
 
Wildtype 
Sham  22.86 + 0.92  70.77 + 2.85  0.32 + 0.014**  21.23 + 1.02 
Ovariectomy  24.48 + 1.09  66.31 + 1.86  0.36 + 0.012  21.36 + 1.02 
SERT+ 
Sham  25.04 + 0.97  73.30 + 2.76  0.34 + 0.015**  20.12 + 0.89 
Ovariectomy  26.42 + 1.17  67.67 + 3.99  0.39 + 0.018***  20.77 + 0.41 
Ovariectomy + vehicle   28.11 + 1.02  75.97 + 4.11  0.38 + 0.014**
†  21.83 + 0.56 
Ovariectomy + estradiol  26.96 + 1.85  96.29 + 5.98  0.28 + 0.011**
‡‡ 20.28 + 0.71 
 
Table 3.1 Ventricle and body weight in WT and SERT+ mice.  Right ventricle (RV) 
weight,  left  ventricle  plus  septum  (LV+S)  weight,  RV/LV+S  ratio  and  body  weight.  
**P<0.01, ***P<0.001 cf. normoxic mice; †P<0.05 cf. WT mice; ‡‡P<0.01 cf. vehicle 
mice; §§P<0.01 cf. sham mice.  Data expressed as mean + SEM.  n=8-11.    
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Parameter   WT sham  SERT+ sham  SERT+ OVX  SERT+ OVX+ E2
   
 
Normoxic 
 
RVSP, mmHg  20.19 + 0.72  26.93 + 1.73
††  21.99 + 0.77
§§  26.95 + 0.99
‡‡ 
RVMP, mmHg  7.59 + 0.46  9.99 + 0.70
†  8.07 + 0.41
§  9.97 + 0.53
‡ 
RVDP, mmHg  1.26 + 0.29  1.39 + 0.33  1.11 + 0.24  1.44 + 0.60
  
SAP, mmHg  109 + 4.56  112 + 6.46  116 + 7.20  121 + 9.48 
MAP, mmHg  87.37 + 3.34  90.50 + 4.19  93.43 + 4.24  97.62 + 5.23   
DAP, mmHg  76.2 + 2.23  79.75 + 2.99  87.14 + 3.87  85.93 + 2.11 
Heart rate, bpm  370 + 12  372 + 14  399 + 20  431 + 40   
 
Hypoxic 
 
RVSP, mmHg  31.07 + 2.69**  40.28 + 2.91***
†  29.47 + 1.36*
§§  36.55 + 2.62**
‡‡ 
RVMP, mmHg  12.58 + 1.32**  16.16 + 1.71***  12.40 + 0.99**
§  15.06 + 1.44**
‡ 
RVDP, mmHg  3.34 + 0.55*  4.15 + 0.59**  3.87 + 0.78*  4.29 + 0.95* 
 
  
SAP, mmHg  112 + 6.69  117 + 9.00  118 + 9.54  114 + 10.22 
MAP, mmHg  88.01 + 3.45  91.83 + 4.58  92.83 + 4.85  92.56 + 4.90 
DAP, mmHg  76.78 + 1.79  73.50 + 3.21  79.57 + 2.88  81.84 + 1.84 
Heart rate, bpm  388 + 12  408 + 20  376 + 9  388 + 23 
   
 
Table 3.2 Haemodynamics in WT and SERT+ mice.  Right ventricular systolic pressure 
(RVSP), right ventricular mean pressure (RVMP), right ventricular diastolic pressure (RVDP), 
systemic  systolic  arterial  pressure  (SAP),  mean  arterial  pressure  (MAP),  diastolic  arterial 
pressure (DAP) and heart rate measurements in normoxic and chronically hypoxic female WT 
and SERT+ mice. ovariectomy, OVX; 17β estradiol, E2  *P<0.05, **P<0.01, ***P<0.001 cf. 
normoxic  mice;  †P<0.05,  ††P<0.01  cf.  WT  mice;  §P<0.05,  §§P<0.01  cf.  SERT+  mice; 
‡P<0.05, ‡‡P<0.01 cf. SERT+ OVX mice.  Data expressed as mean + SEM.  n=6-9.    
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3.2.3  Ovariectomized Wildtype Mice Develop PAH  
We also studied the effects of ovariectomy on the development of PAH in wildtype mice.  
In  normoxia,  we  observed  that  ovariectomized  mice  developed  increased  RVSP  and 
pulmonary vascular remodelling compared to sham-operated mice (Figure 3.10).  Increases 
in  both  of  these  indices  were  observed  in  the  absence  of increased  RVH.    In  chronic 
hypoxia, ovariectomized females did not develop exaggerated hypoxia-induced PAH, as 
assessed  by  no  further  elevation  of  RVSP,  pulmonary  vascular  remodelling  and  RVH 
compared to sham-operated mice.  No effect on MAP (Figure 3.11) or HR (Figure 3.12) 
was reported in ovariectomized mice.     
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Figure  3.10  Ovariectomized  wildtype  mice  exhibit  PAH.  OVX  WT  mice  exhibit 
increased RVSP (A) and PVR (B).  Increased RVH (C) is reported in chronically hypoxic 
OVX mice compared to chronically hypoxic sham mice.  Data are expressed as mean + 
SEM and analysed by two-way ANOVA followed by Bonferroni’s post-hoc test.  *P<0.05, 
**P<0.01, ***P<0.001 cf. normoxic mice; ††P<0.01 cf. normoxic sham mice; §P<0.05 cf. 
hypoxic sham mice.  n=8-10.  
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Figure  3.11  Ovariectomy  has  no  effect  on  systemic  arterial  pressure  in  either 
normoxic or chronically hypoxic wildtype mice.  Mean systemic arterial pressure (MAP) 
is unaffected in normoxic and chronically hypoxic mice following ovariectomy.  Data are 
expressed as mean + SEM; n=7-8.   
 
 
Figure 3.12 Ovariectomy has no effect on heart rate in either normoxic or chronically 
hypoxic  wildtype  mice.  Heart  rate  (HR)  is  unaffected  in  normoxic  and  chronically 
hypoxic mice following ovariectomy.  Data are expressed as mean + SEM; n=7-8.   
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3.2.4  Ovariectomy Increases Body Weight and Decreases Uterine 
Weight 
To  confirm  that  ovariectomy  was  successfully  performed  in  mice,  we  assessed  body 
weight and uterine weight.  In ovariectomized WT mice, we observed a marked increase in 
body weight (Figure 3.13) whilst a decrease in uterine weight (Figure 3.14) was recorded 
in  all ovariectomized  groups, indicative  of successful removal of the ovaries.  Similar 
observations have been previously reported in mice following ovariectomy (Windahl et al., 
2009).  Further,  increased  uterine  weight  was  observed  in  17β  estradiol-treated 
ovariectomized  SERT+  mice,  as  a  consequence  of  17β  estradiol-mediated  uterine 
hypertrophy.   
 
3.2.5  Male SERT+ Mice Do Not Develop PAH Following 17β Estradiol 
Administration 
We previously observed that 17β estradiol is critical to the development of spontaneous 
PAH  and  exaggerated  hypoxia-induced  PAH  in  female  SERT+  mice.    To  further 
investigate the role of this hormone in SERT+ mice in vivo, we administered male SERT+ 
mice  with  17β  estradiol  (1.5mg/kg/21  days)  to  determine  if  this  established  a  PAH 
phenotype.  We observed that 17β estradiol did not uncover a PAH phenotype in these 
mice, as assessed by no change in RVSP, pulmonary vascular remodelling or RVH (Figure 
3.15).  Similarly, no changes in MAP (Figure 3.16) or HR (Figure 3.17) were reported in 
these mice. 
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Figure 3.13 Body weight is increased in wildtype mice following ovariectomy.  WT 
mice exhibit increased body weight following ovariectomy however SERT+ mice remain 
unaffected.  Data  are  expressed  as  mean  +  SEM  and  analysed  by  two-way  ANOVA 
followed by Bonferroni’s post-hoc test; **P<0.01 cf. sham-operated controls.  n=8-11.     
 
Figure  3.14  Uterine  weight  is  decreased  in  normoxic  and  chronically  hypoxic 
ovariectomized  wildtype  and  SERT+  mice.    Uterine  weight  is  decreased  in  both 
wildtype and SERT+ mice following ovariectomy.  Data are expressed as mean + SEM 
and analysed by two-way ANOVA followed by Bonferroni’s post-hoc test; ***P<0.001 cf. 
sham-operated controls.  n=10-11.    
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Figure 3.15 17β estradiol has no effect on PAH phenotype in male SERT+ mice.  17β 
estradiol administration does not increase RVSP (A), PVR (B) or RVH (C) in male SERT+ 
mice.  Data are expressed as mean + SEM.  n=9-12.  
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Figure 3.16 17β estradiol has no effect on systemic arterial pressure in male SERT+ 
mice.  Mean  systemic  arterial  pressure  (MAP)  is  similar  in  normoxic  and  chronically 
hypoxic male SERT+ mice dosed with 17β estradiol when compared against their vehicle-
dosed controls.  Data are expressed as mean + SEM; n=8-9.   
 
 
Figure 3.17 17β estradiol has no effect on heart rate in male SERT+ mice.  Heart rate 
(HR) is similar in normoxic and chronically hypoxic male SERT+ mice dosed with 17β 
estradiol when compared against their vehicle-dosed controls.  Data are expressed as mean 
+ SEM; n=8-9. 
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3.2.6  17β Estradiol Prevents Hypoxia-Induced PAH in Male Wildtype 
Mice  
Previously, we reported that ovariectomized WT mice develop moderate PAH.  We were 
interested in further investigating the effects of 17β estradiol in the development of PAH in 
WT  mice.  In  normoxia,  the  administration  of  17β  estradiol  had  no  effect  on  RVSP, 
pulmonary  vascular remodelling  or  RVH  in  male  WT  mice.    In  chronic  hypoxia,  17β 
estradiol protected against the development of PAH via a reduction in RVSP, pulmonary 
vascular remodelling and RVH (Figure 3.18).  We observed no effects on MAP (Figure 
3.19) or HR (Figure 3.20) in 17β estradiol-dosed male WT mice compared to their vehicle-
dosed WT controls.        
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Figure 3.18 17β estradiol attenuates hypoxia-induced PAH in male wildtype mice.  
17β estradiol attenuates RVSP (A), PVR (B) and RVH (C) in chronically hypoxic male 
wildtype mice.  No effects are reported in normoxia.  Data are expressed as mean + SEM 
and  analysed  by  two-way  ANOVA  followed  by  Bonferroni’s  post-hoc  test.    *P<0.05, 
**P<0.01, ***P<0.001, cf. normoxic  mice; §P<0.05, §§P<0.01 cf. vehicle-dosed  mice.  
n=7-9. 
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Figure 3.19 17β estradiol has no effect on systemic arterial pressure in normoxic and 
chronically  hypoxic  male  wildtype  mice.  Mean  systemic  arterial  pressure  (MAP)  is 
similar in normoxic and chronically hypoxic male wildtype mice dosed with 17β estradiol, 
when compared against their respective vehicle-dosed controls.  Data are expressed as 
mean + SEM; n=8-9.   
 
 
Figure 3.20 17β estradiol has no effect on heart rate in normoxic and chronically 
hypoxic male wildtype mice.  Heart rate (HR) is similar in normoxic and chronically 
hypoxic  male  wildtype  mice  dosed  with  17β  estradiol,  when  compared  against  their 
respective vehicle-dosed controls.  Data are expressed as mean + SEM; n=8-9. 
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3.2.7  Effects of Ovariectomy and 17β Estradiol on Serotonin Induced 
Pulmonary Vascular Contraction  
To determine if pulmonary vascular reactivity is affected in mice following ovariectomy or 
17β  estradiol  administration,  we  assessed  serotonin-induced  vasoconstriction  in  the 
pulmonary  arteries.    As  previously  reported,  the  potency  of  serotonin  is  decreased  in 
SERT+ mice and this was not further affected following ovariectomy.  Serotonin-induced 
vasoconstriction was also similar in both ovariectomized and sham-operated wildtype mice 
(Figure 3.21).  Similarly, ovariectomy had no effect on serotonin-induced vasoconstriction 
in the pulmonary arteries of chronically hypoxic wildtype and SERT+ mice (Figure 3.22).  
As  ovariectomized  SERT+  mice  develop  PAH  following  the  administration  of  17β 
estradiol,  we  were  also  interested  in  investigating  any  possible  changes  in  pulmonary 
vascular  reactivity.    However,  no  changes  in  serotonin-induced  vasoconstriction  were 
apparent  in  either  normoxic  (Figure  3.23)  or  chronically  hypoxic  (Figure  3.24)  17β 
estradiol-dosed SERT+ mice compared to vehicle-dosed SERT mice.     
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Figure 3.21 Serotonin-induced pulmonary arterial contraction is unaffected following 
ovariectomy in both normoxic wildtype and SERT+ mice.  The potency of serotonin is 
decreased in the pulmonary arteries of SERT+ mice compared to wildtype mice, however 
is unaffected following ovariectomy.  Data are expressed as mean + SEM.  n=6-8.   
 
 
 
Figure 3.22 Serotonin-induced pulmonary arterial contraction is unaffected following 
ovariectomy  in  chronically  hypoxic  wildtype  and  SERT+  mice.    The  potency  of 
serotonin is decreased in the pulmonary arteries of SERT+ mice compared to wildtype 
mice, however is unaffected following ovariectomy. Data are expressed as mean + SEM.  
n=6-7.  
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Figure 3.23 Serotonin-induced pulmonary arterial contraction is unaffected following 
17β estradiol administration in ovariectomized SERT+ mice.  Data are expressed as 
mean + SEM.  n=6. 
 
 
 
 
 
 
Figure 3.24 Serotonin-induced pulmonary arterial contraction is unaffected following 
17β  estradiol  administration  in  chronically  hypoxic  ovariectomized  SERT+  mice.  
Data are expressed as mean + SEM.  n=6. 
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3.2.8  Effects of 17β Estradiol, Estrone, Estriol and Progesterone in 
PASMCs 
In  summary  of  our  in  vivo  findings,  we  identified  that  female  SERT+  mice  develop 
spontaneous PAH and exaggerated hypoxia-induced PAH whilst male SERT+ mice remain 
unaffected,  compared  to  their  respective  WT  controls.    Through  multiple  intervention 
studies we confirmed that ovariectomy reversed PAH in SERT+ mice, and disease was 
successfully  re-established  following  17β  estradiol  administration.    Collectively,  this 
evidence suggests a critical role for 17β estradiol in the progression of PAH in SERT+ 
mice.  To further test this hypothesis, male SERT+ mice were subjected to 17β estradiol 
administration.    However  SERT+  males  failed  to  develop  PAH,  confirming  that  17β 
estradiol effects are limited to SERT+ females.  In WT mice, ovariectomy resulted in the 
development  of  PAH,  whilst  17β  estradiol  attenuated  hypoxia-induced  PAH  in  males, 
suggesting  that female  hormones  and 17β  estradiol are  protective  against PAH in  WT 
mice.  To further delineate the role of female hormones in PAH, we assessed their effects 
in cultured pulmonary vascular cells.          
 
We examined the effects of 17β estradiol on human pulmonary artery smooth muscle cell 
(PASMC) proliferation.  This was investigated at physiological circulating concentrations 
(0.1-1nmol/L).    For  comparison,  we  also  examined  the  effects  of  estrone,  estriol  and 
progesterone  on  PASMC  proliferation.    At  1nmol/L,  17β  estradiol  stimulated  PASMC 
proliferation  (Figure  3.25)  as  assessed  by  increased  cell  number  and  DNA  synthesis, 
whereas estrone (Figure 3.26), estriol (Figure 3.27) and progesterone (Figure 3.28) had no 
effect on PASMC proliferation.  These proliferative effects of 17β estradiol are consistent 
with our in vivo findings.   
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Figure  3.25  17β  estradiol  stimulates  human  pulmonary  artery  smooth  muscle  cell 
proliferation.  17β estradiol stimulates both cell number (A) and DNA synthesis (B) in 
PASMCs  at  1nmol/L.    *P<0.05,  **P<0.01  increased  proliferation  cf.  2.5%  FBS 
stimulation.    Data  are  expressed  as  mean  +  SEM  and  analysed  by  one-way  ANOVA 
followed by Dunnett’s post-hoc test.  n=3 and performed in duplicate. 
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Figure 3.26 Estrone has no effect on human pulmonary artery smooth muscle cell 
proliferation.  Estrone has no effect on cell number (A) or DNA synthesis (B) at a range 
of concentrations (0.1-1nmol/L).  Data are expressed as mean + SEM.  n=3 and performed 
in duplicate. 
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Figure 3.27 Estriol has no effect on human pulmonary artery smooth muscle cell 
proliferation.  Estriol has no effect on cell number (A) or DNA synthesis (B) at a range of 
concentrations (0.1-1nmol/L).  Data are expressed as mean + SEM.  n=3 and performed in 
duplicate. 
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Figure 3.28 Progesterone has no effect on human pulmonary artery smooth muscle 
cell proliferation.  Progesterone has no effect on cell number (A) or DNA synthesis (B) at 
a range of concentrations (0.1-1nmol/L).  Data are expressed as mean + SEM.  n=3 and 
performed in duplicate. 
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3.2.9  17β Estradiol Has No Effect on Serotonin Induced Proliferation in 
PASMCs 
Following our observation that 17β estradiol is critical to the development of PAH in a 
serotonin-dependent  model  of  PAH  (SERT+  mice),  we  investigated  if  this  hormone 
potentiates  serotonin-induced  proliferation  in  cultured  PASMCs.    We  observed  that, 
although both serotonin and 17β estradiol stimulate PASMC proliferation, their cumulative 
effect does not stimulate proliferation to a greater extent (Figure 3.29).       
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Figure 3.29 17β estradiol has no effect on serotonin-induced proliferation in human 
pulmonary  artery  smooth  muscle  cells.  Both  1nmol/L  17β  estradiol  and  1μmol/L 
serotonin stimulate PASMC proliferation however their cumulative effect does not further 
stimulate proliferation.  Data are expressed as mean + SEM and analysed by one-way 
ANOVA followed by Dunnett’s post-hoc test.  **P<0.01 cf. 2.5% FBS proliferation.  n=4 
and cell counts performed in duplicate. 
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3.2.10  17β Estradiol Increases Tryptophan Hydoxylase-1, 5-HT1B 
Receptor and Serotonin Transporter Expression in PASMCs 
To  determine  if  17β  estradiol  regulates  the  expression  of  key  mediators  in  serotonin 
signalling we stimulated PASMCs with 1nmol/L 17β estradiol at multiple time-points and 
investigated  protein  expression  of  TPH1,  the  5-HT1B  receptors  and  SERT.    Following 
exposure of PASMCs to 17β estradiol for greater than 4 hours, we observed increased 
expression of TPH1 (Figure 3.30), the 5-HT1B receptors (Figure 3.31) and SERT (Figure 
3.32). 
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Figure 3.30 17β estradiol increases tryptophan hydroxylase-1 expression in human 
pulmonary  artery  smooth  muscle  cells.  Representative  immunoblotting  (A)  and 
densitometrical  analysis  (B)  showing  that  1nmol/L  17β  estradiol  increases  TPH1 
expression in PASMCs.  Quantitative data is shown as mean + SEM and analysed using 
one-way ANOVA followed by Dunnett’s post-hoc test.  *P<0.05 cf. untreated PASMCs.  
n=3. 
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Figure 3.31 17β estradiol increases 5-HT1B receptor expression in human pulmonary 
artery  smooth  muscle  cells.  Representative  immunoblotting  (A)  and  densitometrical 
analysis (B) showing that 1nmol/L 17β estradiol increases 5-HT1B receptor expression in 
PASMCs.    Quantitative  data  is  shown  as  mean  +  SEM  and  analysed  using  one-way 
ANOVA followed by Dunnett’s post-hoc test.  *P<0.05 cf. untreated PASMCs.  n=3. 
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Figure  3.32  17β  estradiol  increases  serotonin  transporter  expression  in  human 
pulmonary  artery  smooth  muscle  cells.  Representative  immunoblotting  (A)  and 
densitometrical  analysis  (B)  showing  that  1nmol/L  17β  estradiol  increases  SERT 
expression in PASMCs.  Quantitative data is shown as mean + SEM and analysed using 
one-way ANOVA followed by Dunnett’s post-hoc test.  *P<0.05 cf. untreated PASMCs.  
n=3. 
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3.2.11  Serotonin Pathway Inhibitors Prevent 17β Estradiol 
Induced Proliferation in PASMCs 
Following the observation that 17β estradiol increases expression of key serotonin pathway 
mediators  (TPH1,  5-HT1B  receptors,  SERT)  critical  to  the  development  of  PAH,  we 
investigated if the serotonin system was also involved in 17β estradiol-induced PASMC 
proliferation.    To  test  this,  we  investigated  the  effects  of  inhibitors  for  TPH  (p-
chlorophenylalanine, PCPA 10µmol/L), the 5-HT receptors (5-HT1B antagonist, SB224289 
300nmol/L; 5-HT2A antagonist. ketanserin 30nmol/L) and SERT (citalopram 1µmol/L) on 
1nmol/L 17β estradiol-mediated proliferation of PASMCs (Figure 3.33).  Although none of 
the inhibitors had any effect on FBS-induced proliferation, both the TPH inhibitor PCPA 
and  the  5-HT1B  receptor  antagonist  SB224289  successfully  inhibited  17β  estradiol-
stimulated proliferation.  Of interest, the 5-HT2A receptor antagonist ketanserin and the 
SERT inhibitor citalopram had no effect.   
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Figure 3.33 Effects of inhibitors for serotonin synthesis, 5-HT receptors and serotonin 
transporter  on  17β  estradiol-stimulated  proliferation.  17β  estradiol  (1nmol/L) 
increases cell number (A) and DNA synthesis (B) in PASMCs.  This is inhibited by the 
tryptophan hydroxylase (TPH) inhibitor para-chlorophenylalanine (PCPA; 10µmol/L) and 
the  5-HT1B  receptor  antagonist  SB224289  (300nmol/L)  but  unaffected  by  the  5-HT2A 
receptor antagonist ketanserin (30nmol/L) and the SERT inhibitor citalopram (1µmol/L).  
*P<0.05, **P<0.01 increased proliferation cf. 2.5% FBS; † P<0.05, †† P<0.01 decreased 
proliferation cf. 1nmol/L 17β estradiol.  Data are expressed as mean   SEM and analysed 
by  one-way  ANOVA  followed  by  Dunnett’s  post-hoc  test.    n=3  and  performed  in 
duplicate. 
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3.3  Discussion 
Both  idiopathic  PAH  and  heritable  PAH  occur  more  in  females  than  in  males.    For 
example, in recent epidemiological studies carried out in Scotland, France and USA, 60%, 
65% and 77% of patients studied respectively were female (Peacock et al., 2007; Humbert 
et al., 2006; Thenappan et al., 2007).  The reasons for this increased frequency in females 
are unclear and under investigated.  One reason for this under investigation is the absence 
of a suitable animal model.  Paradoxically, it is observed that male rats exhibit severe 
hypoxia-induced PAH compared to female rats (Rabinovitch et al., 1981) and estrogens 
protect against monocrotaline-induced PAH (Farhat et al., 1993). 
 
This  is  the  first  complete  study  to  describe  an  animal  model  of  PAH  with  female 
susceptibility.  Preliminary evidence suggests that increased susceptibility in female mice 
may also be observed in dexfenfluramine-induced PAH (Dempsie et al., 2009; Dempsie et 
al., 2010) and VEGF receptor antagonist (SU 5416) + hypoxia-induced PAH (Tofovic and 
Rafikova, 2009).  In the current study, only female SERT+ mice develop PAH and we 
provide experimental evidence that interactions between 17β estradiol and the serotonin 
system  may  contribute  towards  this  PAH  pathogenesis.    We  demonstrate  that  female 
SERT+  mice  develop  PAH  as  indicated  by  elevated  right  ventricular  pressure  and 
pulmonary vascular remodelling, whereas male SERT+ mice remain unaffected.  These 
results suggest that sex hormones are critical to the development of PAH in this model.  To 
investigate this hypothesis, we ovariectomized these mice and assessed the PAH phenotype 
after twelve weeks.  Ovariectomy completely prevented both the development of PAH and 
severe hypoxia-induced PAH in SERT+ mice.  These results suggest a detrimental role for 
ovarian-derived hormones in SERT+ mice. 
  
  136 
To determine if 17β estradiol is the hormone critical to the development of PAH in vivo, 
we  assessed  the  effects  of  its  re-introduction  into  ovariectomized  SERT+  mice.    As 
previously  mentioned,  ovariectomy  protects  SERT+  mice  against  the  development  of 
PAH, however 17β estradiol completely re-established a disease phenotype in these mice.  
Similarly, this hormone also re-established severe hypoxia-induced PAH in ovariectomized 
SERT+ mice.  These results confirm that female gender, via the influence of ovarian-
derived 17β estradiol, is critical to the development of PAH in SERT+ mice. 
 
The potency of serotonin is decreased in the pulmonary arteries of SERT+ mice, as has 
been previously reported (MacLean et al., 2004).  This is thought to occur via a reduction 
in  extracellular  serotonin  concentration,  arising  as  a  consequence  increased  SERT-
mediated  serotonin  uptake.    Here,  we  investigated  the  effects  of  ovariectomy  and  17β 
estradiol administration on serotonin-induced vasoconstriction in the pulmonary arteries of 
both  normoxic  and  chronically  hypoxic  wildtype  and  SERT+  mice.    However,  we 
observed no changes in serotonin potency or efficacy in any of these mice.  Similarly, 
serotonin-induced pulmonary vasoconstriction was also unchanged following 17β estradiol 
dosing in these mice.          
 
We wished to establish a cellular model in order to investigate possible mechanisms of 
action of 17β estradiol and also examine the relevance of our in vivo study to human cells. 
We chose PASMCs as these have been extensively studied to investigate critical pathways 
in  PAH.  For  example,  PASMCs  proliferate  to  serotonin  via  stimulation  of  the  5HT1B 
receptors and SERT (Lawrie et al., 2005), and have also been studied to further investigate 
BMPR-II signalling in PAH (Yang et al., 2008). We observed that 17β estradiol stimulated 
proliferation, whereas estrone, estriol and progesterone had no effect.  This is consistent 
with our observation that 17β estradiol re-established a PAH phenotype in ovariectomized 
SERT+ mice. 1nmol/L 17β estradiol was sufficient to promote PASMC proliferation and  
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similar growth effects have been previously reported in rat PASMCs (Farhat et al., 1992).  
This is physiologically relevant as 17β estradiol circulates at concentrations between 0.1-
1nmol/L (Rosselli et al., 1994) and smooth muscle hyperplasia is a hallmark of PAH.   
 
The suggestion that 17β estradiol is involved in the pathogenesis of experimental PAH is 
consistent with recent findings in human PAH.  Decreased expression of the 17β estradiol-
metabolising enzyme CYP1B1 has been reported in female PAH patients harbouring a 
BMPR-II mutation compared to unaffected female carriers
8.  Multiple factors modulate the 
levels of estrogen-metabolizing enzymes in the liver and target tissues, and the biological 
effects of an estrogen will therefore depend on the profile of metabolites formed and the 
biological activities of each of these metabolites (Zhu and Conney, 1998).  17β estradiol is 
metabolised to both pro- and anti-proliferative metabolites and its effects will depend on its 
metabolism.  17β estradiol can be converted to estrone and subsequently metabolized to 
16 -hydroxyestrone  (16-OHE1)  via  CYP3A4.    Or  alternatively,  17β  estradiol  is 
metabolized  to  2-hydroxyestradiol  (2-OHE)  via  the  estrogen  metabolizing  enzymes 
CYP1A1/2 and to a lesser extent via CYP1B1 (Hanna et al., 2000; Tsuchiya et al., 2005).  
2-OHE  can  itself  be  metabolized  to  2-methoxyestradiol  (2-ME)  via  catechol  O-
methyltransferase (COMT).  Both 2-OHE and 2-ME have anti-proliferative effects on cells 
(Tofovic  et  al.,  2006),  whereas  16 -OHE1  stimulates  proliferation  by  constitutively 
activating  the  estrogen  receptor  (Swaneck  and  Fishman,  1988).    Metabolism  of  17β 
estradiol will therefore be species, gender and strain-dependent and differential disruption 
in the balance of metabolites may therefore account for the differential effects of female 
hormones in different models of PAH.  Consistent with this, 17β estradiol did not promote 
PAH in male SERT+ mice suggesting gender differences in estrogen metabolism and/or its 
effects.   
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As discussed above, in other models of PAH it would appear that male gender predisposes 
to PAH and 17β estradiol may actually be protective in PAH.  It has, for example, been 
shown to improve both right ventricular hypertrophy and pulmonary vascular remodeling 
in  hypoxia-induced  and  monocrotaline-induced  PAH  (Farhat  et  al.,  1993;  Resta  et  al., 
2001).  Our studies are consistent with this as we show that male WT mice developed more 
severe hypoxia-induced PAH compared to female wildtype mice and 17β estradiol ablated 
hypoxia-induced PAH in these males.  17β estradiol also reduced RVH in ovariectomized 
SERT+  mice.    In  addition  to  the  anti-proliferative  effects  of  various  17β  estradiol 
metabolites, it  is also an established nitric oxide-dependent vasodilator in rat pulmonary 
arteries (Lahm et al., 2008), up-regulates endothelial nitric oxide synthase expression in 
pulmonary  arterial  endothelial  cells  (MacRitchie  et  al.,  1997)  and  suppresses  hypoxia-
induced endothelin-1 gene expression (Earley and Resta, 2002).  These effects may protect 
against the development of PAH in some species and/or strains.  However, our results 
suggest that when SERT is up-regulated, 17β estradiol loses these protective effects and 
this may be via facilitating the mitogenic effects of serotonin.  The implications of our 
study may translate clinically and help explain the inconsistency of the occurrence of PAH 
which may depend on multiple influences on 17β estradiol metabolism including age, early 
menopause, gender and various other factors that affect 17β estradiol metabolism. 
 
There are multiple serotonin effects within the pulmonary circulation which promote PAH 
including microthrombosis, arterial vasoconstriction and proliferation.  Indeed, it has been 
previously shown that TPH1, SERT and the 5-HT1B receptors are all implicated in both 
human and experimental PAH.  For example, the expression of TPH1, the rate-limiting 
enzyme  involved  in  peripheral  serotonin  synthesis,  is  increased  in  the  lungs  of  IPAH 
patients (Eddahibi et al., 2006).  The exogenous administration of serotonin uncovers a 
PAH phenotype in BMPR-II+/- mice (Long et al., 2006) and also increases the severity of 
hypoxia-induced  PAH  in  rats  (Eddahibi  et  al.,  1997).    In  addition,  mice  deficient  of  
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peripheral serotonin (tph1-/- mice), achieved through deletion of the tph1 gene, do not 
develop hypoxia-induced PAH (Morecroft et al., 2007) or dexfenfluramine-induced PAH 
(Dempsie et al., 2008).  Serotonin effects within the pulmonary vasculature are mediated in 
part via SERT.  For example, PASMCs derived from IPAH patients proliferate to a greater 
extent than those from controls following serotonin stimulation and this is dependent on 
SERT  activity  (Eddahibi  et  al.,  2001).    A  genetic  polymorphism  leading  to  increased 
activity/expression  of  SERT  has  been  identified  in  a  small  cohort  of  PAH  patients 
(Eddahibi et al., 2001).  Subsequent studies in larger patient studies have failed to support 
these findings although patients with the SERT polymorphism may present at an earlier 
age than those without (Machado et al., 2006; Willers et al., 2006).  As previously reported 
(MacLean et al., 2004) and further observed in the current study, mice over-expressing 
SERT develop PAH and severe hypoxia-induced PAH.  Conversely, mice devoid of the 
SERT gene are less susceptible to the development of hypoxia-induced PAH (Eddahibi et 
al., 2000).  Here, our findings demonstrate that female gender is also a risk factor in the 
development of PAH in SERT+ mice. 
 
In the central nervous system, estrogens influence serotonin signalling via up-regulation of 
multiple pathway mediators including TPH and SERT (Pecins-Thompson et al., 1996; Lu 
et al., 2003).  On this premise, we hypothesised that 17β estradiol was similarly affecting 
the serotonin system within the pulmonary circulation and this was the mechanism through 
which  serotonin  and  17β  estradiol  synergise  to  facilitate  PAH.  Thus,  we  investigated 
whether  17β  estradiol  regulated  expression  of  any  serotonin  pathway  mediators  in 
PASMCs.  Here, we report for the first time that TPH1 is present in PASMCs, and this is 
markedly increased following stimulation with 17β estradiol.  In addition, 17β estradiol 
also increased both 5-HT1B receptor and SERT expression in  PASMCs.  This  may be 
relevant, as both have previously been shown to interact to promote serotonin-induced 
PASMC proliferation (Lawrie et al., 2005).  Based on these findings, we were interested in  
  140 
determining if 17β estradiol mediated PASMC proliferation via a serotonergic mechanism.  
Indeed, we report that 17β estradiol-induced proliferation is completely abolished in the 
presence of the TPH inhibitor PCPA and the 5-HT1B receptor antagonist SB224289.  This 
suggests  that  serotonin  synthesis,  and  subsequent  activation  of  the  5-HT1B  receptor,  is 
essential in mediating the proliferative response of PASMCs to 17β estradiol.  It could be 
expected  that  the  increased  SERT  expression  may  also  increase  the  SERT-dependent 
serotonin activation of small GTPases within the cytoplasm (‘serotonylation’), to further 
promote  the  mitogenic  effects  of  serotonin.    However,  the  observation  that  the  SERT 
inhibitor  citalopram  was  not  sufficient  to  block  proliferation  suggests  a  minor  role, 
although  co-operation  between  the  5-HT1B  receptors  and  SERT  have  previously  been 
shown to mediate serotonin-induced proliferation and therefore a role for SERT in 17β 
estradiol-induced proliferation cannot be ruled out.  These findings are consistent with a 
role for serotonin in PAH as TPH1, the 5HT1B receptors and SERT have all previously 
been implicated in the pathogenesis of both experimental and human PAH, as discussed 
above. 
   
We have previously reported that un-dosed SERT+ mice develop elevated RVSP in the 
absence of RVH (MacLean et al., 2004).  Conversely, chronically hypoxic tph1-/- mice 
develop RVH in the absence of increased RVSP (Morecroft et al., 2007).  The present 
study confirms dissociation of these indices in SERT+ mice.  Further, we now show that 
ovariectomy decreased RVSP in SERT+ mice whilst having no effect on RVH, and the 
administration of 17β estradiol to ovariectomized SERT+ mice increased RVSP whilst 
decreasing RVH.    One  explanation  for  this  dissociation  is  that  both  17β  estradiol  and 
serotonin have direct effects on ventricular cardiomyocytes.  17β estradiol exerts both pro- 
and anti-hypertrophic effects on these cells (Kilic et al., 2009).  Serotonin is considered a 
survival factor in cardiomyocytes (Nebigil et al., 2003) and apoptosis is a pre-dominant 
feature of ventricular remodelling (Williams, 1999).    
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In conclusion, here we have shown that female gender pre-disposes SERT+ mice to the 
development of PAH and 17β estradiol is critical to this.  17β estradiol appears to increase 
serotonin  synthesis  in  PASMCs.    This,  in  combination  with  17β  estradiol-mediated 
upregulation  of  SERT  and  the  5-HT1B  receptor,  may  act  to  enhance  serotonin-induced 
proliferation.  The SERT and the 5-HT1B receptor have previously been shown to mediate 
both serotonin-induced proliferation of PASMCs (Lawrie et al., 2005; Morecroft et al., 
2010) and serotonin-induced constriction of pulmonary arteries (Morecroft et al., 2005).  
These findings may offer insight into the gender differences apparent in human PAH. 
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Chapter 4 
The Serotonin Transporter, Gender and 
Hypoxia: Microarray Analysis in the 
Pulmonary Arteries of Mice Identifies 
Genes with Relevance to Human PAH 
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4.1  Introduction 
Gender bias exists in both HPAH and IPAH, with women up to three-fold more likely to 
present with disease (Humbert et al., 2006; Peacock et al., 2007; Thenappan et al., 2007).  
The underlying reasons for these differences remain to be characterised.  Estrogen is one 
risk factor in PAH (Lahm et al., 2008).  Genotyping studies have revealed alterations in 
estrogen  signalling  in  PAH.      For  example,  female  PAH  patients  exhibit  increased 
expression levels of ESR1 (estrogen recptor-1), which is the gene encoding for estrogen 
receptor alpha, compared to unaffected females (Rajkumar et al., 2010), and decreased 
cytochrome P450 1B1 (CYP1B1) expression is reported in HPAH (Austin et al., 2009). 
 
Multiple  studies  have  implicated  serotonin  in  the  pathobiology  of  PAH,  as  previously 
discussed.  For example, peripheral serotonin synthesis is required for the development of 
both hypoxia-induced PAH (Morecroft et al., 2007) and dexfenfluramine-induced PAH 
(Dempsie et al., 2008).  Mice over-expressing the SERT (SERT+ mice) also develop PAH 
and exaggerated hypoxia-induced PAH (MacLean et al., 2004).  Consistent with this, mice 
with targeted SERT over-expression in the PASMCs under the guidance of its own SM22 
promoter develop PAH and severe hypoxia-induced PAH (Guignabert et al., 2006).  SERT 
expression  is  increased  in  human  pulmonary  artery  smooth  muscle  cells  (PASMCs) 
derived  from  IPAH  patients,  and  mediates  enhanced  serotonin-induced  proliferation  in 
these cells (Eddahibi et al., 2006).  Taken together, this evidence highlights a critical role 
of smooth muscle-SERT in mediating serotonin effects in experimental and human PAH.  
 
In this study, we characterised genotypic differences in the development of PAH in SERT+ 
mice.  Female SERT+ mice develop PAH and exaggerated hypoxia-induced PAH whereas 
male SERT+ mice remain unaffected compared to their respective wildtype controls.  This 
was only apparent at 5 months of age.  This experimental model of PAH is the first to  
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exhibit female susceptibility, and may provide insight into the female bias observed in 
human  PAH.    To  investigate  genotypic  changes  associated  with  the  development  and 
progression  of  PAH,  microarray  analysis  was  performed  in  the  pulmonary  arteries  of 
normoxic and hypoxic 2 month old SERT+ mice.  A total of thirty two microarrays were 
performed  (n=4  biological  replicates  each  group).    The  dysregulation  of  biological 
pathways was observed to a much greater extent in female SERT+ mice compared to male 
SERT+ mice.  Ingenuity Pathway Analysis (IPA) gene mapping identified three key genes 
of interest for further validation (CEBPB, CYP1B1, FOS).  Genes of interest were further 
assessed via quantitative RT-PCR and immunoblotting.  With relevance to human PAH, 
CEBPB, CYP1B1and  FOS expression  was also  investigated in  PASMCs  derived from 
IPAH patients. 
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4.2  Results 
4.2.1  Female SERT+ Mice Exhibit Right Ventricular Hypertrophy in 
Chronic Hypoxia at 2 Months and PAH at 5 Months 
In normoxia, right ventricular systolic pressure (RVSP), pulmonary vascular remodelling 
(PVR; % remodelled vessels) and right ventricular hypertrophy (RVH) were similar in 2 
month  old  male  (Figure  4.1-3)  and  female  (Figure  4.4-6)  wildtype  and  SERT+  mice.  
However, at 5 months of age female SERT+ mice exhibited PAH, as assessed by increased 
RVSP,  PVR  and  RVP,  whereas  male  SERT+  mice  remained  unaffected.    Following 
exposure to chronic hypoxia, all groups developed hypoxia-induced PAH as indicated by 
significant increases in RVSP, PVR and RVH.  However at 2 months of age, chronically 
hypoxic female SERT+ mice exhibited increased RVH compared to WT mice.  Similarly, 
at 5 months of age these mice exhibited increased RVSP, PVR and RVH compared to 5 
month WT mice.  Exaggerated hypoxia-induced PAH was not apparent in male SERT+ 
mice at 2 or 5 months of age.  There were no systemic effects reported in both female and 
male normoxic and chronically hypoxic SERT+ mice compared to WT mice, as assessed 
by no changes in systemic arterial pressure or heart rate (data not shown). 
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Figure  4.1  Male  SERT+  mice  do  not  exhibit  increased  right  ventricular  systolic 
pressure  in  normoxia  or  chronic  hypoxia.  RVSP  is  unaffected  in  normoxic  male 
SERT+  mice  at  2  and  5  months  of  age  compared  to  their  respective  wildtype  (WT) 
controls.  Chronic hypoxia elevated RVSP in all groups.  Chronically hypoxic 2 month 
SERT+  mice  do  not  exhibit  any  change  in  RVSP  compared  to  their  respective  WT 
controls.  Data are expressed as mean   SEM and analysed by two-way ANOVA followed 
by Bonferroni’s post-hoc test.   **P<0.01, ***P<0.001 cf. normoxic controls; n=6-8. 
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Figure  4.2  Male  SERT+  mice  do  not  exhibit  increased  pulmonary  vascular 
remodelling.  Pulmonary vascular remodelling is unaffected in normoxic male SERT+ 
mice  compared  to  their  respective  wildtype  (WT)  controls.    Chronic  hypoxia  elevated 
pulmonary vascular remodelling in all groups.  Chronically hypoxic 2 month SERT+ mice 
do not exhibit any change in pulmonary vascular remodelling compared to their respective 
WT controls.  Data are expressed as mean   SEM and analysed by two-way ANOVA 
followed by Bonferroni’s post-hoc test.  ***P<0.001 cf. normoxic controls; n=5. 
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Figure 4.3 Male SERT+ mice do not exhibit increased right ventricular hypertrophy.  
RVH is unaffected in normoxic male SERT+ mice compared to their respective wildtype 
(WT) controls.  Chronic hypoxia increased RVH in all groups.  Chronically hypoxic 2 
month SERT+ mice do not exhibit any change in RVH compared to their respective WT 
controls.  Data are expressed as mean   SEM and analysed by two-way ANOVA followed 
by Bonferroni’s post-hoc test.  *P<0.05, **P<0.01 cf. normoxic controls.  n=6-8. 
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Figure 4.4 Female SERT+ mice exhibit increased right ventricular systolic pressure 
in normoxia and chronic hypoxia at 5 months of age.  RVSP is increased in normoxic 
SERT+ mice at 5 months of age but unaffected at 2 months of age compared to their 
respective  wildtype  (WT)  controls.    Chronic  hypoxia  elevated  RVSP  in  all  groups.  
Chronically  hypoxic  5  month  SERT+  mice  also  exhibit  increased  RVSP.    Data  are 
expressed as mean   SEM and analysed by two-way ANOVA followed by Bonferroni’s 
post-hoc test.   *P<0.05, **P<0.01 cf. normoxic controls; §§P>0.01 cf. WT mice. n=6-8. 
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Figure 4.5 Female SERT+ mice exhibit increased pulmonary vascular remodelling in 
normoxia and chronic hypoxia at 5 months of age.  Pulmonary vascular remodelling 
(PVR)  is  increased  in  normoxic  SERT+  mice  at  5  months  of  age  but  unaffected  at  2 
months of age compared to their respective wildtype (WT) controls.  Chronic hypoxia 
elevated PVR in all groups.  Chronically hypoxic 5 month SERT+ mice exhibit increased 
PVR.  Data are expressed as mean   SEM and analysed by two-way ANOVA followed by 
Bonferroni’s post-hoc test.   *P<0.05, **P<0.01 cf. normoxic controls; §§P<0.01 cf. WT 
mice. n=5. 
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Figure 4.6 Female SERT+ mice exhibit increased right ventricular hypertrophy in 
chronic hypoxia at both 2 and 5 months of age. Right ventricular hypertrophy (RVH) is 
unaffected in normoxic SERT+ mice at both 2 and 5 months of age compared to their 
respective  wildtype  (WT)  controls.    Chronic  hypoxia  elevated  RVH  in  all  groups.  
Chronically hypoxic SERT+ mice exhibit increased RVH at both 2 and 5 months of age.  
Data  are  expressed  as  mean    SEM  and  analysed  by  two-way  ANOVA  followed  by 
Bonferroni’s post-hoc test.   *P<0.05, **P<0.01 cf. normoxic controls §P<0.05 cf. WT 
mice. n=6-8. 
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4.2.2  Genotypic Differences in SERT+ Mice 
We were interested in exploring the genotypic differences associated with the development 
and progression of PAH in female SERT+ mice.  In total, we identified 155 genes that 
were significantly (P<0.05) differentially expressed in female SERT+ mice compared to 
their  wildtype  controls.    71  genes  show  increased  expression  (Table  4.1),  whilst  the 
remaining 84 genes show reduced expression (Table 4.2).  To determine their biological 
relevance, we functionally categorized these genes by biological processes. A considerable 
number  of  these  genes (>40%)  were  assigned to  one  or  more  biological  processes,  of 
which 15 categories were present in total (Figure 4.7).  Specifically, a large number of 
these genes were assigned to biological functions with relevance to PAH.  These included 
oxidation-reduction,  cell  differentiation,  regulation  of  transcription,  apoptosis,  muscle 
contraction, cellular calcium ion homeostasis and glycolysis. 
 
In order to further investigate the genotypic changes underlying these gender differences in 
SERT+ mice, we also performed microarray analysis in the pulmonary arteries of male 
SERT+  mice.    We  observed  that  a  total  of  148  genes  were  significantly  differentially 
expressed in male SERT+ mice compared to male WT mice. Of these, 110 genes were 
increased (table 4.5) whilst the remaining 38 genes were decreased (table 4.6).  When 
categorised by biological processes, only 25% of these genes were assigned to biological 
function and 9 categories were represented in total. 
 
Hierarchal cluster analysis between the 4 normoxic groups (258 genes in total) revealed 
distinct gene expression patterns between female SERT+ and female WT which were not 
apparent in the identical male SERT+ and WT comparison. 
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4.2.3  Genotypic Differences in Hypoxic SERT+ Mice 
We  were  also  interested  in  investigating  the  genotypic  differences  associated  with 
exaggerated hypoxia-induced PAH in female SERT+ mice.  Following exposure to chronic 
hypoxia, female SERT+ mice exhibited a greater than two-fold increase in the number of 
differentially expressed genes compared against the identical normoxic comparison.  In 
total, 316 genes were differentially expressed.  We observed that 254 genes were increased 
(Table  4.3),  whilst  the  remaining  62  genes  showed  decreased  expression  (Table  4.4).  
When  arranged  by  biological  processes,  53%  of  genes  were  assigned  to  a  total  of  26 
distinct  pathways.    Moreover,  a  significant  number  of  these  dysregulated  pathways 
observed in chronically hypoxic female SERT+ mice have been previously associated with 
PAH including apoptosis, inflammation, transcription and metabolism (Figure 4.8).                             
 
In contrast, a large number of these changes were not apparent in hypoxic male SERT+ 
mice.  A total of 145 genes were differentially expressed in male SERT+ mice, with 87 
showing increased expression (Table 4.7) and 58 showing decreased expression (Table 
4.8).    When  categorised  by  biological  processes,  42%  of  these  genes  were  assigned  a 
biological function.  12 categories were represented in total.   
 
Hierarchal cluster analysis of the differentially expressed genes between the 4 hypoxic 
groups revealed distinct gene expression patterns which were unique to female SERT+ 
mice.  This may be critical to the exaggerated hypoxia-induced PAH phenotype observed 
in these mice.  
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Table 4.1 List of genes up-regulated in the pulmonary arteries of 2 month female SERT+ mice 
compared to 2 month female wildtype mice, arranged by biological process.  
 
 
Gene Symbol  Gene Name          Accession No    Fold  False 
                      Change   Discovery 
                      Rate 
   
Oxidation Reduction       
CYP2S1     cytochrome P450, family 2, subfamily s, polypeptide 1   NM_028775.2    1.52  0.046 
SCD1     stearoyl-Coenzyme A desaturase 1       scl52445.7_23    2.51  0.009 
FASN     fatty acid synthase          scl014104.1_1    1.70  0.044 
ALDH1A7  aldehyde dehydrogenase family 1, subfamily A7    scl52665.13.1_14    2.20  0.018 
GPD1     glycerol-3-phosphate dehydrogenase 1      NM_010271.2    2.74  0.010 
CYP1B1   cytochrome P450, family 1, subfamily b, polypeptide 1   scl49594.5.189_22   1.54  0.037 
     
Cell Differentiation      
CEBPB    CCAAT/enhancer binding protein       NM_009883.1    1.50  0.049 
LGALS3   lectin, galactose binding, soluble 3       NM_010705.1    1.76  0.022 
DMKN     dermokine           scl32804.19.1_0    1.92  0.017 
   
Regulation of transcription 
CEBPB     CCAAT/enhancer binding protein       NM_009883.1    1.50  0.049 
FOS     FBJ osteosarcoma oncogene        NM_010234.2    2.79  0.017 
Xbp1     X-box binding protein 1         NM_013842.2    1.56  0.029 
HOXA4     homeo box A4           NM_008265.2    2.02  0.018 
HOXB5     homeo box B5           NM_008268.1    1.90  0.015 
AXUD1     AXIN1 up-regulated 1         scl35215.8_496    1.87  0.017 
   
Immune Response       
CFD     complement factor D         NM_013459.1    1.86  0.045 
SPON2     spondin 2, extracellular matrix protein      NM_133903.2    1.76  0.017 
   
Apoptosis      
CIDEC     cell death-inducing DFFA-like effector c     NM_178373.2    2.91  0.014 
SRGN     serglycin            scl019073.1_109    1.62  0.021 
AXUD1     AXIN1 up-regulated 1         scl35215.8_496    1.87  0.017 
   
Metabolic Process       
UGT1A10  UDP glycosyltransferase 1 family, polypeptide A10   scl0394435.7_126    1.66  0.046 
ACLY     ATP citrate lyase           NM_134037.2    1.68  0.044 
FASN     fatty acid synthase          scl014104.1_1    1.70  0.044 
ALDH1A7  aldehyde dehydrogenase family 1, subfamily A7    scl52665.13.1_14    2.20  0.018 
AACS     acetoacetyl-CoA synthetase         NM_030210.1    1.94  0.026 
GPD1     glycerol-3-phosphate dehydrogenase 1      NM_010271.2    2.74  0.010 
UAP1    UDP-N-acetylglucosamine pyrophosphorylase 1    NM_133806.2    1.74  0.026 
   
Lipid Metabolic Process       
SCD1     stearoyl-Coenzyme A desaturase 1       NM_011182.2    2.51  0.009 
AACS     acetoacetyl-CoA synthetase         NM_030210.1    1.94  0.026 
     
Lipid Biosynthetic Process       
SCD1     stearoyl-Coenzyme A desaturase 1       scl52445.7_23    2.51  0.009 
ACLY     ATP citrate lyase           NM_134037.2    1.68  0.044 
FASN     fatty acid synthase          scl014104.1_1    1.70  0.044 
ELOVL6 ELOVL family member 6          scl00170439.1_29    2.16  0.014 
   
Brown Fat Celll Differentiation       
SCD1     stearoyl-Coenzyme A desaturase 1       scl52445.7_23    2.51  0.009 
ADIPOQ   adiponectin, C1Q and collagen domain containing   scl49310.3_131    2.66  0.017 
UCP1     uncoupling protein 1         NM_009463.2    15.14  0.000 
CEBPB     CCAAT/enhancer binding protein       NM_009883.1    1.50  0.049 
BC054059  cDNA sequence BC054059         scl19994.5.1_11    2.54  0.017 
   
Glycolysis       
ENO2     enolase 2, gamma neuronal         NM_013509.2    1.61  0.045 
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Table 4.2 List of genes down-regulated in the pulmonary arteries of 2 month female SERT+ mice 
compared to 2 month female wildtype mice, arranged by biological process.  
 
 
Gene Symbol  Gene Name          Accession No    Fold  False 
                      Change   Discovery 
                      Rate 
   
Oxidation Reduction       
SC4MOL    sterol-C4-methyl oxidase-like       NM_025436.1    2.09  0.034 
PRDX2     peroxiredoxin 2           NM_011563.2    2.89  0.017 
   
Cell Differentiation      
TRIM54     tripartite motif-containing 54        NM_021447.1    2.58  0.026 
OBSCN     obscurin, cytoskeletal calmodulin and titin-interacting   scl40175.7.1_79    2.13  0.042 
    RhoGEF 
CSRP3     cysteine and glycine-rich protein 3       NM_013808.3    5.14  0.003 
   
Regulation of transcription       
TBX20     T-box 20            NM_194263.1    2.06  0.041 
   
Immune Response       
PRG4    proteoglycan 4           scl000882.1_25    2.57  0.019 
   
Apoptosis      
ACTC1     actin, alpha, cardiac         NM_009608.1    2.17  0.037 
COMP    cartilage oligomeric matrix protein       scl33728.21.1_0    4.73  0.011 
   
Metabolic Process       
PGAM2     phosphoglycerate mutase 2         scl40555.3.1_120    8.59  0.003 
   
Lipid Metabolic Process      
CPT1B    carnitine palmitoyltransferase 1b, muscle     NM_009948.1    2.81  0.022 
LPL    lipoprotein lipase           scl0016956.1_234    1.92  0.047 
   
Heart Development      
MB    myoglobin           NM_013593.2    22.71  0.000 
TNNI3    troponin I, cardiac          NM_009406.2    6.86  0.003 
MYL2    myosin, light polypeptide 2, regulatory, cardiac, slow   scl27267.9.1_12    70.40  0.000 
TNNT2    troponin T2, cardiac         NM_011619.1    3.18  0.015 
   
Muscle Contraction       
MYBPC3  myosin binding protein C, cardiac       NM_008653.1    3.34  0.014 
ACTN2    actinin alpha 2          NM_016798.2    9.71  0.003 
TBX20    T-box 20            NM_194263.1    2.06  0.041 
MYOM2   myomesin 2          scl34033.37.1_91    2.40  0.028 
TTN    titin            scl19104.8.1_3    6.48  0.003 
TNNT2    troponin T2, cardiac         NM_011619.1    3.18  0.015 
   
Lipid Biosynthetic Process       
SC4MOL    sterol-C4-methyl oxidase-like       NM_025436.1    2.09  0.034 
   
Cellular Calcium Ion Homeostasis     
PLN    phospholamban          scl38924.3_494    6.93  0.003 
TNNI3    troponin I, cardiac          NM_009406.2    6.86  0.003 
CSRP3    cysteine and glycine-rich protein 3       NM_013808.3    5.14  0.003 
   
Brown Fat Cell Differentiation       
MB     myoglobin           NM_013593.2    22.71  0.000 
 
Glycolysis       
ENO3    enolase 3, beta muscle         NM_007933.2    3.82  0.010 
PGAM2    phosphoglycerate mutase 2         scl40555.3.1_120    8.59  0.003 
   
Sarcomere Organization     
MYBPC3  myosin binding protein C, cardiac       NM_008653.1    3.34  0.014 
MYH6    myosin, heavy polypeptide 6, cardiac muscle, alpha   scl46291.1.1_325    2.60  0.018 
TTN    titin            scl19104.8.1_3    6.48  0.003 
TNNT2     troponin T2, cardiac         NM_011619.1    3.18  0.015 
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Regulation of Heart Contraction       
MYBPC3  myosin binding protein C, cardiac       NM_008653.1    3.34  0.014 
HRC    histidine rich calcium binding protein       NM_010473.1    3.71  0.011 
MYH6    myosin, heavy polypeptide 6, cardiac muscle, alpha   scl46291.1.1_325    2.60  0.018 
TNNT2     troponin T2, cardiac         NM_011619.1    3.18  0.015 
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                      Change   Discovery 
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apoptosis    
PGLYRP1  peptidoglycan recognition protein 1       scl33021.4.288_87   3.30  0.000 
CIDEC     cell death-inducing DFFA-like effector c     NM_178373.2    1.84  0.000 
SRGN     serglycin            scl019073.1_109    1.32  0.048 
KRT8     keratin 8            scl0016691.1_37    3.13  0.000 
CIDEA    cell death-inducing DNA fragmentation factor, alpha  NM_007702.1    2.38  0.000 
    subunit-like effector A   
induction of apoptosis     
CEBPB     CCAAT/enhancer binding protein       NM_009883.1    1.67  0.004 
CIDEC     cell death-inducing DFFA-like effector c     NM_178373.2    1.84  0.000 
ERN2     endoplasmic reticulum         scl30713.22.1_242   2.08  0.003 
   
brown fat cell differentiation     
SCD1     stearoyl-Coenzyme A desaturase 1       scl52445.7_23    1.97  0.000 
ADIPOQ    adiponectin, C1Q and collagen domain containing   scl49310.3_131    1.87  0.025 
UCP1     uncoupling protein 1         NM_009463.2    2.60  0.000 
CEBPB     CCAAT/enhancer binding protein       NM_009883.1    1.67  0.004 
BC054059  cDNA sequence BC054059         scl19994.5.1_11    1.86  0.004 
NUDT7     nudix   NM_024446.2  1.57 
MRAP     melanocortin 2 receptor accessory protein     NM_029844.1    1.96  0.001 
ALDH6A1  aldehyde dehydrogenase family 6, subfamily A1    NM_134042.1    1.65  0.021 
PPARG     peroxisome proliferator activated receptor gamma   NM_011146.1    1.75  0.000 
 
carbohydrate metabolic process      
AMY1     amylase 1, salivary  scl077379.3_13  1.66 
PDK4     pyruvate dehydrogenase kinase, isoenzyme 4     scl29310.11_209    2.95  0.005 
PYGL     liver glycogen phosphorylase       NM_133198.1    1.86  0.000 
GPD1     glycerol-3-phosphate dehydrogenase 1      NM_010271.2    2.00  0.001 
CHST1     carbohydrate           NM_023850.1    1.42  0.031 
PPP1R3C  protein phosphatase 1, regulatory       NM_016854.1    1.54  0.025 
KLB    klotho beta           scl27771.5.1_89    1.87  0.005 
   
cell adhesion     
MYBPC2   myosin binding protein C, fast-type       NM_146189.1    1.34  0.031 
LGALS3BP   lectin, galactoside-binding, soluble, 3 binding protein   scl39273.6_263    1.66  0.011 
1110049B09RIK   RIKEN cDNA 1110049B09 gene       scl42544.15.6_29    1.39  0.017 
CDH5    cadherin 5          NM_009868.4    1.75  0.030 
CD93     CD93 antigen           scl18542.4.1_65    1.99  0.034 
   
cell-cell adhesion     
CDH5    cadherin 5          scl33446.12_65    1.75  0.030 
CD93     CD93 antigen           scl18542.4.1_65    1.99  0.034 
     
chemotaxis      
CYSLTR1   cysteinyl leukotriene receptor 1       NM_021476.2    1.33  0.041 
CMTM8    CKLF-like MARVEL transmembrane domain containing 8 NM_027294.1    1.34  0.047 
CXCL12    chemokine           scl0001073.1_120    1.77  0.007 
   
defense response to bacterium      
PGLYRP1  peptidoglycan recognition protein 1       scl33021.4.288_87   3.30  0.000 
HAMP2     hepcidin antimicrobial peptide 2       NM_183257.1    5.38  0.000 
FCER1G    Fc receptor, IgE, high affinity I, gamma polypeptide   scl15940.5.1_15    2.29  0.016 
H2-K1     histocompatibility 2, K1, K region       scl0014972.1_210    1.61  0.016 
 
DNA replication      
POLN     DNA polymerase N         scl0272158.1_149    1.69  0.031 
SUPT16H  suppressor of Ty 16 homolog       NM_033618.1    1.76  0.021 
POLK     polymerase           scl43651.15_178    1.29  0.047 
   
immune response      
PGLYRP1  peptidoglycan recognition protein 1       scl33021.4.288_87   3.30  0.000 
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CXCL12    chemokine           scl0001073.1_120    1.77  0.007 
CFD     complement factor D         NM_013459.1    1.68  0.007 
CD300LG  CD300 antigen like family member G       scl40868.8_408    1.72  0.049 
H2-T23    histocompatibility 2, T region locus 23      NM_010398.1    1.37  0.036 
H2-K1     histocompatibility 2, K1, K region       scl0014972.1_210    1.61  0.016 
   
inflammatory response      
REG3G     regenerating islet-derived 3 gamma       NM_011260.1    2.97  0.049 
CHST1    carbohydrate           NM_023850.1    1.42  0.031 
KNG1     kininogen 1           NM_023125.2    1.79  0.006 
PPARG     peroxisome proliferator activated receptor gamma   NM_011146.1    1.75  0.000 
   
integrin-mediated signaling pathway      
ADAM9    a disintegrin and metallopeptidase domain 9     NM_007404.1    1.39  0.018 
   
lipid biosynthetic process      
SCD1     stearoyl-Coenzyme A desaturase 1       scl52445.7_23    1.97  0.000 
PCX     pyruvate carboxylase         scl000483.1_20    1.74  0.002 
ACLY     ATP citrate lyase           NM_134037.2    1.81  0.009 
FASN     fatty acid synthase          scl014104.1_1    1.97  0.004 
ELOVL6    ELOVL family member 6, elongation of long    scl00170439.1_29    2.86  0.000 
    chain fatty acids 
ELOVL5    ELOVL family member 5, elongation of long    NM_134255.2    1.39  0.031 
    chain fatty acids 
DGAT2     diacylglycerol O-acyltransferase 2       scl31009.10_67    2.20  0.000 
   
lipid metabolic process   
HSD11B1  hydroxysteroid 11-beta dehydrogenase 1     scl000857.1_11    1.55  0.054 
SCD1     stearoyl-Coenzyme A desaturase 1       scl52445.7_23    1.97  0.000 
HADHB    hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-  NM_145558.1    1.52  0.001 
    Coenzyme A thiolase/enoyl-Coenzyme A hydratase 
CPT1B     carnitine palmitoyltransferase 1b, muscle     NM_009948.1    1.94  0.013 
AACS    acetoacetyl-CoA synthetase         NM_030210.1    1.47  0.028 
CPT2    carnitine palmitoyltrasferase 2      scl000022.1_12    1.56  0.006 
ACADVL  acyl-Coenzyme A dehydrogenase, very long chain   scl40004.19.1_140   1.41  0.042 
ACAA2     acetyl-Coenzyme A acyltransferase 2       scl0002163.1_25    1.40  0.033 
ACADL     acyl-Coenzyme A dehydrogenase, long-chain     NM_007381.2    2.12  0.000 
ACSM3     acyl-CoA synthetase medium-chain family member 3   scl000249.1_5    1.67  0.010 
DGAT2     diacylglycerol O-acyltransferase 2       scl31009.10_67    2.20  0.000 
PNPLA2    patatin-like phospholipase domain containing 2     scl8719.1.1_106    1.79  0.006 
LPL     lipoprotein lipase           scl0016956.1_234    1.86  0.007 
ADIPOR2  adiponectin receptor 2         scl28480.7_231    1.50  0.041 
CIDEA     cell death-inducing DNA fragmentation factor, A   NM_007702.1    2.38  0.000 
    alpha subunit-like effector 
metabolic process      
HSD11B1  hydroxysteroid 11-beta dehydrogenase 1     scl000857.1_11    1.55  0.005 
PCX     pyruvate carboxylase         scl000483.1_20    1.74  0.002 
ACLY     ATP citrate lyase           NM_134037.2    1.81  0.009 
FASN     fatty acid synthase          scl014104.1_1    1.97  0.004 
AMY1     amylase 1, salivary          scl077379.3_13    1.66  0.005 
AGPAT2    1-acylglycerol-3-phosphate O-acyltransferase 2     NM_026212.1    2.76  0.002 
ALAS2     aminolevulinic acid synthase 2, erythroid     scl54562.12.1_64    1.29  0.034 
HADHB    hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-  NM_145558.1    1.52  0.001 
    Coenzyme A thiolase/enoyl-Coenzyme A hydratase 
AACS     acetoacetyl-CoA synthetase         NM_030210.1    1.47  0.028 
GPD1     glycerol-3-phosphate dehydrogenase 1      NM_010271.2    2.00  0.000 
EPHX2     epoxide hydrolase 2, cytoplasmic       scl45408.20.1_29    1.48  0.021 
ALDH3A1  aldehyde dehydrogenase family 3, subfamily A1    NM_007436.1    1.92  0.003 
ACO2     aconitase 2, mitochondrial         NM_080633.1    1.89  0.000 
UAP1     UDP-N-acetylglucosamine pyrophosphorylase 1    NM_133806.2    3.48  0.000 
ACADVL  acyl-Coenzyme A dehydrogenase, very long chain   scl40004.19.1_140   1.41  0.042 
GSTA3     glutathione S-transferase, alpha 3       scl18127.10.1_92    2.43  0.000 
GSTO1     glutathione S-transferase omega 1       NM_010362.1    2.01  0.034  
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ACAA2     acetyl-Coenzyme A acyltransferase 2       scl0002163.1_25    1.40  0.033 
EYA3     eyes absent 3 homolog         NM_010166.2    2.10  0.002 
NAT8L     N-acetyltransferase 8-like         scl27919.3_374    1.47  0.040 
ALDH6A1  aldehyde dehydrogenase family 6, subfamily A1    NM_134042.1    1.65  0.021 
ACADL     acyl-Coenzyme A dehydrogenase, long-chain     NM_007381.2    2.12  0.000 
ACSM3     acyl-CoA synthetase medium-chain family member 3   scl000249.1_5    1.67  0.010 
ACSS1     acyl-CoA synthetase short-chain family member 1   NM_080575.1    1.47  0.012 
PNPLA2   patatin-like phospholipase domain containing 2     scl8719.1.1_106    1.79  0.006 
GSTA4     glutathione S-transferase, alpha 4       NM_010357.1    2.61  0.000 
   
 
muscle contraction    
MYBPC2  myosin binding protein C, fast-type       NM_146189.1    1.34  0.031 
TBX20     T-box 20            NM_194263.1    1.57  0.034 
PPARG     peroxisome proliferator activated receptor gamma   NM_011146.1    1.75  0.000 
   
oxidation reduction    
CYP2S1     cytochrome P450, family 2, subfamily s, polypeptide 1   NM_028775.2    1.56  0.034 
HSD11B1  hydroxysteroid 11-beta dehydrogenase 1     scl000857.1_11    1.55  0.005 
SCD1     stearoyl-Coenzyme A desaturase 1       scl52445.7_23    1.97  0.000 
GPX2     glutathione peroxidase 2         NM_030677.1    1.53  0.045 
FASN     fatty acid synthase          scl014104.1_1    1.97  0.000 
GPX3     glutathione peroxidase 3         NM_008161.1    1.55  0.007 
CYP2E1    cytochrome P450, family 2, subfamily e, polypeptide 1   NM_021282.1    2.09  0.003 
GPD2     glycerol phosphate dehydrogenase 2, mitochondrial   NM_010274.2    1.52  0.007 
ETFDH     electron transferring flavoprotein, dehydrogenase   NM_025794.1    1.64  0.047 
DLD     dihydrolipoamide dehydrogenase       NM_007861.2    1.41  0.046 
GPD1     glycerol-3-phosphate dehydrogenase 1      NM_010271.2    2.00  0.000 
ALDH3A1  aldehyde dehydrogenase family 3, subfamily A1    NM_007436.1    1.92  0.003 
ACADVL  acyl-Coenzyme A dehydrogenase, very long chain   scl40004.19.1_140   1.41  0.046 
CYP2F2     cytochrome P450, family 2, subfamily f, polypeptide 2   scl32906.13.1_13    8.61  0.000 
CYP2A5    cytochrome P450, family 2, subfamily a, polypeptide 5   NM_009997.1    1.85  0.022 
CYP4A12B  cytochrome P450, family 4, subfamily a, polypeptide 12B   scl013118.12_302    3.42  0.000 
ALDH6A1  aldehyde dehydrogenase family 6, subfamily A1    NM_134042.1    1.65  0.021 
ACADL     acyl-Coenzyme A dehydrogenase, long-chain     NM_007381.2    2.12  0.000 
PRDX2     peroxiredoxin 2           NM_011563.2    6.22  0.000 
     
response to toxin   
EPHX2     epoxide hydrolase 2, cytoplasmic       scl45408.20.1_29    1.48  0.021 
CES3     carboxylesterase 3          scl34490.14.1_30    2.18  0.002 
CYP2F2     cytochrome P450, family 2, subfamily f, polypeptide 2   scl32906.13.1_13    8.61  0.000 
PON1     paraoxonase 1           NM_011134.1    2.09  0.001 
   
signal transduction      
RERG     RAS-like, estrogen-regulated, growth-inhibitor     NM_181988.1    2.02  0.001 
GPR109A  G protein-coupled receptor 109A       NM_030701.1    1.61  0.009 
CYSLTR1  cysteinyl leukotriene receptor 1       NM_021476.2    1.33  0.042 
ELTD1     EGF, latrophilin seven transmembrane domain    NM_133222.1    2.08  0.001 
    containing 1 
FCER1G    Fc receptor, IgE, high affinity I, gamma polypeptide   scl15940.5.1_15    2.29  0.016 
   
small GTPase mediated signal transduction      
KNDC1     kinase non-catalytic C-lobe domain       scl31927.18.1_9    2.41  0.002 
RAB25     RAB25, member RAS oncogene family     scl21969.5.1_66    1.31  0.047 
G3BP2     GTPase activating protein         scl0023881.1_86    1.33  0.021 
   
temperature homeostasis   
GPX2     glutathione peroxidase 2         NM_030677.1    1.53  0.045 
ACADVL  acyl-Coenzyme A dehydrogenase, very long chain   scl40004.19.1_140   1.41  0.042 
ACADL    acyl-Coenzyme A dehydrogenase, long-chain     NM_007381.2    2.12  0.001 
CIDEA     cell death-inducing DNA fragmentation factor,    NM_007702.1    2.38  0.000 
    alpha subunit-like effector A 
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transcription      
FOS     FBJ osteosarcoma oncogene        NM_010234.2    2.34  0.000 
SUPT16H  suppressor of Ty 16 homolog       NM_033618.1    1.76  0.021 
KLF5     Kruppel-like factor 5         scl45215.1.1_294    1.99  0.001 
CEBPB     CCAAT/enhancer binding protein       NM_009883.1    1.67  0.002 
TBX20     T-box 20            NM_194263.1    1.57  0.034 
PPARG     peroxisome proliferator activated receptor gamma   NM_011146.1    1.75  0.000 
ZFP367     zinc finger protein 367         NM_175494.2    1.22  0.031 
 EYA3     eyes absent 3 homolog         NM_010166.2    2.10  0.002 
     
transport      
UCP1     uncoupling protein 1         NM_009463.2    2.60  0.000 
SLC5A6    solute carrier family 5         scl26744.20.688_4   1.38  0.024 
APOC1     apolipoprotein C-I          NM_007469.2    1.95  0.001 
NDUFB4 NADH   dehydrogenase (ubiquinone) 1 beta subcomplex 4   scl48493.1_0    1.34  0.028 
ETFB     electron transferring flavoprotein, beta polypeptide   NM_026695.2    1.29  0.044 
ETFA     electron transferring flavoprotein, alpha polypeptide   NM_145615.2    1.42  0.043 
ETFDH     electron transferring flavoprotein, dehydrogenase   NM_025794.1    1.64  0.047 
CPT1B     carnitine palmitoyltransferase 1b, muscle     NM_009948.1    1.94  0.013 
CPT2    carnitine palmitoyltrasferase 2      scl000022.1_12    1.56  0.007 
RAB25     RAB25, member RAS oncogene family     scl21969.5.1_66    1.31  0.047 
FXYD3     FXYD domain-containing ion transport regulator 3   NM_008557.1    1.84  0.003 
GABRP     gamma-aminobutyric acid         scl0001520.1_108    2.35  0.022 
ATP5K     ATP synthase, H+ transporting, mitochondrial F1F0  scl011958.2_29    1.49  0.033 
    complex, subunit e 
G3BP2     GTPase activating protein         scl0023881.1_86    1.33  0.021 
MFI2     antigen p97           scl0001844.1_62    1.45  0.014 
SLC25A1  solute carrier family 25         NM_153150.1    1.71  0.002 
MTCH2     mitochondrial carrier homolog 2       NM_019758.2    1.41  0.033 
   
triglyceride metabolic process      
APOC1     apolipoprotein C-I          NM_007469.2    1.95  0.001 
   
Other      
CISH     cytokine inducible SH2-containing protein     scl012700.3_170    1.60  0.004 
STMN2    stathmin-like 2           scl23400.7_310    1.65  0.000 
SOCS3     suppressor of cytokine signaling 3       NM_007707.2    1.41  0.022 
TUBA8     tubulin, alpha 8           scl29555.5_307    1.71  0.020 
DNAHC2  dynein, axonemal, heavy chain 2       scl40034.27.1_30    1.57  0.004   
SCGB1A1  secretoglobin, family 1A, member 1       NM_011681.1    9.55  0.000 
HSPA5     heat shock 70kD protein 5         NM_022310.2    1.75  0.005 
DUSP1     dual specificity phosphatase 1       NM_013642.1    1.64  0.021 
DUSP23    dual specificity phosphatase 23       NM_026725.2    1.45  0.044 
BMPER     BMP-binding endothelial regulator       NM_028472.1    1.95  0.004 
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brown fat cell differentiation         
MB     myoglobin           NM_013593.2    1.89  0.003 
 
carbohydrate metabolic process        
IGF2     insulin-like growth factor 2         scl30469.7_1    1.82  0.015 
RPE    ribulose-5-phosphate-3-epimerase       scl0227227.1_0    2.13  0.019 
 
Cell adhesion      
VCAN    versican            scl013003.1_89    1.11  0.025 
STAB1    stabilin 1            NM_138672.1    1.39  0.030 
SELP     selectin, platelet           NM_011347.1    1.38  0.021 
ITGA3    integrin alpha 3           NM_013565.2    1.25  0.017 
ITGB1    integrin beta 1           NM_010578.1    1.72  0.008 
 
cell-cell adhesion       
TNXB     tenascin XB           NM_031176.1    1.71  0.021 
 
cellular iron ion homeostasis      
LTF    lactotransferrin           NM_008522.2    11.84  0.000 
ALAS2    aminolevulinic acid synthase 2, erythroid     scl54562.12.1_64    1.29  0.033 
HAMP2    hepcidin antimicrobial peptide 2       NM_183257.1    5.38  0.000 
MFI2     antigen p97           scl0001844.1_62    1.45  0.014 
 
chemotaxis        
CCL21B    chemokine           scl0018829.1_65    2.04  0.026 
 
DNA replication       
NFIC    nuclear factor I/C           scl068530.1_6    2.03  0.005 
RBBP4    retinoblastoma binding protein 4       scl24919.4.1_260    2.09  0.021 
   
heart development       
MB    myoglobin           NM_013593.2    1.89  0.004 
MYL2    myosin, light polypeptide 2, regulatory, cardiac, slow   scl27267.9.1_12    6.36  0.001 
VCAN    versican            scl013003.1_89    1.11  0.025 
OSR1    oxidative-stress responsive 1       scl35223.18_513    1.53  0.007 
   
immune response        
H2-EA    histocompatibility 2, class II antigen E alpha     NM_010381.2    1.17  0.030 
CCL21B   chemokine           scl0018829.1_65    2.04  0.026 
 
inflammatory response 
STAB1    stabilin 1            NM_138672.1    1.39  0.030 
CCL21B   chemokine           scl0018829.1_65    2.04  0.026 
SELP    selectin, platelet           NM_011347.1    1.38  0.021 
 
integrin-mediated signaling pathway       
ITGA3    integrin alpha 3           NM_013565.2    1.25  0.018 
ITGB1    integrin beta 1           NM_010578.1    1.72  0.009 
   
lipid biosynthetic process       
PRKAG2    protein kinase, AMP-activated, gamma 2 non-catalytic subunit NM_145401.1    2.38  0.021 
   
lipid metabolic process     
PTPN11    protein tyrosine phosphatase, non-receptor type 11   NM_011202.2    1.88  0.040 
TNXB     tenascin XB           NM_031176.1    1.71  0.022 
   
metabolic process        
RPE     ribulose-5-phosphate-3-epimerase       scl0227227.1_0    2.13  0.019 
   
muscle contraction       
TTN    titin            scl19104.8.1_3    1.18  0.037 
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ZBTB7A    zinc finger and BTB domain containing 7a     scl0016969.1_242    3.43  0.002 
 
oxidation reduction      
4933406E20RIK  RIKEN cDNA 4933406E20 gene       NM_028944.2    1.24  0.009 
 
signal transduction      
RAP2C     RAP2C, member of RAS oncogene family     scl54266.5_48    2.00  0.025 
 
transcription     
CREBBP    CREB binding protein         scl48815.9.1_11    2.07  0.033 
SKI    superkiller viralicidic activity 2-like (S.cerevisiae)  scl23441.8_64    1.98  0.003 
RBBP4     retinoblastoma binding protein 4       scl24919.4.1_260    2.09  0.021 
NFIC     nuclear factor I/C           scl068530.1_6    2.03  0.005 
 
transport      
MB     myoglobin           NM_013593.2    1.89  0.004 
LTF     lactotransferrin           NM_008522.2    11.84  0.000 
TRAM1     translocating chain-associating membrane protein 1   NM_028173.1    1.72  0.036 
RAMP1     receptor             scl17654.5.1_10    1.54  0.034 
RAB17    RAB17, member RAS oncogene family     NM_008998.2    2.33  0.006 
 
triglyceride metabolic process       
PTPN11    protein tyrosine phosphatase, non-receptor type 11   NM_011202.2    1.88  0.040 
TNXB     tenascin XB           NM_031176.1    1.71  0.022 
 
Other        
GUCY1A3  guanylate cyclase 1, soluble, alpha 3       scl0060596.1_205    1.03  0.011 
BMX     BMX non-receptor tyrosine kinase       NM_009759.2    1.62  0.030 
KIF1B    kinesin family member 1B         scl0002773.1_49    2.29  0.021 
ZBTB7A    zinc finger and BTB domain containing 7a     scl0016969.1_242    3.43  0.002 
PRRX1     paired related homeobox 1         scl018933.1_11    1.78  0.021 
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Transport       
SCNN1G    sodium channel, nonvoltage-gated 1 gamma     scl32105.12.878_39  1.90  0.029 
CLIC6     chloride intracellular channel 6       NM_172469.1    2.28  0.009 
SLC39A4  solute carrier family 39         NM_028064.2    2.04  0.021 
RAB25    RAB25, member RAS oncogene family     scl21969.5.1_66    2.04  0.021 
GABRP     gamma-aminobutyric acid         scl0001520.1_108    2.83  0.002 
Ltf     lactotransferrin           NM_008522.2    11.43  0.000 
 
Transport; oxygen transport       
MB     myoglobin           NM_013593.2    2.74  0.000 
HBB-B2    hemoglobin, beta adult minor chain       NM_016956.2    2.35  0.000 
   
Signal transduction      
FCER1G    Fc receptor, IgE, high affinity I, gamma polypeptide   scl15940.5.1_15    2.68  0.002 
GRB7     growth factor receptor bound protein 7      scl40936.14_9    1.86  0.021 
   
Cell adhesion       
MUC4     mucin 4             scl0140474.33_123   1.82  0.031 
WISP2     WNT1 inducible signaling pathway protein 2     NM_016873.1    1.92  0.010 
SPON2     spondin 2, extracellular matrix protein      NM_133903.2    1.54  0.045 
   
Oxidation reduction       
CYP2E1    cytochrome P450, family 2, subfamily e, polypeptide 1   NM_021282.1    1.98  0.008 
CYP2F2     cytochrome P450, family 2, subfamily f, polypeptide 2   scl32906.13.1_13    12.08  0.000 
CYP2A5    cytochrome P450, family 2, subfamily a, polypeptide 5   NM_009997.1    3.32  0.004 
CYP4A12B  cytochrome P450, family 4, subfamily a, polypeptide 12B   scl013118.12_302    4.46  0.001 
ABP1     amiloride binding protein 1         NM_029638.1    1.62  0.044 
GPX2     glutathione peroxidase 2         NM_030677.1    2.20  0.004 
ALDH3A1  aldehyde dehydrogenase family 3, subfamily A1    NM_007436.1    2.10  0.013 
ALDH1A1  aldehyde dehydrogenase family 1, subfamily A1    scl011668.12_94    2.55  0.027 
PRDX2     peroxiredoxin 2           NM_011563.2    2.25  0.012 
   
Immune response       
PGLYRP1  peptidoglycan recognition protein 1       scl33021.4.288_87   2.08  0.035 
CXCL15    chemokine           scl27600.3.1_4    5.76  0.000 
SPON2     spondin 2, extracellular matrix protein      NM_133903.2    1.54  0.045 
   
Metabolic process       
ALDH3A1  aldehyde dehydrogenase family 3, subfamily A1    NM_007436.1    2.10  0.013 
ALDH1A1  aldehyde dehydrogenase family 1, subfamily A1    scl011668.12_94    2.55  0.027 
GSTA3     glutathione S-transferase, alpha 3       scl18127.10.1_92    2.14  0.014 
GSTO1     glutathione S-transferase omega 1       NM_010362.1    2.92  0.004 
   
Hemopoiesis       
CXCL15    chemokine           scl27600.3.1_4    5.76  0.000 
   
Regulation of transcription       
IRX5     Iroquois related homeobox 5        NM_018826.2    1.94  0.025 
OTX1     orthodenticle homolog 1         scl40460.6_595    1.72  0.038 
IRX3     Iroquois related homeobox 3        scl34499.5.1_0    1.69  0.024 
FOXA1     forkhead box A1           scl42430.2_236    1.84  0.015 
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Table 4.6 List of genes down-regulated in the pulmonary arteries of 2 month male SERT+ mice 
compared to 2 month male wildtype mice, arranged by biological process.  
 
 
Gene Symbol  Gene Name          Accession No    Fold  False 
                      Change   Discovery 
                      Rate 
   
Transport: oxygen transport     
HBB-B1    hemoglobin, beta adult major chain       NM_008220.2    2.41  0.019 
 
Signal transduction        
LGR6     leucine-rich repeat-containing G protein-coupled   scl00329252.1_132   1.86  0.011 
    receptor 6 
Oxidation reduction       
JARID1B  lysine (K)-specific demethylase 5B      scl17448.26_107    1.65  0.032 
SC4MOL    sterol-C4-methyl oxidase-like       NM_025436.1    2.25  0.003 
 
Hemopoiesis      
PICALM    phosphatidylinositol binding clathrin assembly protein   scl32408.23_56    3.80  0.001 
HBB-B1    hemoglobin, beta adult major chain       NM_008220.2    2.41  0.019 
 
Regulation of transcription        
TEF     thyrotroph embryonic factor        scl0002562.1_0    1.82  0.022 
DBP     D site albumin promoter binding protein     NM_016974.1    2.45  0.002 
PER2     period homolog 2           NM_011066.1    1.89  0.013 
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Table 4.7 List of genes up-regulated in the pulmonary arteries of 2 month hypoxic male SERT+ 
mice compared to 2 month hypoxic male wildtype mice, arranged by biological process.  
 
 
Gene Symbol  Gene Name          Accession No    Fold  False 
                      Change   Discovery 
                      Rate 
   
transport      
LBP     lipopolysaccharide binding protein       scl20002.16.7_10    1.92  0.019 
LTF     lactotransferrin           NM_008522.2    6.63  0.000 
APOC1     apolipoprotein C-I          NM_007469.2    1.95  0.020 
SLC4A1    solute carrier family 4         NM_011403.1    2.28  0.004 
HBB-B1    hemoglobin, beta adult major chain       NM_008220.2    3.05  0.032 
ABCC9     ATP-binding cassette, sub-family C       scl0001165.1_35    2.25  0.015 
SLC1A3    solute carrier family 1         NM_148938.2    1.85  0.011 
LCN2     lipocalin 2           NM_008491.1    1.65  0.021 
 
signal transduction, protein binding       
FGL1    fibrogen-like protein 1        scl34887.7.1_10    2.48  0.007 
ANGPTL4  angiopoietin-like 4         scl50042.7_106    1.89  0.019 
TNC    tenascin C           scl0002731.1_70    1.77  0.018 
 
immune response       
CCL7    chemokine           scl41159.3.1_10    2.02  0.014 
CFD     complement factor D         NM_013459.1    1.78  0.042 
CCL2     chemokine           scl020296.2_11    2.03  0.014 
CLEC4D    C-type lectin domain family 4, member d     scl017474.5_5    1.54  0.034 
C3     complement component 3         scl49743.39.1_15    1.74  0.042 
C1S     complement component 1, s subcomponent     NM_144938.1    3.34  0.003 
PRG4    PREDICTED:  proteoglycan 4       scl000882.1_25    2.34  0.003 
SPON2     spondin 2, extracellular matrix protein      NM_133903.2    1.98  0.019 
CXCL14    chemokine           scl43911.4.1_38    1.52  0.031 
 
proteolysis     
DPEP2     dipeptidase 2           scl34381.6_178    1.40  0.047 
CTSK     cathepsin K           NM_007802.2    1.56  0.014 
CFD     complement factor D         NM_013459.1    1.78  0.042 
CPXM1     carboxypeptidase X 1         NM_019696.1    1.25  0.020 
CTSC     cathepsin C           NM_009982.2    1.75  0.020 
C1S     complement component 1, s subcomponent     NM_144938.1    3.34  0.003 
HP     haptoglobin           NM_017370.1    3.13  0.002 
 
cell adhesion     
CNTN2     contactin 2           scl0021367.1_277    2.19  0.017 
CPXM1     carboxypeptidase X 1         NM_019696.1    1.25  0.020 
COL8A2   collagen, type VIII, alpha 2        scl24964.1.1958_52  1.98  0.018 
CYR61     cysteine rich protein 61         NM_010516.1    1.66  0.039 
TNC     tenascin C           scl0002731.1_70    1.77  0.018 
SPP1     secreted phosphoprotein 1         NM_009263.1    2.51  0.006 
SPON2     spondin 2, extracellular matrix protein      NM_133903.2    1.98  0.019 
COMP    cartilage oligomeric matrix protein      scl33728.21.1_0    1.85  0.025 
FN1    fibronectin 1           scl16639.44.189_5   1.57  0.013 
 
apoptosis      
CIDEC     cell death-inducing DFFA-like effector c     NM_178373.2    1.90  0.046 
COMP    cartilage oligomeric matrix protein      scl33728.21.1_0    1.85  0.025 
 
lipid metabolic process        
SLC27A3  solute carrier family 27         scl21918.10.1_222   1.74  0.031 
LPL    lipoprotein lipase           scl0016956.1_234    1.71  0.018 
 
innate immune response     
LBP    lipopolysaccharide binding protein       scl20002.16.7_10    1.92  0.019 
CFD     complement factor D         NM_013459.1    1.78  0.042 
C3     complement component 3         scl49743.39.1_15    1.74  0.042 
C1S     complement component 1, s subcomponent     NM_144938.1    3.34  0.003 
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Table 4.7 Continued  
 
 
Gene Symbol  Gene Name          Accession No    Fold  False 
                      Change   Discovery 
                      Rate 
   
brown fat cell differentiation       
ADIPOQ    adiponectin, C1Q and collagen domain containing   scl49310.3_131    2.30  0.003 
LRG1     leucine-rich alpha-2-glycoprotein 1       NM_029796.2    2.31  0.004 
 
skeletal system development       
RUNX1     runt related transcription factor 1       scl48188.1.1_190    2.07  0.011 
COL1A1    procollagen, type I, alpha 1         scl012842.26_28    2.15  0.007 
 
blood vessel development       
COL3A1    procollagen, type III, alpha 1        NM_009930.1    1.57  0.039 
COL1A1    procollagen, type I, alpha 1         scl012842.26_28    2.15  0.007 
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Table 4.8 List of genes down-regulated in the pulmonary arteries of 2 month hypoxic male SERT+ 
mice compared to 2 month hypoxic male wildtype mice, arranged by biological process.  
 
 
Gene Symbol  Gene Name          Accession No    Fold  False 
                      Change   Discovery 
                      Rate 
   
transport      
UCP1    uncoupling protein 1         NM_009463.2    3.84  0.000 
KCNAB1  potassium voltage-gated channel, shaker-related 1   NM_010597.2    1.68  0.025 
    subfamily, beta member 
KCNH2     potassium voltage-gated channel, subfamily H     NM_013569.1    1.74  0.014 
TOMM22  translocase of outer mitochondrial membrane 22 homolog   scl47742.5_273    3.76  0.000 
RAMP1     receptor (calcitonin) activity modifying protein 1    scl17654.5.1_10    1.59  0.046 
RAB17     RAB17, member RAS oncogene family     NM_008998.2    1.92  0.006 
 
proteolysis       
MIPEP     mitochondrial intermediate peptidase       NM_027436.1    1.50  0.046 
DPEP1     dipeptidase 1           NM_007876.1    1.70  0.031 
CORIN     corin             NM_016869.1    1.84  0.014 
 
cell adhesion       
MCAM     melanoma cell adhesion molecule       NM_023061.1    1.51  0.046 
PKP4    plakophilin 4           scl0003206.1_31    1.70  0.025 
 
apoptosis      
ACTC1     actin, alpha, cardiac         NM_009608.1    1.14  0.018 
CIDEA     cell death-inducing DNA fragmentation factor, alpha  NM_007702.1    1.88  0.018 
    subunit-like effector A 
PAWR     PRKC, apoptosis, WT1, regulator       scl38461.7.1_1    1.67  0.031 
 
lipid metabolic process      
TNXB     tenascin XB           NM_031176.1    1.91  0.013 
CIDEA     cell death-inducing DNA fragmentation factor, alpha  NM_007702.1    1.88  0.018 
    subunit-like effector A 
 
heart development           
PDLIM3    PDZ and LIM domain 3         NM_016798.2    1.59  0.028 
EDN1     endothelin 1           NM_010104.2    1.55  0.046 
TNNT2     troponin T2, cardiac         NM_011619.1    1.62  0.004 
 
brown fat cell differentiation       
UCP1    uncoupling protein 1         NM_009463.2    3.84  0.000 
 
skeletal system development       
GJA5     gap junction membrane channel protein alpha 5     NM_008121.2    1.55  0.042 
 
blood vessel development     
GJA5    gap junction membrane channel protein alpha 5     NM_008121.2    1.55  0.042 
GJA4     gap junction membrane channel protein alpha 4     NM_008120.2    1.80  0.014 
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Table 4.9 Primer pairs used for PCR analysis 
Gene Symbol   Accession No   Sense-primer         Anti-sense primer 
    Mouse 
HAMP2    NM_183257.2   5'-AGCAGAACAGGAGGCATGAT-3'   5'-GCAGATGGGAAGTTGATGT-3' 
CEBPB     NM_009883.1   5'-CAAGCTGAGCGACGAGTACA-3'   5'-AGCTGCTCCACCTTCTTCTG-3' 
CYP1B1   NM_009994.1   5'-GCGACGATTCCTCCGGGCTG-3'    5'-CTCATGCAGGGCAGGCGGTC-3' 
TNNC1     NM_009393.1   5'-GGAATTCATGAAGGGTGTGG-3'   5'-GGAATGGGGAGAGAAAGTCC-3' 
PLN     NM_023129   5'-ATCTTGCTGTGTTGGCTGTG-3'     5'-AGGGGACAACCACTTCCTCT-3' 
MYL3     NM_010859   5'-GATGCTGACACCATGTCTGG-3'    5'-TAAGGCCACAGGGTGGATAC-3' 
MB     NM_013593.3   5'-CCTGGGTACCATCCTGAAGA-3'    5'-GAGCATCTGCTCCAAAGTCC-3' 
NPPA     NM_008725.2   5'-CCTAAGCCCTTGTGGTGTGT-3'    5'-CAGAGTGGGAGAGGCAAGAC-3' 
FOS     NM_010234   5'-CTCCCGTGGTCACCTGTACT-3'    5'-TTGCCTTCTCTGACTGCTCA-3' 
COX6A2   NM_009943.2   5'-CGGTTATGAGCACCCTTGAT-3'    5'-CTGTTCCCAAAGAGCCAGAG-3' 
β-ACTIN   NM_007393.2  5'-AGCCATGTACGTAGCCATCC-3'     5'-TCTCAGCTGTGGTGGTGAAG-3' 
     
   Human 
CEBPB    NM_005194  5’-GACAAGCACAGCGACGAGTA-3’    5’-AGCTGCTCCACCTTCTTCTG-3’ 
CYP1B1   NM_005252  5’-AACCGCAACTTCAGCAACTT-3’   5’-GAGGATAAAGGCGTCCATCA-3’ 
FOS    NM_000104.3  5’-AGCAATGAGCCTTCCTCTGA-3’   5’-TGAGTCCACACATGGATGCT-3’ 
β-ACTIN   NM_001101  5’-TCCCTGGAGAAGAGCTACGA-3’    5’-AGCACTGTGTTGGCGTACAG-3’ 
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Figure 4.7 Representation of differentially expressed genes in normoxic female and 
male wildtype and SERT+ mice by hierarchical cluster analysis and gene ontology.  
Hierarchical cluster analysis of the differentially expressed genes in normoxic female and 
male WT and SERT+ mice (A).  Representation of the differentially expressed genes in 
female SERT+ mice (B) and male SERT+ mice (C), arranged by biological processes.  
n=4. 
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Figure  4.8  Representation  of  differentially  expressed  genes  in  chronically  hypoxic 
female and male wildtype and SERT+ mice by hierarchical cluster analysis and gene 
ontology.  Hierarchical cluster analysis of the differentially expressed genes in chronically 
hypoxic female and male WT and SERT+ mice (A).  Representation of the differentially 
expressed  genes  in  female  SERT+  mice  (B)  and  male  SERT+  mice  (C),  arranged  by 
biological processes.  n=4. 
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4.2.4  qRT-PCR Analysis in the Pulmonary Arteries of SERT+ Mice  
For validation of the microarray study, we employed qRT-PCR.  To perform this, we 
selected three differentially expressed genes for each of the 4 group comparisons (Table 
4.9).  Our genes of interest were FOS, CEBPB, CYP1B1, MYL3, HAMP2, LTF, PLN, 
NPPA, UCP1 and C1S.  In concordance with our microarray data, expression of these 
genes was significantly altered in relevant groups (Figure 4.9-12).  Of particular interest, 
qRT-PCR  analysis  confirmed  that  FOS,  CEBPB  and  CYP1B1  were  considerably  up-
regulated (4-fold, 20-fold and 8-fold respectively) in female SERT+ mice.   
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Figure 4.9 FOS, CEBPB and CYP1B1 mRNA expression in the pulmonary arteries of 
normoxic female wildtype and SERT+ mice.  FOS (A), CEBPB (B) and CYP1B1 (C) 
mRNA  expression  is  increased  in  normoxic  female  SERT+  mice,  concordant  with 
microarray analysis.  Data are expressed as mean   SEM and analysed by Students t-test; 
*P<0.05, **P<0.01, ***P<0.001 cf. normoxic female WT mice.  n=4 and performed in 
triplicate. 
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Figure 4.10 MYL3, HAMP2 and CEBPB mRNA expression in the pulmonary arteries 
of chronically hypoxic female wildtype and SERT+ mice.   MYL3 (A), HAMP2 (B) and 
CEBPB (C) mRNA expression is increased in chronically hypoxic female SERT+ mice, 
concordant with microarray analysis.  Data are expressed as mean   SEM and analysed by 
Students t-test; *P<0.05, ***P<0.001 cf. chronically hypoxic female WT mice.  n=4 and 
performed in triplicate. 
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Figure 4.11 LTF, PLN and NPPA mRNA expression in the pulmonary arteries of 
normoxic male wildtype and SERT+ mice.  LTF (A) mRNA expression is increased and 
PLN (B) and NPPA (C) mRNA expression is decreased in normoxic male SERT+ mice, 
concordant with microarray analysis.  Data are expressed as mean   SEM and analysed by 
Students t-test; *P<0.05, ***P<0.001 cf. normoxic male WT mice.  n=4 and performed in 
triplicate. 
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Figure  4.12  UCP1, LTF and C1S  mRNA expression  in the  pulmonary arteries  of 
chronically hypoxic male wildtype and SERT+ mice.  UCP1 (A) mRNA expression is 
increased and LTF (B) and C1S (C) mRNA expression is decreased in chronically hypoxic 
male SERT+ mice, concordant with microarray analysis.  Data are expressed as mean   
SEM and analysed by Students t-test; *P<0.05, ***P<0.001 cf. chronically hypoxic male 
WT mice.  n=4 and performed in triplicate. 
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4.2.5  C/EBPβ, CYP1B1 and c-FOS Protein Expression is Increased in 
Female SERT+ Mice 
To further investigate interesting gene expression differences observed in female SERT+ 
mice, we assessed expression of CEBPB, CYP1B1 and FOS at protein level.  In agreement 
with our qRT-PCR findings, protein expression of C/EBPβ (Figure 4.13), CYP1B1 (Figure 
4.14) and c-FOS (Figure 4.15) were also up-regulated in the pulmonary arteries of female 
SERT+ mice.   
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Figure  4.13  C/EBPβ expression  in the  pulmonary arteries  of female wildtype  and 
SERT+  mice.  Representative  immunoblotting  (A)  and  densitometrical  analysis  (B) 
confirming  that  C/EBPβ  expression  is  increased  in  the  pulmonary  arteries  of  female 
SERT+ mice compared to female WT mice.  Data are expressed as mean   SEM and 
analysed by Students t-test; *P<0.05 cf. WT mice.  n=4 and performed in triplicate.  
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Figure 4.14 CYP1B1 expression in the pulmonary arteries of female wildtype and 
SERT+  mice.  Representative  immunoblotting  (A)  and  densitometrical  analysis  (B) 
confirming  that  CYP1B1expression  is  increased  in  the  pulmonary  arteries  of  female 
SERT+ mice compared to female WT mice.  Data are expressed as mean   SEM and 
analysed by Students t-test; *P<0.05 cf. WT mice.  n=4 and performed in triplicate.  
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Figure  4.15  c-FOS  expression  in  the  pulmonary  arteries  of  female  wildtype  and 
SERT+  mice.  Representative  immunoblotting  (A)  and  densitometrical  analysis  (B) 
confirming that c-FOS expression is increased in the pulmonary arteries of female SERT+ 
mice compared to female WT mice.  Data are expressed as mean   SEM and analysed by 
Students t-test; *P<0.05 cf. WT mice.  n=4 and performed in triplicate.  
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4.2.6  Serotonin and 17β Estradiol Stimulate C/EBPβ, CYP1B1 and c-
FOS Expression in PASMCs 
To determine if serotonin and 17β estradiol stimulate expression of C/EBPβ, CYP1B1 and 
c-FOS, we investigated expression of these in PASMCs following 24 hour stimulation with 
serotonin and 17β estradiol.  Stimulation with serotonin or 17β estradiol for 24 hours was 
sufficient to increase C/EBPβ (Figure 4.16), CYP1B1 (Figure 4.17) and c-FOS (Figure 
4.18) expression in PASMCs.        
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Figure  4.16  C/EBPβ  expression  in  human  PASMCs  following  serotonin  and  17β 
estradiol stimulation.  Representative immunoblotting (A) and densitometric analysis (B) 
confirming increased protein expression of C/EBPβ in human PASMCs following 24 hours 
stimulation  with  1µmol/L  serotonin  (5-HT)  or  1nmol/L  17β  estradiol  (E2).    Data  are 
expressed as mean   SEM and analysed by one-way ANOVA followed by Dunnetts post-
hoc test; *P<0.05 cf. control PASMCs.  n=3 and performed in triplicate.   
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Figure  4.17  CYP1B1  expression  in  human  PASMCs  following  serotonin  and  17β 
estradiol stimulation.  Representative immunoblotting (A) and densitometric analysis (B) 
confirming  increased  protein  expression  of  CYP1B1  in  human  PASMCs  following  24 
hours stimulation with 1µmol/L serotonin (5-HT) or 1nmol/L 17β estradiol (E2).  Data are 
expressed as mean   SEM and analysed by one-way ANOVA followed by Dunnetts post-
hoc test.  *P<0.05 cf. control PASMCs.  n=3 and performed in triplicate.   
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Figure  4.18  c-FOS  expression  in  human  PASMCs  following  serotonin  and  17β 
estradiol stimulation.  Representative immunoblotting (A) and densitometric analysis (B) 
confirming increased protein expression of c-FOS in human PASMCs following 24 hours 
stimulation  with  1µmol/L  serotonin  (5-HT)  or  1nmol/L  17β  estradiol  (E2).  Data  are 
expressed as mean   SEM and analysed by one-way ANOVA followed by Dunnetts post-
hoc test.  *P<0.05 cf. control PASMCs.  n=3 and performed in triplicate.   
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4.2.7  C/EBPβ, CYP1B1 and c-FOS mRNA and Protein Expression is 
Increased in PASMCs Derived From IPAH Patients 
To identify if these findings translate with relevance to human PAH, we investigated the 
expression  of  CEBPB,  CYP1B1  and  FOS  in  PASMCs  derived  from  IPAH  patients.  
PASMCs from non-PAH donors were studied as controls.  Interestingly, CEBPB, CYP1B1 
and  FOS  expression  appeared  significantly  increased  in  mRNA  extracted  from  IPAH 
PASMCs (Figure 4.19).  Similarly, Western blot analysis confirmed that protein expression 
of C/EBPβ (Figure 4.20), CYP1B1 (Figure 4.21) and c-FOS (Figure 4.22) is also increased 
in IPAH PASMCs compared to control PASMCs. 
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Figure 4.19 CEBPB, CYP1B1 and FOS mRNA expression in PASMCs derived from 
control and IPAH patients.  Expression of CEBPB (A), CYP1B1 (B) and FOS (C) is 
increased in PASMCs derived from IPAH patients.  Data are expressed as mean   SEM 
and analysed by Students t-test; **P<0.01, ***P<0.001 cf. control.  n=3 and performed in 
triplicate. 
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Figure 4.20 C/EBPβ expression is increased in PASMCs derived from IPAH patients.  
Representative  immunoblotting  (A)  and  densitometrical  analysis  (B)  confirming  that 
C/EBPβ is increased in PASMCs derived from IPAH patients.  Data are expressed as mean 
  SEM  and  analysed  by  Students  t-test;  *P<0.05  cf.  control.    n=3  and  performed  in 
triplicate. 
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Figure 4.21 CYP1B1 expression is increased in PASMCs derived from IPAH patients.  
Representative  immunoblotting  (A)  and  densitometrical  analysis  (B)  confirming  that 
CYP1B1 is increased in PASMCs derived from IPAH patients.  Data are expressed as 
mean   SEM and analysed by Students t-test; *P<0.05 cf. control.  n=3 and performed in 
triplicate. 
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Figure 4.22 c-FOS expression is increased in PASMCs derived from IPAH patients.  
Representative immunoblotting (A) and densitometrical analysis (B) confirming that c-
FOS is increased in PASMCs derived from IPAH patients.  Data are expressed as mean   
SEM and analysed by Students t-test; *P<0.05 cf. control.  n=3 and performed in triplicate. 
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4.3  Discussion 
Despite increased mortality reported in men (Humbert et al., 2010), the incidence of both 
IPAH and HPAH remains up to three-fold more common in women.  This is highlighted in 
recent epidemiological studies carried out in Scotland, France and USA, where 60%, 65% 
and 77% of the patients studied respectively were female (Peacock et al., 2007; Humbert et 
al., 2006; Thenappan et al., 2007).  Established experimental models of PAH have failed to 
provide insight into this increased occurrence.  Paradoxically, several experimental models 
of PAH exhibit male susceptibility compared to their female counterparts (Rabinovitch et 
al., 1981; Hansmann et al., 2007; Said et al., 2007; Miller et al., 2005).  Here, we describe 
an experimental model of PAH which exhibits female susceptibility.   Female SERT+ mice 
develop PAH and exaggerated hypoxia-induced PAH whereas male SERT+ mice remain 
unaffected, when compared against their respective WT controls.  We were interested in 
determining the genotypic differences associated with the development and progression of 
PAH  in  SERT+  mice.    To  investigate  this,  microarray  analysis  was  performed  in  the 
pulmonary  arteries  of  SERT+  mice  at  2  months  of  age,  where  no  PAH  phenotype  is 
reported. 
 
Through microarray analysis we have identified a large number of differentially expressed 
genes in the pulmonary arteries of SERT+ mice.  In total, we identified 155 genes changed 
in female SERT+ mice whilst 148 genes were changed in male SERT+ mice.  Heat map 
analysis identified gene expression changes in females which were not apparent in males.  
When  assigned  to  biological  processes,  we  also  identified  that  over  40%  of  the 
differentially expressed genes in female SERT+ mice were directly involved in biological 
pathways.  In total, fifteen known biological pathways were dysregulated in female SERT+ 
mice  and  included  oxidation-reduction,  cell  differentiation,  regulation  of  transcription, 
apoptosis, muscle contraction, cellular calcium ion homeostasis and glycolysis.  This may  
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be relevant to the development of PAH in SERT+ mice, as dysregulation of these pathways 
has been previously implicated in the pathogenesis of PAH (Rehman and Archer, 2010; 
Sakao et al., 2009).  Indeed, similar pathway changes have also been described in the lungs 
of VIP-/- mice (Hamidi et al., 2008) and BMPR-II mutant mice (Tada et al., 2007).  In 
contrast to female SERT+ mice, only 25% of altered genes in male SERT+ mice were 
associated with biological function and as a consequence resulted in the dysregulation of 
pathways to a much lesser extent.  
 
In chronic hypoxia, there were also a large number of differentially expressed genes in 
SERT+ mice compared to their respective WT controls.  We observed a total of 316 genes 
altered in females whilst less than half (154) of these were altered in males.  In hypoxic 
female SERT+ mice, 53% of genes were associated with biological function.  Similar to 
the normoxic female comparison, altered genes were related to apoptotic, inflammatory, 
transcription and metabolic processes, all of which are well-described in PAH (Hassoun et 
al., 2009).  In total, 26 biological pathways were identified as dysregulated.  As expected, 
fewer genes were reported as changed in male SERT+ mice.  These differences may help 
explain the exaggerated hypoxia-induced PAH phenotype in female SERT+ mice. 
 
The female hormone 17β estradiol is one risk factor in PAH.  Decreased expression of the 
17β estradiol metabolising enzyme cytochrome P450 1B1 (CYP1B1), resulting in altered 
estrogen metabolism, has been identified in female PAH patients harbouring a BMPR-II 
mutation compared to unaffected female carriers (Austin et al., 2009).  Multiple factors 
modulate the levels of estrogen-metabolizing enzymes in the liver and target tissues, and 
the biological effects of an estrogen will depend on the profile of metabolites formed and 
the  biological  activities  of  each  of  these  metabolites  (Zhu  and  Conney,  1998).    17β 
estradiol is metabolised to both pro- and anti-proliferative metabolites and its effects will 
depend on its metabolism.  17β estradiol can be converted to estrone and subsequently  
  191 
metabolized  to  16 -hydroxyestrone  (16-OHE1)  via  CYP3A4.    Or  alternatively,  17β 
estradiol  is  metabolized  to  2-hydroxyestradiol  (2-OHE)  via  the  estrogen  metabolizing 
enzymes CYP1A1/2 and to a lesser extent via CYP1B1 (Hanna et al., 2000; Tsuchiya et 
al., 2005).  2-OHE can itself be metabolized to 2-methoxyestradiol (2-ME) via catechol O-
methyltransferase (COMT).  Both 2-OHE and 2-ME have anti-proliferative effects on cells 
(Tofovic  et  al.,  2006),  whereas  16 -OHE1  stimulates  proliferation  by  constitutively 
activating  the  estrogen  receptor  (Swaneck  and  Fishman,  1988).    Metabolism  of  17β 
estradiol will therefore be species, gender and strain-dependent and differential disruption 
in the balance of metabolites may therefore account for the differential effects of female 
hormones in different models of PAH.  Consistent with this, our microarray findings show 
that CYP1B1 mRNA expression is increased in female SERT+ mice.  In further support of 
this, immunoblotting confirmed that CYP1B1 protein expression is also increased in the 
pulmonary arteries of female SERT+ mice.  Of further interest, both serotonin and 17β 
estradiol  stimulation  increased  CYP1B1  expression  in  PASMCs.  Indeed,  similar  17β 
estradiol effects have been previously described in cancer cells (Tsuchiya et al., 2004).    
On this evidence, serotonin and 17β estradiol may be accountable for increased CYP1B1 
expression in female SERT+ mice.    
 
CCAAT/enhancer-binding protein beta (C/EBPβ) is a transcription factor encoded by the 
CEBPB  gene.    C/EBPβ  has  been  previously  shown  to  regulate  inflammation,  cell 
differentiation and cell proliferation (Ramji and Foka, 2002).  For example, C/EBPβ is 
essential in the pathogenesis of multiple proliferative disorders including skin, breast and 
ovarian cancer (Zhu et al., 2002; Raught et al., 1996; Sundfeldt et al., 1999).  In line with 
this, C/EBPβ deficient mice appear resistant to tumorigenesis (Sterneck et al., 2006).  The 
role  of  C/EBPβ  in  the  development  of  PAH  is  poorly  defined.    Increased  C/EBPβ 
expression has been reported in the lungs of chronically hypoxic rats (Teng et al., 2002), 
where it appears to stimulate inducible nitric oxide synthase expression.  Reduced CEBPB  
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expression has also been previously reported in the lungs of SERT knockout mice (Crona 
et al., 2009).  Conversely, our microarray data shows the up-regulation CEBPB in female 
SERT+ mice.  Increased CEBPB mRNA expression was confirmed by qRT-PCR analysis.  
We also identified that C/EBPβ protein expression was increased in the pulmonary arteries 
of female SERT+ mice.  In support of this, we observed that serotonin and 17β estradiol 
increased C/EBPβ expression in human PASMCs.  These findings suggest that serotonin 
and 17β estradiol may stimulate C/EBPβ expression in vivo, and this contributes to the 
pathogenesis of PAH in female SERT+ mice.      
         
We observed increased FOS expression in the pulmonary arteries of female SERT+ mice.  
FOS is a proto-oncogene which exists as an immediate early gene transcription factor, and 
is transactivated in response to various stimuli (Herschman, 1991).  For example, FOS 
expression is increased in the heart following exposure to hypoxia (Deindl et al., 2003).  In 
bovine  PASMCs,  serotonin  is  also  a  potent  inducer  of  FOS  expression  via  a  MAPK-
dependent  pathway  (Simon  et  al.,  2005).    In  agreement  with  this,  we  observed  that 
serotonin stimulation also increased c-FOS expression in human PASMCs.  Of interest, 
expression was also increased in 17β estradiol stimulated cells.  Similar effects have also 
been described in rat hepatoctyes (Lee and Edwards, 2001).  In vivo, c-FOS expression is 
increased in the pulmonary arteries of female SERT+ mice.  Here, our evidence suggests 
serotonin and 17β estradiol stimulate c-FOS expression, and this may be relevant to the 
pathogenesis of PAH in female SERT+ mice. 
  
With  relevance  to  human  PAH  we  further  examined  CEBPB,  CYP1B1  and  FOS 
expression in PASMCs derived from IPAH patients.  We observed that expression of these 
three genes (CEBPB, CYP1B1 and FOS) was increased in IPAH PASMCs.  We observed 
at least five-fold increases in CEBPB and FOS mRNA expression compared to control 
PASMCs.  Immunoblotting confirmed that the upregulation of C/EBPβ and c-FOS was  
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also  apparent  at  protein  level.    Since  these  genes  are  involved  in  inflammation  and 
proliferation, both of which are essential components in disease pathogenesis (Tuder et al., 
2009),  our  findings  suggest  their  importance  in  human  PAH.  Their  role  in  the 
pathobiology of experimental and human PAH is of particular interest.  We also observed 
increased  CYP1B1  mRNA  and  protein  expression  in  IPAH  PASMCs,  suggesting  the 
importance of CYP1B1-mediated estrogen metabolism in PAH.  However, these findings 
are inconsistent with previous studies in Epstein Barr virus immortalized B cells derived 
from female BMPR-II PAH patients (West et al., 2008), where decreased CYP1B1 mRNA 
expression was described.  Most likely, this is attributable to the differences in cell type 
investigated.    This  study  focuses  on  changes  in  PASMCs,  which  represent  a  more 
physiologically relevant cell type in PAH.  The dysfunction in estrogen metabolism, and 
particularly  CYP1B1,  appears  a  causative  factor  in  human  PAH  and  merits  further 
investigation. 
 
We have previously reported that SERT+ mice develop elevated RVSP in the absence of 
RVH (MacLean et al., 2004).  This phenomenon is particular to normoxic mice as we, like 
others, have shown that mice develop RVH following exposure to hypoxia (MacLean et 
al., 2004; Keegan et al., 2001). We are not alone in observing this phenomenon as other 
studies have similarly demonstrated elevated RVSP in transgenic mice in the absence of 
RVH.  For example, mice that express BMPR-II 
R899X in smooth muscle or molecular loss 
of BMPR-II signaling in smooth muscle demonstrate elevated RVSP with no change in 
RVH (Tada et al., 2007; West et al., 2004).  The observation that this only occurs in 
normoxic  mice  suggests  that  hypoxia  induces  an  effect  on  RVH  that  may  indeed  be 
independent of RVSP. 
 
The distal arteries are typically those most susceptible to pulmonary vascular remodelling 
in PAH, however microarray analysis was performed in the proximal pulmonary arteries of  
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mice as these were the smallest that could be practically dissected out from whole lung.  
Therefore,  these  gene  changes  may  not  be  entirely  representative  of  gene  expression 
changes  in  smaller  resistance  arteries.    For  example,  our  microarray  results  show  that 
hypoxic  female  SERT+  mice  exhibit  increased  PPAR-γ  expression  relative  to  hypoxic 
female WT mice.  However, previous observations confirm that PPAR-γ expression is 
reduced in the distal pulmonary arteries of PAH patients (Ameshima et al., 2003), and its 
targeted deletion in pulmonary artery smooth muscle or endothelial cells is sufficient to 
cause PAH in mice (Hansmann et al., 2008; Guignabert et al., 2009).  This contrast in 
findings may well result from the effect of hypoxia per se or an indirect compensatory 
change in response to PAH in SERT+ mice. 
 
Additional bioinformatics analysis may help further identify ‘gene networks’ which are 
dysfunctional in SERT+ mice.  Additionally, it would be relevant to further investigate any 
dysregulated genes/pathways also present in alternative models of PAH and human PAH.  
Specific to this study, dysregulation of associated genes ‘upstream’ or ‘downstream’ of 
CEBPB, CYP1B1 and FOS would be of particular interest.   
 
In  conclusion,  through  microarray  analysis  we  have  identified  a  large  number  of 
differentially expressed genes in the pulmonary arteries of SERT+ mice.  These findings 
offer further insight into the gender differences observed in this serotonin-dependent model 
of PAH.  At least three of these genes (CEBPB, CYP1B1 and FOS) are also up-regulated 
at protein level in these mice.  With relevance to human PAH, we identified that mRNA 
and  protein expression of CEBPB, CYP1B1  and  FOS  was  also  increased  in  PASMCs 
derived  from  IPAH  patients.    This  study  has  described  genotypic  differences  in  a 
serotonin-dependent model of PAH and these findings at least in part, may be relevant to 
the pathogenesis observed in human PAH.   
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General Discussion 
Serotonin  is  a  monoamine  synthesized  from  dietary  tryptophan.    In  the  pulmonary 
vasculature, it is a potent mitogen and vasoconstrictor (MacLean and Dempsie, 2009).  
These effects are well established in the pathogenesis of both experimental and human 
PAH.  The exogenous administration of serotonin exaggerates hypoxia-induced PAH in 
rats (Eddahibi et al., 1997), and uncovers a PAH phenotype in BMPR-II mutant mice 
(Long  et  al.,  2006).    Also,  mice  devoid  of  peripheral  serotonin  are  resistant  to  the 
development  of  both  hypoxia-induced  (Morecroft  et  al.,  2007)  and  dexfenfluramine-
induced PAH (Dempsie et al., 2008).  TPH1, which is the rate-limiting enzyme involved in 
serotonin  synthesis,  is  increased  in  the  lungs  and  PAECs  derived  from  IPAH  patients 
(Eddahibi et al., 2006).  Serotonin is thought to mediate its effects via SERT.  For example, 
serotonin-induced proliferation of PASMCs is abolished by the SERT inhibitor citalopram 
(Welsh et al., 2004).  Indeed, SERT+ mice develop PAH and exaggerated hypoxia-induced 
PAH (MacLean et al., 2004) whilst mice devoid of the SERT gene are resistant to hypoxia-
induced PAH (Eddahibi et al., 2000).  Targeted over-expression of SERT in PASMCs is 
also sufficient for the development of PAH in mice (Guignabert et al., 2006).      
 
Increased female susceptibility in human PAH is well-described.  This is highlighted in 
recent epidemiological studies carried out in Scotland, USA and France, where a female 
bias of up to three-fold is observed (Peacock et al., 2007; Thenappan et al., 2007; Humbert 
et  al.,  2006).    Currently,  no  animal  model  of  PAH  has  recapitulated  this  female 
susceptibility.  Paradoxical to this, male susceptibility is reported in several experimental 
models  (Said  et  al.,  2007;  Rabinovitch  et  al.,  1981).    This  absence  of  a  suitable 
experimental model has limited research to date.  In the central nervous system, estrogen 
regulates expression of several key serotonin signalling components including TPH, SERT 
and the 5-HT receptors.  Most likely, this results in enhanced serotonin signalling.  On this  
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evidence,  we  hypothesized  that  similar  observations  were  apparent  in  the  pulmonary 
circulation, and that this may be responsible for increased female susceptibility in PAH.  
We investigated this in a serotonin-dependent model of PAH (SERT+ mice). 
 
Here, we provide evidence that females are at an increased risk to the development of 
PAH, via the effects of 17β estradiol (Chapter 3).  Involvement of the serotonin pathway 
appears  critical  to  this.    We  observed  that  female  SERT+  mice  exhibit  PAH  and 
exaggerated  hypoxia-induced  PAH  whilst  male  SERT+  mice  remained  unaffected 
compared to their respective WT controls.  Ovariectomy abolished this PAH phenotype in 
SERT+ mice confirming the involvement of ovarian-derived female hormones in disease 
pathogenesis.  The administration of 17β estradiol, which is the pre-dominant circulating 
hormone in pre-menopausal females, in ovariectomized SERT+ mice fully re-established 
PAH and exaggerated hypoxia-induced PAH.  These findings highlight the critical role of 
17β estradiol in the development of PAH in SERT+ mice.  Surprisingly, male SERT+ mice 
subjected  to  17β  estradiol  did  not  develop  an  exaggerated  PAH  phenotype.  This 
observation  must  be  further  investigated,  but  one  hypothesis  to  explain  this  is  via  the 
differential effects of 17β estradiol and its metabolism in males compared to females.  For 
example,  altered  estrogen  metabolism  arising  from  polymorphisms  in  the  estrogen-
metabolising  enzyme  CYP1B1  has  been  associated  with  the  development  of  PAH  in 
women (West et al., 2008).  Here, we propose that dysfunctional estrogen metabolism, 
likely  via  altered  expression  of  key  estrogen  metabolising  enzymes,  is  essential  in 
‘switching’ estrogen effects from disease-preventing to disease-promoting.  For example, 
SERT+ PAH is unique to female mice suggesting involvement of the serotonin pathway in 
this, and requires further investigation.  In humans, the SERTLPR polymorphism results in 
increased  transcription,  translation  and  function  of  SERT.    Therefore,  it  would  be  of 
interest to determine the precise gender bias in PAH patients who carry the SERTLPR  
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polymorphism.  Based on this evidence, we propose that female carriers are at a much 
greater risk to the development of PAH than male carriers.          
 
To translate clinical relevance to our findings, we further investigated the effects of female 
hormones in human PASMCs.  Consistent with our in vivo findings, we observed that 
physiological  concentrations  of  17β  estradiol  stimulate  proliferation  as  assessed  by 
increased DNA synthesis and cell number, whereas estrone, estriol and progesterone had 
no effect.  The proliferation of pulmonary vascular cells is essential for pulmonary vascular 
remodelling and currently considered an irreversible component in PAH (Humbert et al., 
2004).  These 17β estradiol effects may be relevant to the increased female susceptibility 
observed  in  PAH.    We  also  observed  that  activation  and  utilisation  of  the  serotonin 
pathway is essential for 17β estradiol-induced proliferation.  This was apparent as presence 
of the TPH inhibitor PCPA or the 5-HT1B receptor antagonist SB224289 was sufficient to 
completely inhibit 17β estradiol stimulated proliferation.  On this evidence, it would be of 
interest to establish if inhibition of TPH1 or the 5-HT1B receptors is sufficient to abolish 
PAH in female SERT+ mice in vivo.  In contrast, the 5-HT2A receptor antagonist ketanserin 
had no effect on proliferation suggesting a minor role of this receptor, and is consistent 
with  previous  reports  in  human  PASMCs  (Morecroft  et  al.,  2010).    Immunoblotting 
performed in PASMC lysates treated with 17β estradiol also confirmed that TPH1, SERT 
and 5-HT1B receptor expression was increased.  These findings are the first to describe the 
expression of TPH1 in PASMCs and suggest the possible existence of autocrinic serotonin 
signalling in pulmonary vascular cells.  Increased SERT and 5-HT1B receptor expression in 
PASMCs  are  also  sufficiently  important,  as  both  have  been  previously  implicated  in 
serotonin-induced PASMC proliferation (Morecroft et al., 2010).  Along these lines, it 
would  be  of  interest  to  investigate  if  TPH1,  SERT  and  5-HT1B  receptor  expression  is 
similarly  altered  in  the  lungs  of  ovariectomized  and  estrogen-dosed  SERT+  mice.    In 
conclusion  of  these  findings,  we  have  described  the  first  experimental  model  of  PAH  
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which exhibits female susceptibility.  Specifically, female mice appear at increased risk to 
the  development  of  PAH  via  the  proliferative  effects  of  17β  estradiol.    This  is  likely 
achieved via 17β estradiol-mediated increased expression of TPH1, SERT and the 5-HT1B 
receptors to enhance PASMC proliferation and pulmonary vascular remodelling. 
 
Given the gender differences we observed in the development of PAH in SERT+ mice, we 
further investigated possible underlying genotypic differences which may help explain this 
(Chapter 4).  Through microarray analysis in the pulmonary arteries, we identified a large 
number of differentially expressed genes which were apparent in SERT+ mice compared to 
their respective WT controls.  When assigned to biological function, 43% of these genes 
were important in females whilst only 27% were important in males.  Similarly, these 
dysregulated genes in female SERT+ mice were associated with a large number (>15) of 
biological pathways whereas this was apparent to a much lesser extent in male SERT+ 
mice.  Moreover, a large number of altered pathways in females were associated with 
inflammation, metabolism and contraction, all of which have been previously implicated in 
the pathogenesis of PAH (Tuder and Voelkel, 1998; Rehman and Archer, 2010).  This 
suggests that dysregulation of these pathways is sufficient in promoting the development of 
PAH, and this is unique to female SERT+ mice.  Hierarchical cluster analysis also revealed 
gene expression patterns in female SERT+ mice which were not apparent in male SERT+ 
mice.    We  also  repeated  microarray  analysis  in  the  pulmonary  arteries  of  chronically 
hypoxic SERT+ mice to investigate the genotypic differences associated with exaggerated 
hypoxia-induced  PAH.    We  observed  a  total  of  316  differentially  expressed  genes  in 
females whilst less than half of this number (145) was altered in males.  Similar to the 
normoxic  comparison,  when  assigned  to  biological  function  over  half  (53%)  were 
important in females whereas significantly less (42%) appeared important in males.  As 
expected, the dysregulation of multiple pathways with relevance to PAH was observed in 
chronically hypoxic females.   
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For  validation  of  the  microarray  study,  we  performed  RT-PCR  analysis  in  three 
differentially  expressed  genes  across  each  group  comparison.  These  results  were 
concordant with the microarray data.  Specifically, following interim Ingenuity Pathway 
Analysis (IPA) analysis, we focused our interest on three genes which were up-regulated in 
female SERT+ mice (CEBPB, CYP1B1 and FOS). 
 
The CEBPB gene encodes for CCAAT-enhancer binding protein beta (C/EBPβ).  It is 
important  in  inflammation  and  proliferation,  both  of  which  are  essential  in  the 
pathogenesis of PAH (Rehman and Archer, 2010; Humbert et al., 2004).  CEBPB mRNA 
is intronless and is usually translated into three distinct isoforms termed full-length liver-
activating  protein  (LAP),  medium-length  LAP  and  short-length  liver-inhibitory  protein 
(LIP).  The translated C/EBPβ isoform is determined by the inherent translation start codon 
site.    Although  LIP  is  a  dominant-negative  isoform  with  no  biological  function,  the 
opposing effects of medium and full-length LAP are thought to determine function.  For 
example,  in  mouse  embryonic  fibroblasts  (MEFs)  full-length  LAP  is  a  transcriptional 
activator whereas medium-length LAP is a transcriptional repressor (Qiu et al., 2008).  In 
vivo,  we  observed  increased  CEBPB  mRNA  and  protein  expression  in  the  pulmonary 
arteries of female SERT+ mice compared to female WT mice.  In agreement with this, 
CEBPB is decreased in the lungs of SERT knockout mice (Crona et al., 2009), whilst 
expression is increased in the lungs of rats following exposure to chronic hypoxia (Teng et 
al., 2002).  Serotonin and 17β estradiol increased C/EBPβ expression in PASMCs, which 
may be relevant to these in vivo findings.  In relation to human PAH, both mRNA and 
protein expression is increased in PASMCs derived from IPAH patients, suggesting its 
importance  in  human  PAH.    On  this  evidence,  we  propose  that  C/EBPβ  is  a  key 
inflammatory component in the progression of PAH.  
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Estrogen is one risk factor in PAH.  Decreased expression of the estrogen-metabolising 
enzyme cytochrome P450 1B1 (CYP1B1) has been previously described in PAH (West et 
al.,  2008).    Here,  we  also  observed  alterations  in  CYP1B1  expression.    However,  in 
contrast we reported increased CYP1B1 mRNA and protein expression in the pulmonary 
arteries of female SERT+ mice.  One explanation for this disparity in findings may be the 
different cell types investigated.  Here, we focused on pulmonary vascular cells, which 
may be more relevant cell type to study.  Serotonin and 17β estradiol may be important 
regulators of this, as stimulation with these increase   CYP1B1  expression  in  PASMCs.  
With respect to human PAH, we similarly observed increased CYP1B1 mRNA and protein 
in  PASMCs  derived  from  IPAH  patients  compared  against  control  PASMCs.    Our 
evidence suggests a role for CYP1B1 in the pathogenesis of experimental and human PAH.  
It would also be of interest to further investigate C/EBPβ expression in PAECs and PAFs.  
Relevant to this, CYP1B1 is also over-expressed in pro-proliferative tumour cells (Murray 
et al., 2001; Murray et al., 1997), and polymorphisms in this gene are associated with 
increased incidence of tumorigenesis (Sasaki et al., 2004; Sasaki et al., 2003; Tanaka et al., 
2002; Van Emburgh et al., 2008; Cussenot et al., 2007).  One hypothesis we propose is that 
CYP1B1-derived estrogen metabolites are pro-proliferative in pulmonary vascular cells, 
and  this  alteration  in  estrogen  metabolism  is  promoting  the  development  of  PAH  in 
females.  Therefore, it would be of interest to assess the proliferative effects of CYP1B1-
derived  estrogen  metabolites  in  PASMCs.  Recently,  vaccine-based  CYP1B1 
immunotherapy  successfully  completed  phase  I  clinical  trial  and  appears  a  promising 
preventative treatment for cancer (Luby, 2008).  CYP1B1 appears an important mediator 
of  estrogen  signalling  in  PAH  via  regulation  of  its  metabolism,  and  merits  further 
investigation. 
 
We also investigated c-FOS expression in SERT+ PAH and human PAH.  FOS is a proto-
oncogene  which  exists  as  an  immediate  early  gene  transcription  factor,  and  is  
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transactivated in response to various stimuli.  It is also involved in cellular proliferation 
(Herschman, 1991).  In bovine PASMCs, serotonin is a potent inducer of c-FOS expression 
via the ERK pathway (Simon et al., 2005).  Here, we observed increased expression of 
both FOS mRNA and c-FOS protein in the pulmonary arteries of female SERT+ mice.  
With relevance, stimulation of human PASMCs with either serotonin or 17β estradiol was 
sufficient to increase c-FOS expression. Of further interest, FOS mRNA and c-FOS protein 
was  also  up-regulated  in  IPAH  PASMCs.    Given  this  increased  expression  in  both 
experimental  and  human  PAH,  c-FOS  may  be  an  important  signalling  regulator  in 
pulmonary vascular mitogenesis, however requires further investigation.   
 
Through microarray analysis we identified a large number of novel genes which appear to 
be promoting the development of PAH in a serotonin-dependent model of female PAH.  
Moreover, at least three of these genes (CEBPB, CYP1B1 and FOS) are up-regulated at 
protein  level  in  mice  and  also  up-regulated  in  PASMCs  derived  from  IPAH  patients, 
further suggesting their importance in human PAH.  These novel genes may be essential in 
promoting a PAH phenotype in females. 
 
In summary of these findings, through a translational approach we have provided evidence 
which greatly advances our understanding as to why increased female susceptibility exists 
in PAH.  This includes the upregulation of key genes which appear to be promoting a PAH 
phenotype  in  females.  Both  serotonin  and  estrogen  are  critical  to  this.  In  future 
perspective, the therapeutic target of these dysregulated pathways may be one potential 
treatment strategy in women with PAH.   
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Future Perspective 
Therapeutic target of the estrogen pathway appears a promising candidate in PAH.  From 
findings  previously  discussed,  the  therapeutic  potential  of  CYP1B1  inhibition  in  the 
prevention and reversal of experimental PAH is of particular interest.  To test this, effects 
of the CYP1B1 inhibitor TMS in hypoxia-induced PAH should be considered.  Along 
these lines, the characterisation of PAH in CYP1B1 deficient mice is also of interest.  In 
translational perspective to human PAH, CYP1B1 inhibition via immunotherapy is one 
approach currently in phase I development for the treatment of cancer (Luby, 2008), and 
may be of potential clinical interest in the treatment of PAH if pre-clinical studies appear 
promising.      
 
In addition, those signalling pathways activated by estrogen and/or its metabolites must be 
further delineated.  It is likely that one or more ER isoforms (ERα, ERβ and GPR30) are 
directly involved in PAH, or at least indirectly via regulating expression of key estrogen 
metabolizing enzymes including CYP1B1, as previously reported (Tsuchiya et al., 2004).  
Therefore, inhibition of ERs via selective antagonists and/or SERMs is also of interest.  
Indeed, SERMs are already an effective therapeutic approach in the treatment of multiple 
other estrogen-dependent diseases including breast cancer (Veronesi et al., 2005).  C/EBPβ 
and FOS may also play an important role in the pathogenesis of PAH.  Here, our data 
suggests that C/EBPβ and FOS act downstream of estrogen-dependent pathways, as 17β 
estradiol increase their expression in PASMCs.  In support of this, C/EBPβ and FOS are 
increased in both experimental PAH and human PAH and further highlights their potential 
importance in PAH progression.   
 
In future perspective, this evidence implicates estrogen in the pathogenesis of PAH, and 
highlights the estrogen pathway as one novel therapeutic target in the treatment of PAH.   
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